Breast Cancer Research and Treatment

Loading...
Breast Cancer Research and Treatment CONTENTS VOL. 106, Supplement 1, December 2007 Special issue 30th Annual SAN ANTONIO BREAST CANCER SYMPOSIUM – December 13–16, 2007 Program

iii–xlviii

Invited Abstracts

S1–S4

Abstracts General Sessions [#11-82] Poster Discussion Sessions [#101-511] Poster Session I [#1001-1119] Poster Session II [#2001-2121] Poster Session III [#3001-3113] Poster Session IV [#4001-4117] Poster Session V [#5001-5119 (excl. 5015)] Poster Session VI [#6001-6119 plus 5015]

S5–S23 S24–S40 S41–S83 S84–S125 S126–S165 S166–S206 S207–S246 S247–S287

Author index for abstracts

S288–S302

Breast Cancer Res Treat (2007) DOI 10.1007/s10549-007-9793-3

© Springer Science+Business Media, LLC. 2007

Photocopying. In the U.S.A.: This journal is registered at the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923 [[email protected]]. Authorizations to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Springer for users registered with the Copyright Clearance Center (CCC). For those organizations that have been granted a photocopy licence, a separate system of payment has been arranged. Authorization does not extend to other kinds of copying, such as that for general distribution, for advertising or for promotional purposes, for creating new collective works, or for resale. The CCC’s services for users can be found on the internet at www.copyright.com. In the rest of the world: Permissions to photocopy must be obtained from the copyright owner. Please apply to Springer Rights & Permissions Department, P.O. Box 17, 3300 AA, Dordrecht, The Netherlands [[email protected]].

Breast Cancer Research and Treatment is published monthly plus 1 additional issue in January, March, May, July, September and November (Volumes 101–106, 3 issues each, 2007). Periodicals postage paid at Rahway, N.J. USPS No. 663–130. U.S. Mailing Agent: Mercury Airfreight International Ltd., 365 Blair Road, Avenel, NJ 07001. Published by Springer, P.O. Box 17, 3300 AA Dordrecht, The Netherlands, and 101 Philip Drive, Norwell, MA 02061, U.S.A. Postmaster: Please send all address corrections to: Breast Cancer Research and Treatment c/o Mercury Airfreight International Ltd., 365 Blair Road, Avenel, NJ 07001, U.S.A. Printed on acid free paper

30t Annual

December 13 – 16, 2007 Henry B. Gonzalez Convention Center 200 E. Market Street, San Antonio, Tx 78205

Sponsors and an NCI-designated Clinical Cancer Center a partnership of

&

Industry And Agency Support (at press time)

Donors

Angel Plus

Adjuvant, Inc. Almac Diagnostics AlphaMed Press AmeriPath, Inc. Aptium Oncology Biocare Medical LLC Biogen Idec Breakthrough Breast Cancer Cambridge University Press Care Wise Medical Products Cianna Medical Clinical Oncology News Coalition of Cancer Cooperative Groups Congressional Directed Medical Research Programs(CDMRP) CURE Media Group Diplomat Specialty Pharmacy Elsevier, Inc. Faxitron X-Ray LLC Hem/Onc Today/SLACK Incorporated ImpediMed, Inc Informa Healthcare Jones and Bartlett Publishers KUBTEC X-Ray Lippincott Williams & Wilkins MedPage Today, LLC National Accreditation Program for Breast Centers The Oncology Group Oncology Nursing Society Springer TRIO (CIRG/TORI) Wiley-Blackwell Women’s Health Boutique, Inc.

Abraxis Oncology AstraZeneca Bristol-Myers Squibb Eli Lilly and Company Genentech BioOncology Genomic Health, Inc. GlaxoSmithKline Novartis Oncology Pfizer Roche sanofi-aventis

Patron Plus Amgen

Patron Eisai, Inc.

Major Supporter Plus Merck Oncology Veridex, A Johnson and Johnson Company

Major Supporter Aperio Technologies, Inc. Bayer HealthCare PharmaceuticalsCarl Zeiss Surgical, Inc. Cytogen Corporation Cytyc CorporationGE Healthcare Monogram Biosciences Valeant Pharmaceuticals.

Contributors Agendia B.V. CBCE CRI Cytori Therapeutics Exagen Diagnostics Gamma Medica-Ideas Molecular Profiling Institute Myriad Genetic Laboratories, Inc. Naviscan PET Systems NeoMatrix Nichols Institute for Oncology North American Scientific Ortho Biotech PhenoPath Laboratories Physicians’ Education Resource Projects in Knowledge, Inc. RadPharm, Inc. Research to Practice SenoRx, Inc. SiteSelect Medical SurgRx, Inc. Sysmex TopoTarget USA, Inc. University of Florida Jacksonville Healthcare, Inc. US Labs Ventana Medical Systems, Inc. Visual Med Clinical Solutions Corp.

Conference Grants National Cancer Institute

Future Symposium Meeting Dates 31st Annual SABCS December 11-14, 2008 (Thursday-Sunday) 32ⁿd Annual SABCS December 10-13, 2009 (Thursday-Sunday) 33rd Annual SABCS December 9-12, 2010 34t Annual SABCS December 7-10, 2011

30th Annual San Antonio Breast Cancer Symposium Program Schedule

10:15

10:30-12:00

Jenny Chang, MD, Co-Moderator Baylor College of Medicine, Houston, TX and Michael Lewis, PhD, Co-Moderator Baylor College of Medicine, Houston, TX

Exhibit Halls A, B, C & D, Ballrooms A & B: Street Level Bridge Hall: Street Level

12:00-7:00

10:30

Introduction

10:30

Breast cancer stem cell: Targets for prevention & therapy Max Wicha, MD University of Michigan Comprehensive Cancer Center Ann Arbor, MI

11:00

Cancer stem cells in therapeutic resistance and as cellular targets Jeremy Rich, MD Duke University Medical Center Durham, NC

11:30

Epigenetic stem cell signatures in breast cancer Peter Laird, PhD USC/Norris Comprehensive Cancer Center Los Angeles, CA

REGISTRATION – Bridge Hall Pre-registered attendees can obtain materials. Those who have not yet registered may do so.

Thursday, December  9:00-9:10

WELCOME – Exhibit Hall D Opening Remarks C. Kent Osborne, MD Charles A. Coltman, Jr., MD

9:10-9:30

PLENARY LECTURE 1 – Exhibit Hall D The worldwide overview: new results for systemic adjuvant therapies

12:00-1:00

LUNCH [Ticket Required] – Exhibit Hall A

1:00-1:30

PLENARY LECTURE 2 – Exhibit Hall D

Richard Peto, for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) University of Oxford Oxford, UNITED KINGDOM

9:30-10:30 9:30

Radiation treatment planning for breast cancer: A journey through time Lori Pierce, MD University of Michigan Medical School Ann Arbor, MI

GENERAL SESSION 1 – Exhibit Hall D 11. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials. Berry DA, Ueno NT, Johnson MM, Lei X, Lopez V, Caputo J, Bregni M, Demirer T. MDACC-EBMT Meta-Analysis Group, Houston, TX.

9:45

12. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Jones S, Holmes F, O’Shaughnessy J, Blum J, Vukelaj S, McIntyre K, Pippen J, Bordelon J, Kirby R, Sandbach J, Hyman W, Khandelwal P, Negron A, Richards D, Mennel R, Boehm K, Meyer W, Asmar L, Muss H, Savin M. US Oncology Research, Inc., Houston, TX; Vermont Cancer Center, Burlington, VT.

10:00

13. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Slamon DJ, Mackey J, Robert N, Crown J, Martin M, Eiremann W, Pienkowski T, Bee V, Taupin H, Villalobos I, Lindsay M-A, Riva A, Hurvitz S, Glaspy J, Pauletti G, Sauter G, Press M. Cancer International Research Group (CIRG), Edmonton, AB, Canada.

MINI-SYMPOSIUM 1 – Exhibit Hall D

STEM CELLS IN BREAST CANCER

Room Locations

Wednesday, December , 

14. Outcome of breast cancer therapies for adjuvant versus advanced disease: how much do they differ? Critical comments towards the present process of randomized trials as a pre-requisite for adjuvant therapy guidelines. Ragaz J, Spinelli JJ. McGill University Health Centre, Montreal, QC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada.

1:30-3:45

GENERAL SESSION 2 – Exhibit Hall D

1:30

21. Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node negative breast cancer. Whelan T, Pignol JP, Julian J, Grimard L, Bowen J, Perera F, Schneider K, Fyles A, Gulavita S, Shelley W, Freeman C, Szechtman B, Levine M. Juravinski Cancer Centre, Hamilton, ON, Canada; McMaster University, Hamilton, ON, Canada; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Ottawa Regional Cancer Centre, Ottawa, ON, Canada; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; London Regional Cancer Centre, London, ON, Canada; Windsor Regional Cancer Centre, Windsor, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Northwestern Regional Cancer Centre, Thunder Bay, ON, Canada; Kingston Regional Cancer Centre, Kingston, ON, Canada; McGill University Health Centre, Montreal, QC, Canada.

1:45

22. dHER2 cancer immunotherapeutic: clinical response in breast cancer patients is associated with an induction of functional antibodies and the generation of specific T cells. Limentani SA, Curigliano G, Campone M, Dorval T, Romieu G, Vogel C, White S, de Boer R, Lehmann F, Cormont F, Louahed J. Blumenthal Cancer Center, Charlotte, NC; Ist Eur Oncol, Milan, Italy; Cent R Ganducheau, Nantes, France; Inst Curie, Paris, France; CRLCC, Montpellier, France; Cancer Res Network, Boca Raton, FL; Austin Hosp, Heidelberg, Australia; Royal Melbourne Hosp, Parkville Vic, Australia; GSK Bio, Rixensart, Belgium.

2:00

23. Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. Kuter I, Hegg R, Singer CF, Badwe R, Lowe E, on behalf of the NEWEST investigators. Massachusetts General Hospital, Boston, MA; University of Sao Paulo & Perola Bygton Hospital, Sao Paulo, Brazil; Medical University of Vienna, Vienna, Austria; Tata Memorial Hospital, Mumbai, India; AstraZeneca, Wilmington, DE.

5:00-7:00

101.

Serial detection and characterization of circulating tumor cells in an animal model. Eliane JP, Luker KE, Brown M, Repollet M, Doyle GV, Hayes DF, Luker GD. University of Michigan Medical School, Huntingdon Valley, PA.

2:15

24. Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells. Borley AC, Barrett-Lee PJ, Gee JMW, Shaw VE, Nicholson RI, Hiscox SE. Velindre Cancer Centre, Cardiff, United Kingdom; Tenovus Centre for Cancer Research, Cardiff, United Kingdom.

102.

2:30

25. The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy. Banerjee SN, Thornhill A, Evans DB, Littlewood-Evans AJ, Dowsett M, Martin L-A. Institute of Cancer Research, London, United Kingdom; Novartis Institute for BioMedical Research-Basel, Basel, Switzerland.

A new system for enrichment and detection of circulating tumor cells in the peripheral blood of patients with metastatic breast cancer. Deng G, Burgess D, Manna E, Krag D, Herrler M. Applied Imaging Corp., San Jose, CA; University of Vermont, College of Medicine, VT.

103.

MagSweeper: an automated system for high efficiency and specificity capture of live circulating tumor cells. Powell AA, Talasaz AAH, Mindrinos M, Carlson R, Pease FW, Davis RW, Jeffrey SS. Stanford University, Stanford, CA.

104.

26. Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid - new results from ABCSG-12. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kaessmann H, Piswanger-Soelkner C, Seifert M, Schippinger W, Menzel C, Dubsky P, Fitzal F, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Jakesz R, on behalf of the ABCSG. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.

Circulating tumor cells as a reliable assessment of treatment efficacy in metastatic breast cancer. Liu MC, Shields P, Isaacs CJD, Warren R, Cohen P, Wilkinson M, Ottaviano Y, Zhang Y, Shen R, Jasti M, Gallagher A. Lombardi Cancer Center, Georgetown University Hospital, Washington, DC; Franklin Square Hospital, Baltimore, MD.

105.

Disseminated tumor cells correlate with estrogen receptor positivity in operable breast cancer patients. Alvarado MD, Brissaud C, Scott J, Magbanua M, Moore D, Ewing CA, Hwang S, Esserman LJ, Park JW. University of California, San Francisco, CA.

106.

27. The effect of zoledronic acid on aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Brufsky A, Bosserman L, Caradonna R, Haley B, Jones M, Moore H, Dong M, Warsi G, Lacerna L, Perez E. Z-FAST Study Group; Novartis Pharmaceuticals, East Hanover, NJ.

Features of patients (pts) with metastatic breast cancer (mBC) and a circulating tumor cell count (CTCc) of 0. Bubis JA, Marsland TA, Justice KM, Edwards D. Integrated Community Oncology Network, Orange Park, FL.

107.

Bone marrow micrometastasis and circulating tumor cells are respectively strong prognostic factors in early and metastatic breast cancer, a comparative study on 759 patients. Bidard F-C, Vincent-Salomon A, Sastre X, Sigal-Zafrani B, Nos C, Mignot L, Dieras V, Asselah J, Thiery JP, Pierga J-Y. Institut Curie, Paris, France; IMCB Biopolis, Singapore, Singapore.

108.

Prognostic value of the detection of circulating tumor cells using a multimarker RT-PCR (CK19, mammaglobin A, HER2/ neu) in early breast cancer. Ignatiadis M, Kallergi G, Ntoulia M, Apostolaki S, Perraki M, Xenidis N, Stathopoulou A, Lianidou E, Georgoulias V, Mavroudis D. University General Hospital of Heraklion, Heraklion, Crete, Greece; School of Medicine, University of Crete, Heraklion, Crete, Greece; University of Athens, Athens, Greece.

109.

Circulating CK-19 mRNA (+) cells in patients with stage I and II breast cancer after the completion of adjuvant chemotherapy: evaluation of their prognostic relevance. Xenidis N, Apostolaki S, Perraki M, Politaki E, Kalbakis K, Ignatiadis M, Kalykaki A, Agelaki S, Georgoulias V, Mavroudis D. University General Hospital of Heraklion, Heraklion, Crete, Greece; School of Medicine, University of Crete, Heraklion, Crete, Greece.

110.

Circulating epithelial tumor cells a new tool for therapy monitoring in breast cancer: a more than tenfold increase in numbers during systemic therapy is highly predictive of relapse. Pachmann K, Camara O, Cavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Runnebaum I, Hoeffken K. Friedrich SchillerUniversität Jena, Jena, Germany.

2:45

3:00

3:15

3:30

3:45-5:00

28. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). Singh S, Cuzick J, Edwards R, Blake G, Truscott J, Coleman J, Eastell R, Howell A. Wolfson Institute of Preventive Medicine, London, United Kingdom; Kings College School of Medicine, London, United Kingdom; University of Leeds, United Kingdom; University of Newcastle, Australia; Christie Hospital, Manchester, United Kingdom; Northern General Hospital, Sheffield, United Kingdom. 29. Risk stratification based on the CYP2D6 tamoxifen metabolizing gene within the Italian tamoxifen prevention trial. Bonanni B, Maisonneuve P, Johansson H, Macis D, Serrano D, Guerrieri-Gonzaga A, Basso D, Zambon C, Plebani M, Nicoloff M, Fontecha M, Hillman G, Wieczorek L, Rotmensz N, Decensi A. European Institute of Oncology (EIO); EIO, Milan, Italy; University-Hospital of Padova, Padova, Italy; Roche Molecular Diagnostics, Pleasanton, CA; E.O. Ospedali Galliera, Genova, Italy.

SUSAN G. KOMEN FOR THE CURE BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Exhibit Hall D

POSTER DISCUSSION 1 & RECEPTION – Ballroom B

Circulating Tumor Cells 101-110

1014

Are the MRI characteristics of malignant breast lesions different for African American women? Jansen SA, Abe H, Shimauchi A, Karczmar GS, Olopade O, Newstead GM. University of Chicago, Chicago, IL.

1015

Pushing the limits: very high spatial resolution spectroscopic MR imaging of human breast. Medved M, Newstead GM, Abe H, Wood AM, Olopade OI, Shimauchi A, Fischer S, Karczmar GS. University of Chicago, Chicago, IL; Philips Medical Systems, Cleveland, OH.

1016

The effect of computer-aided detection on the interpretation of screening mammograms at Intermountain Healthcare facilities. Parkinson B, Belnap T, Rowley B, Blaney S, Kerry A, Pinto K, Nkoy F. Intermountain Healthcare, Salt Lake City, UT.

1017

A new approach to studying the progression of mammary gland carcinoma in mice: high resolution MRI of early cancer and DCIS. Jansen SA, Conzen S, Zamora M, Krausz T, Newstead GM, Karczmar GS. University of Chicago.

Telemammography in a rural community. Lopez AM, Deasy S, Carroll M, Krupinski E, Kreykes L, Weinstein R. University of Arizona, Tucson, AZ; Tuba City Reginal Health Care Corporation, Tuba City, AZ.

1018

Magnetic resonance imaging in predicting pathologic residual disease after primary induction chemotherapy. Anderson CM, Patrick RJ, Rybicki LA, Chellman-Jeffers M, Obi B, Crowe JP. Cleveland Clinic, Cleveland, OH.

Mammography screening and other preventive care among African American and native American women with access to health care. Bachman SI, Shim V. Kaiser Permanente, Oakland, CA.

1019

Initial clinical evaluation of laser optoacoustic imaging system for diagnostic imaging of breast cancer. Oraevsky AA, Ermilov SA, Conjusteau A, Miller T, Gharieb RR, Lacewell R, Mehta K, Radulescu EG, Herzog D, Thompson S, Stein A, McCorvey M, Otto P, Khamapirad T. Fairway Medical Technologies, Houston, TX; Seno Medical Instruments, San Antonio, TX; University of Texas Medical Branch, Galveston, TX; University of Texas Health Science Center, San Antonio, TX.

1020

Sonobreast: a novel predictive model for the risk of malignancy in solid breast nodules with echographic expression. Paulinelli RR, Freitas-Junior R, Lucena CEM, Moreira MAR, Moraes VA, Ruiz AN, Bernardes-Junior JRM, Vidal CSR, Lucato MT, Costa NGS, Teixeira DA. Federal University of Goias, Goiania, Goias, Brazil; Santa Casa de Misericordia, Belo Horizonte, Minas Gerais, Brazil.

1021

High resolution positron emission mammography in breast cancer management. Schilling KJ. Boca Raton Community Hospital, Boca Raton, FL.

1022

A comparison study between multidetector-row CT and histopathological findings in terms of the extension diagnosis of breast cancer. Sumiyoshi K, Kani H, Nohara T, Iwamoto M, Harada T, Tanaka S, Kimura K, Takahashi Y, Shibayama Y, Tsuji M, Kurisu Y, Tanigawa N. Osaka Medical College, Takatsuki, Osaka, Japan.

1023

Correlation of Ki67 expression with FDG-PET positivity in triple negative breast cancer. Tchou J, John T, Basu S, Rosen M, Schnall M, Alavi A. University of Pennsylvania, Philadelphia, PA.

1024

Breast optical tomography: sensitivities and specificities for the detection of cancer. Sharma A, Enfield L, Gibson AP, Everdell NL, Schweiger M, Arridge S, Delpy DT, Hebden JC, Keshtgar M, Sainsbury RS, Douek M. University College London Hospital, London, United Kingdom; University College London, Malet Place, London, United Kingdom.

1025

Mammographic features of triple-negative versus HER2+ and ER+ breast cancers. Yang WT, Dryden M, Broglio K, Dawood S, Valero V, Hortobagyi G, Atchley D, Arun B. M. D. Anderson Cancer Center, Houston, TX.

5:00-7:00

POSTER SESSION 1 & RECEPTION Exhibit Hall B

(#1001-1119) Detection and Diagnosis: Mammography / Imaging 1001-1033 1001

1002

1003

1004

Effect of magnetic resonance imaging on the clinical management of women with newly diagnosed breast cancer. Newstead GM, Abe H, Jansen SA, Shimauchi A, Sennett CA, Schmidt RA, Zak L, Olopade O, Jaskowiak N. University of Chicago, Chicago, IL. Deconvolution-based dynamic contrast enhanced MRI of breast cancer: correlation of tumor blood flow with pathologic and molecular markers. Makkat S, Fontaine C, Stadnik T, Luypaert R, Bourgain C, De Greve J, De Mey J. UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.

1005

How does ER/PR and Her2/Neu status affect the MR characteristics of invasive ductal carcinoma? Jansen SA, Abe H, Shimauchi A, Karczmar GS, Newstead GM. University of Chicago, Chicago, IL.

1006

Breast density assessment using magnetic tesonance imaging and diffuse optical spectroscopy. Klifa CS, Shah NS, Watkins M, Li A, Hattangadi J, Tromberg B, Hylton N. University of California, San Francisco, CA; University of California, Irvine, CA.

1007

MR imaging of tumor response in breast cancer patients following neoadjuvant chemotherapy: correlated with pathological findings. Chen J-H, Agrawal G, Yu H, Carpenter P, Mehta R, Nalcioglu O, Su M-Y. University of California Irvine, Irvine, CA.

1008

The utility of MRI in preoperative planning for breastconserving therapy. Kaufman G, Guth AA, Singh B, Axelrod D, Moy L. NYU School of Medicine, New York, NY.

1009

Does MRI improve chances of obtaining negative surgical margins after localized excision? A retrospective study. Kulkarni K, Newstead GM, Jansen SA, Abe H, Shimauchi A, Schmidt RA, Jaskowiak N. University of Chicago, Chicago, IL.

1010

The role of breast MRI in the preoperative evaluation of patients with newly diagnosed breast cancer. Schell AM, Kaufman PA, Lewis PJ. Dartmouth-Hitchcock Medical Center, Lebanon, NH.

1011

Comparative accuracy of MRI and ultrasound for predicting breast cancer extent after neoadjuvant chemotherapy. Karuna ST, Wechter DG. Virginia Mason Medical Center, Seattle, WA.

1012

Accuracy of preoperative evaluation of the axilla with MRI in breast cancer. Kaufman G, Guth AA, Axelrod D, Moy L. NYU School of Medicine, New York, NY.

1013

Model selection for analysis of dynamic contrast enhanced MRI (DCE-MRI) data. Yankeelov T, Welch EB, Chakravarthy B, Lee R, Freehardt D, Mayer I, Meszoely I, Kelley M, Means-Powell J, Gore J. Vanderbilt University, Nashville, TN; Philips Medical Systems, Cleveland, OH.

1026

1027

Effects of the steroidal aromatase inhibitor exemestane on mammographic breast density and other end-organ functions. Cigler T, Fabian CF, Yaffe MJ, Johnston D, Ingle JN, Nassif E, Brunner R, Wadden N, Pater JL, Richardson H, Tu D, Shangle Q, Goss PE. Massachusetts General Hospital, Boston, MA; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Kansas University Medical Center, Kansas City, KS; Mayo Clinic, Rochester, MN; Notre Dame Hospital, Montreal, QC, Canada; University of Nevada School of Medicine, Reno, NV; Memorial University of Newfoundland, St. John’s, NL, Canada; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; (NCIC CTG) MAP.2. Influence of bilateral breast magnetic resonance imaging in treatment planning for patients with stage I/II breast cancer. Figueredo ND, Carruthers CL, Frazier TG. Lankenau Hospital, Wynnewood, PA; Comprehensive Breast Center, Bryn Mawr Hospital, Bryn Mawr, PA.

1028

Follow-up rather than excision for benign papillary lesions of the breast. Copit DS, Vaidynathan S, Chaudhri Y. Albert Einstein Medical Center, Philadelphia, PA.

1029

Using three-parameter empirical mathematical model to analyze breast DCEMRI data; comparison with conventional BI-RADS classification. Fan X, Arkani S, Karczmar GS, Abe H, Schmidt RA, Newstead GM. University of Chicago, Chicago, IL.

1030

A double-blind randomized controlled trial of paracetamol as a pre-medication for mammography. Freitas-Junior R, Nascente CM, Carvalho AA, Ximenes C, Silva MF, Leite Filho AR, Freitas PF. Goias Federal University, Goiania, GO, Brazil.

1032

Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Prati R, Minami CA, Gornbein JA, DeBruhl N, Chung D, Chang HR. University of California, Los Angeles, CA.

1033

Breast specific gamma imaging and managment of breast cancer. Stern L, Rosenberg AL, Brill KL. Methodist Hospital, Philadelphia, PA; Jefferson Medical College, Kimmel Cancer Center, Philadelphia, PA.

1038

Concordance of contralateral breast cancer for steroid receptor and tumour characteristics. Absar MS, Martin C, Howe M, Zeiton A, Cramer A, Morris J, Bundred NJ. University Hospital of South Manchester, Manchester, United Kingdom.

1039

Breast cancer in the elderly: benefits of screening mammography in the diagnosis. Hines NL, Leibman AJ. Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY.

1040

Utility of echocardiographic screening for late-onset cardiomyopathy in breast cancer survivors treated with cardiotoxic chemotherapy. Wazir S, Budd GT, Moore HCF, LeGrand S, Andresen S, Tang WH. Cleveland Clinic, Cleveland, OH.

Prognosis and Response Predictions: Prognostic Factors I 1041-1074 1041

Does HER-2 status influence locoregional failure rates after mastectomy in patients with pT1-3pN0 early stage breast cancer? Kwan W, Al-Tourah AJ, Speers C, Kennecke H, Norris B, Olivotto I. BC Cancer Agency, Fraser Valley Centre, Surrey, BC, Canada; BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada; BC Cancer Agency, Vancouver Island Centre, Victoria, BC, Canada.

1042

Elevated JAG1 mRNA expression, associated with the basal phenotype, is a poor-prognosis indicator in lymph nodenegative breast cancer. Reedijk M, Dickson BC, Pinnaduwage D, Mulligan AM, Zhang H, Bull SB, O’Malley F, Egan SE, Andrulis IL. University Health Network, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Hospital for Sick Children, The Toronto Medical Discovery Tower, Toronto, ON, Canada.

1043

Recurrence score by oncotype DX evaluated on the primary breast tumor predicts the 2-year survival after first relapse. Bianchini G, Zambetti M, Mariani P, Moliterni A, Bianchi G, Mariani G, Fasolo A, Carcangiu ML, Valagussa P, Gianni L. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

1044

Intracystic papillary carcinoma: a review of 917 cases. Grabowski JE, Saltzstein SL, Sadler GR, Blair SL. UCSD, San Diego, CA; UCSD, La Jolla, CA.

1045

Short term prognostic index for breast cancer: NPI or Lpi. Decock J, Hendrickx W, Van Belle V, Brouckaert O, Pintens S, Van Huffel S, Paridaens R, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Wildiers H, Vergote I, Christiaens M-R, Neven P. UZ Leuven, Leuven, Belgium.

1046

The microstaging of sentinel lymph node biopsies is not associated with disease-free survival in breast cancer. Pugliese MS, Arthurs ZM, Tickman RJ, Allison KH, Beatty JD. Swedish Cancer Institute, Seattle, WA.

1047

Meta-analysis of gene-expression profiles in breast cancer: towards a unified understanding of breast cancer sub-typing and prognosis signatures. Sotiriou C, Wirapati P, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Sengstag T, Schütz F, Goldstein DR, Delorenzi M, Piccart M. Institute Jules Bordet, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium; University of Lausanne, Lausanne, Switzerland.

1048

The presence of a fibrotic focus and expansive growth pattern in breast tumors is associated with gene expression profiles of aggressive tumor biology. Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van Marck EA, Dirix LY, Vermeulen PB, Foekens JA. (Lab Pathology University of Antwerp/University Hospital Antwerp, Wilrijk; Oncology Center, GH St.-Augustinus, Wilrijk, Belgium), Antwerp, Belgium; Erasmus MC-Daniel den Hoed, Rotterdam, Netherlands.

Detection and Diagnosis: Screening 1034-1040 1034

The missing exam in clinical breast exam. Goodson III WH, Moore II DH. California Pacific Medical Center Research Institute, San Francisco, CA; University of California, San Francisco, CA.

1035

Comparing performance measures in opportunistic and organized screening mammography for early breast cancer detection. Hofvind S, Vacek P, Skelly J, Geller BM. The Cancer Registry of Norway, Oslo, Norway; University of Vermont, Burlington, VT.

1036

Cost-effectiveness of breast cancer (BC) screening with contrast enhanced magnetic resonance imaging (MRI) as an adjunct to x-ray mammography (XM) in high-risk women. Taneja C, Edelsberg J, Weycker D, Guo A, Oster G, Weinreb J. Policy Analysis Inc. (PAI), Brookline, MA; Bayer HealthCare Pharmaceuticals, Wayne, NJ; Yale University School of Medicine, New Haven, CT.

1037

High incidence of brain metastases found in patients with HER2 positive metastatic breast cancer. Should these patients be followed by regular MR scans? Langkjer ST, Krøldrup L, Kristiansen C, Enevoldsen K, Edal AL, Ormstrup TE. Vejle Hospital, Vejle, Denmark.

1049

An inflammatory breast carcinoma signature is associated with reduced relapse free survival in patients with noninflammatory breast cancer. Van Laere SJ, Van den Eynden GG, Van der Auwera I, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB. Lab Pathology University Antwerp and Oncology Center, General Hospital SintAugustinus, Wilrijk, Antwerp, Belgium.

1050

Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in nodenegative breast cancer – a prospective study. Würtz SØ, Møller S, Mouridsen H, Hertel PB, Friis E, Brünner N. University of Copenhagen, Frederiksberg, Denmark; Rigshospitalet, Copenhagen, Denmark.

1051

Non-proportional breast cancer mortality patterns according to expression of the HER2 protein, using the residual tissue repository of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. Anderson WF, Luo S, Chatterjee N, Rosenberg PS, Goodman MT, Hernandez BY, Reichman M, Dolled-Filhart MM, O’Regan RM, Perou CM, Jatoi I, Cartun RW, Sherman ME. National Cancer Institute, Rockville, MD; University of Hawaii, Honolulu, HI; Hartford Hospital, Hartford, CT; Emory University, Atlanta, GA; University of North Carolina, Chapel Hill, NC; HistoRx, New Haven, CT; National Naval Medical Center, Bethesda, MD.

1052

Withdrawn

1053

Patterns of metastatic spread in triple negative breast cancer. Dent R, Trudeau M, Sun P, Narod S. Sunnybrook Health Sciences Center, Toronto, ON, Canada; Women’s College Hospital, University of Toronto, Toronto, ON, Canada.

1060

The prognostic significance of human epidermal growth factor receptor-2 over-expression for the development of local recurrence after newly diagnosed breast cancer. Gabos Z, Thoms J, Hanson J, Ghosh S, Deschenes J, Mackey J, Abdulkarim B. Cross Cancer Institute, Edmonton, AB, Canada; University of Alberta, Edmonton, AB, Canada.

1061

Do grade I breast cancers require follow-up after breast conserving treatment? Hamed H, Jones G, Allen D, Kontos M. Guy’s Hospital, London, United Kingdom.

1062

Prognostic factors for BRCA1/2-associated familial breast cancer from Russian population. Lyubchenko LN, Pospechova NI, Lushnikova AA, Portnoy SM, Bryuzgin VV, Karpukhin AV, Garkavtseva RPh. N.Blokhin Cancer Res., Center RAMS, Moscow, Russian Federation; Research Center for Medical Genetics, Moscow, Russian Federation.

1063

Restratification of the Nottingham prognostic index using carcinoembroinic antigen cell adhesion molecule 6. Maraqa L, Cummings M, Peter MB, Hanby AM, Shaaban AM, Horgan K, Speirs V. St James’s University Hospital, Leeds, West Yorkshire, United Kingdom; Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom.

1064

The Amsterdam 70-gene signature predicts outcome in breast cancer patients with 1-3 positive axillary lymph nodes. Mook S, Rutgers EJT, Peterse JL, Nuyten DSA, Horlings H, van de Vijver MJ, van ‘t Veer LJ. Netherlands Cancer Institute, Amsterdam, Netherlands.

1065

Quantitative justification of the change from 10% to 30% for HER-2 scoring in the ASCO-CAP guidelines: tumor heterogeneity in breast cancer and its prognostic and predictive implications. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL. Yale University School of Medicine, New Haven, CT; British Columbia Cancer Agency, Vancouver, BC, Canada.

1054

E-cadherin levels may predeict outcome in inflammatory breast cancer (IBC). Levine PH, Ganesan C, Young HA, Portera C, Yang S, Swain SM. The George Washington University Medical Center, Washington, DC; National Cancer Institute, Bethesda, MD; Washington Hospital Center, Washington, DC.

1055

Impact of hormone replacement therapy on breast cancer: Women’s Healthy Eating and Living (WHEL) study experience. Parker BA, Flatt SW, Mortimer JA, Natarajan L, Gold EB, Bardwell WA, Jones LA, Hollenbach KA, Pierce JP. University of California, La Jolla, CA; University of California, Davis, CA; The University of Texas, Houston, TX.

1066

HER2 status adds prognostic, but not tamoxifen treatment predictive, information in hormone receptor positive premenopausal primary breast cancer. Rydén L, Fernö M, Stål O, Landberg G, Bendahl P-O. Clinical Science, Lund, Sweden; Biomedicine and Surgery, Linköping, Sweden; Laboratory Medicine, Malmö University Hospital, Malmö, Sweden.

1056

Survival outcomes in pregnancy-associated breast cancer. Ali A, Wang Y, Kelly J, Falk J, Sehgal R, Vogel V. University of Pittsburgh Medical Centre, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA.

1067

1057

Clinicopathological and prognostic relevance of uptake level revealed by 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18FFDG PET/CT) in primary breast cancer. Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K. National Defense Medical College, Tokorozawa, Saitama, Japan.

Prospective prognostic value of proliferation in small, lowgrade, lymph-node negative breast cancers. Baak JPA, Van Diest PJ, Janssen EAM, Voorhorst F, and Other MMMCP Collaborators. Stavanger University Hospital, Stavanger, Norway; The Gade Institute, University of Bergen, Bergen, Norway; University Medical Center, Utrecht, Netherlands; Free University Medical Center, Amsterdam, Netherlands.

1068

Identification of IGFBP4 as a marker of tamoxifen failure in primary breast cancer. Hadad SM, Robertson KE, Baker L, Bray SE, Purdie CA, Jordan L, Vendrell JA, Cohen PA, Thompson AM. Ninewells Hospital and Medical School, Dundee, United Kingdom; Universite Lyon, Lyon, France.

1069

Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Hwang K-T, Han W, Lee JW, Cho J, Ko E, Kim EK, Jung S-Y, Jeong E-M, Kang JJ, Yang S-J, Kim S-W, Noh D-Y. Seoul National University Boramae Hospital, Seoul, Republic of Korea; College of Medicine, Seoul National University, Seoul, Republic of Korea; Cancer Research Institute, College of Medicine, Seoul National University, Seoul, Republic of Korea; Macrogen, Inc., Seoul, Republic of Korea.

1058

1059

Prognostic differences of WHO-assessed mitotic activity index (MAI) and mitotic impression by quick scanning in invasive ductal breast cancer patients under 55 years of age. Skaland I, van Diest PJ, Janssen EAM, Gudlaugsson E, Søiland H, Baak JPA. Stavanger University Hospital, Stavanger, Norway; University Medical Center, Utrecht, Netherlands; University of Bergen, Bergen, Norway; Free University, Amsterdam, Netherlands. Complementary and alternative therapies among long-term breast cancer survivors. Carpenter CL, Ganz PA, Bernstein L. Keck School of Medicine at USC, Los Angeles, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA.

1070

Prognostic value of the shed antigen of HER-2/neu in premenopausal breast cancer patients in the TABLE-study. Lueftner DI, Pechlivanis K, Geppert R, Possinger K. Charite Campus Mitte, Berlin, Germany.

1071

Down regulation of EFEMP1 is associated with unfavourable prognosis in sporadic breast cancer patients. Ramser J, Harbeck N, Sadr-Nabavi A, Naehrig J, Busch R, KiechleBahat M, Meindl A. Tech. University, Munich, Germany.

1072

Cell cycle proteins add independent prognostic information to Nottingham Prognostic Index (NPI). Loddo M, Kingsbury S, Sainsbury R. University College London, United Kingdom.

1073

The prognostic significance of androgen receptor expression in breast cancer. Peter M, Maraqa L, Horgan K, Speirs V, Shaaban A. University of Leeds, Leeds, W Yorks, United Kingdom; Leeds General Infirmary, Leeds, W Yorks, United Kingdom.

1074

Comparative analysis of uPA/PAI-1 in core biopsies versus surgical breast cancer samples. Vetter M, Lantzsch T, Abraha-Späth RS, Olenik C, Thomssen C, Dittmer J. Martin-Luther University, Halle/Saale, Germany; St. Elisabeth & St. Barbara Hospital, Halle/Saale, Germany; University Hospital Eppendorf, Hamburg, Germany; American Diagnostica GmbH, Pfungstadt, Germany.

Treatment: Chemotherapy – General 1075-1087 1075

Risk of dementia in older breast cancer survivors: a population-based cohort study of the effect of chemotherapy. Baxter NN, Durham SB, Phillips K-A, Virnig EA, Virnig BA. University of Toronto, Toronto, ON, Canada; University of Minnesota, Minneapolis, MN; Peter MacCallum Cancer Centre, Melbourne, Australia.

1076

Final results of the AGO breast cancer study group MAMMA-3 trial: first-line capecitabine + paclitaxel vs epirubicin + paclitaxel for high-risk metastatic breast cancer. Lück H-J, du Bois A, Schrader I, Huober J, Heilmann V, Fasching PA, Stähle A, Jackisch C, Marth C, Richter B, von Minckwitz G. HSK, Klinik für Gynäkologie und Gynäkologische Onkolgie, Wiesbaden, Germany; Henriettenstiftung, Frauenklinik, Hannover, Germany; Universitäts-Frauenklinik Tübingen, Tübingen, Germany; Universitäts-Frauenklinik and Poliklinik Ulm, Ulm, Germany; Universitätsklinikum Erlangen, Frauenklinik, Erlangen, Germany; St. Vincentius-Krankenhäuser, Frauenklinik, Karlsruhe, Germany; Klinik für Gynäkologie und Geburtshilfe Klinikum Offenbach, Offenbach, Germany; Universitätsklinik für Frauenheilkunde Innsbruck, Innsbruck, Austria; Elbland-Kliniken Meißen-Radebeul, Standort Radebeul, Frauenklinik, Radebeul, Germany; Zentrum Frauenheilkunde und Geburtshilfe, Frankfurt, Germany.

1077

Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: preliminary results (multicenter BOOG-study; 2002-02). Hamberg P, Bontenbal M, Vernhout RM, Bos MM, Braun HJ, Erdkamp F, Stouthard JML, van Deijk GA, Schmitz PIM, Seynaeve C, Klijn JGM. Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, Netherlands; Reinier de Graaf Hospital, Delft, Netherlands; Vlietland Hospital, Vlaardingen, Netherlands; Maasland Hospital, Sittard, Netherlands; Haga Hospital, Den Haag, Netherlands; Medical Center Rijnmond-Zuid, Rotterdam, Netherlands; Erasmus University Medical Center, Rotterdam, Netherlands.

1078

Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results. Chan S, Romieu G, Huober J, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Carrasco E, Thareau Vaury A, Fumoleau P. Nottingham City Hospital, Nottingham, United Kingdom; CRLC Val d’Aurelle, Montpellier Cedex 5, France; University of Tuebingen, Tuebingen, Germany; Centre Rene Huguenin, Saint Cloud, France; University of Heidelberg, Heidelberg, Germany; Hospital Clinico de Valencia, Valencia, Spain; Hospital Arnau de Villanova, Lerida, Spain; Dr. HorstSchmidt-Klinik, Wiesbaden, Germany; Eli Lilly Spain, Madrid, Spain; Eli Lilly France, Suresnes Cedex, France; Centre GeorgesFrancois Leclerc, Dijon, France.

1079

Analysis of chemotherapy-induced amenorrhea by three different chemotherapy regimens in premenopausal women with early breast cancer. Han HS, Lee KS, Kim SY, Ro J. National Cancer Center, Goyang-si, Korea.

1080

A descriptive study of pharmacokinetic alterations of epirubicin as a function of body size. Madarnas Y, Clemons M, Walker S, McLean H, Nakatsu K, Sawka C. Queen’s University; University of Toronto; Cancer Centre of Southeastern Ontario; Toronto-Sunnybrook Regional Cancer Centre; Princess Margaret Hospital.

1081

A multicenter, randomized, double-blind, parallelgroup phase II study of gefitinib (IRESSA) or placebo in combination with docetaxel, as first-line treatment in patients with metastatic breast cancer. Tubiana-Hulin M, Spielmann M, Dieras V, Fumoleau P, Delaloge S, Mefti F, Girre V. Centre Rene Huguenin, Saint Cloud, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Centre G.F. Leclerc, Dijon, France.

1082

Vinflunine in combination with trastuzumab: an active combination in the treatment of HER2 positive metastatic breast cancer. Paridaens R, Wildiers H, Dalenc F, Rixe O, Roche H, Cadic V, Delgado F-M. UZ Gasthuisberg, Leuven, Belgium; Institut Claudius Regaud, Toulouse, France; Hopital Pitie-Salpetriere, Paris, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France.

1083

A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer. Willemse PH, Munck L, Creemers GJ, Graaf H, Smit W, Erjavec Z, Stouthard JM, Deijk G, Bochove A, Vader W, Westermann AM. UMC, Groningen, Netherlands; Comprehensive Cancer Centre North-Netherlands, Groningen, Netherlands; Catharina Ziekenhuis, Eindhoven, Brabant, Netherlands; MCL Zuid, Leeuwarden, Friesland, Netherlands; Medisch Spectrum Twente, Enschede, Overijssel, Netherlands; Delfzigt Ziekenhuis, Delfzijl, Groningen, Netherlands; MCR-Zuid, Rotterdam, Zuid-Holland, Netherlands; HAGA Ziekenhuis-Rode Kruis, Den Haag, ZuidHolland, Netherlands; ZaansMC, Zaandam, Noord-Holland, Netherlands; Sanofi-Aventis, Gouda, Zuid-Holland, Netherlands; AMC, Amsterdam, Noord-Holland, Netherlands.

1084

Benchmarking quality oncology care in the community setting. Schwartzberg LS, Tauer K, Blakely J, Johnson R, Reed J, Somer B, Wheeler B, Walker MS, Stepanski EJ, Fortner BV. The West Clinic, Memphis, TN; Accelerated Community Oncology Research Network, Memphis, TN.

1085

Age and prognosis – how did adjuvant therapies influence the real prognosis? Morishita M, Thomas G, Leonard R. South West Wales Cancer Institute, Swansea, United Kingdom; Velindre Hospital, Cardiff, United Kingdom; Imperial College School of Medicine, London, United Kingdom.

1086

Dexamethasone, metoclopropamide and omperazole combination is simple, safe and effective for delayed nausea and vomiting control in adjuvant chemotheray for early breast cancer. Sanchetee SC. Sanchetee Hospital and Cancer Insitute, Jodhpur, Rajasthan, India.

1087

N0332 phase II trial of weekly irinotecan and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group trial. Tan WW, Hillman D, Salim M, Northfelt DW, Anderseon DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Frances P, Perez PA. Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Allan Blair Cancer Center, Saskatchewan, Canada; Mayo Clinic Scottsdale, Scottsdale, AZ; Abbott Northwestern Hospital, Minneapolis, MN; Michigan Cancer Research Consortium, Ann Arbor, MI; Duluth CCOP, Duluth, MN; Geisinger Clinic & Medical Center, Danville, PA; Missouri Valley Cancer Consortium, Omaha, NE.

1093

Predictors of weight gain in patients with early stage breast cancer. Mills JB, Gui J, Mulrooney TJ, Schwartz GN. DartmouthHitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH.

1094

Memory loss after adjuvant chemotherapy for breast cancer: a preliminary analysis of mediating variables utilizing crosssectional correlations and multilevel longitudinal analysis. Beadle G, Rolfe M, Vearncombe K, Andrew B, Mengersen K, Wright M. Queensland Institute of Medical Research, Brisbane, Queensland, Australia; Southern Cross University, Lismore, New South Wales, Australia; University of Queensland, Brisbane, Queensland, Australia; Queensland University of Technology, Brisbane, Queensland, Australia.

1095

Research on optimal recovery practices in breast cancer: the RESTORE trial. Kimmick GG, McCoy TP, Milhalko SL, Ribisl PM, Anderson RT. Wake Forest University School of Medicine, Winston-Salem, NC; Wake Forest University, Winston-Salem, NC; Duke University Medical Center, Durham, NC.

1096

Breaking bad news: experiences receiving breast cancer diagnosis in a specialty breast center versus community practice. Smith RL, Crawford BJ, Petersen LR, Johnson RE, Mandrekar J, Cha S, Rhodes DJ, Hartmann LC. Mayo Clinic, Rochester, MN.

1097

Appraisals, coping and distress among couples dealing with breast cancer. Hernandez AM, Bigatti SM. Indiana University Purdue University Indianapolis, Indianapolis, IN.

1098

The psychosocial issues for women diagnosed with breast cancer who have a concurrent pregnancy or want the option of a subsequent pregnancy. Ives A, Longman G, Saunders C, White K. The University of Western Australia, Perth, WA, Australia; University of Sydney, Sydney, NSW, Australia.

1099

Prevalence of cognitive complaints is not higher in postmenopausal breast cancer patients before adjuvant hormonal therapy compared to healthy controls. Schilder CM, van Dam F, Boogerd WS, Seynaeve C, van de Velde CJ, Nortier HW, Linn SC, Schagen SB. Netherlands Cancer Institute, Amsterdam; Erasmus Medical Center, Rotterdam; University Medical Center, Leiden, Netherlands.

1100

Unexpected effects of reassurance in women with low-risk breast cancer. Griggs JJ, Corbin K, Weiss M, Shields CG. University of Michigan, Ann Arbor, MI; University of Rochester School of Medicine and Dentistry, Rochester, NY; breastcancer.org, Narberth, PA.

1101

Breast reconstruction in a university-based public hospital. Levine SM, Vaksman A, Hiotis K, Levine JP. New York University Medical Center, New York, NY.

Treatment: Chemotherapy – Support 1088-1090 1088

1089

1090

Reduced incidence of febrile neutropenia and related complications in elderly breast cancer patients receiving chemotherapy with pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from an integrated analysis. Aapro M, Schwenkglenks M, Lyman G, Lopez Pousa A, Easton V, Skacel T, Bacon P, Von Minckwitz G. Clinique de Genolier, Genolier, Switzerland; University of Basel, Basel, Switzerland; University of Rochester, Rochester; Hospital Sant Pau, Barcelona, Spain; Amgen Ltd, Cambridge, United Kingdom; Amgen (Europe) GmbH, Zug, Switzerland; University of Frankfurt, Frankfurt, Germany. Pegfilgrastim promotes neutrophil recovery in elderly breast cancer patients following anthracycline-containing chemotherapy. Brugger W, Bacon P, Lawrinson S, Romieu G. Schwarzwald-Baar Clinic, University of Freiburg, Villingen-Schwenningen, Germany; Amgen (Europe) GmbH, Zug, Switzerland; Amgen Ltd, Uxbridge, United Kingdom; CRLC Val d’Aurelle, Montpellier, France. Pre-treatment differential white blood cell counts can be used to identify patients who are at increased risk of severe myelosuppression following adjuvant chemotherapy. Jenkins P, Benstead K, Owen R, Elyan S, Ingledew I, Bristol J, Chan C, Freeman S. Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom; University of Birmingham, Birmingham, Edgbaston, United Kingdom.

Treatment: Psychosocial Aspects 1091-1101

Tumor Cell Biology: Angiogenesis 1102-1109

1091

Quality of life in the Intergroup Exemestane Study (IES) 5 years post-randomisation. Fallowfield LJ, Langridge CI, Kilburn LS, Jones SE, Snowdon CF, Bliss JM, Coombes C. Brighton & Sussex Medical School, Falmer, United Kingdom; Institute of Cancer Research, Sutton, United Kingdom; US Oncology Research, TX; Imperial College London, United Kingdom; on behalf of the IES Group.

1102

Anti-tumor activity of motesanib diphosphate alone and in combination with docetaxel or tamoxifen in xenograft models of human breast carcinoma. Coxon A, Bush T, Belmontes B, Saffran D, Ona V, Rex K, Caenepeel S, Hughes P, Kaufman S, Radinsky R, Kendall R, Price J, Polverino A. Amgen Inc, Thousand Oaks, CA; UT MD Anderson Cancer Center, Houston, TX.

1092

Prospective multi-center study of the impact of the 21-gene recurrence score assay on patient satisfaction, anxiety and decisional conflict for adjuvant breast cancer treatment selection. Mumby PB, Lo SS, Norton J, Smerage J, Joseph K, Chew HK, Hayes D, Albain KS. Loyola University Medical Center, Maywood, IL; University of Michigan, Ann Arbor, MI; Edward Hospital, Naperville, IL; University of California, Sacramento, CA.

1103

Non-invasive in vivo subcellular multicolor imaging of the tumor microenvironment and drug response in real time. Yang M, Jiang P, Al-Zaid M, Hoffman RM. AntiCancer, Inc., San Diego, CA; University of California, San Diego, CA.

1104

Anti-angiogenic potential of coenzyme Q10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Panchanatham S. DR. A.L.M.P-G.I.B.M.S., University of Madras, Tarmani Campus, Chennai, Tamilnadu, India.

1105

Molecular imaging in the mouse model of breast cancer based on optical illumination and ultrasonic detection. Oraevsky AA, Ermilov SA, Eghtedari MA, Conjusteau A, Miller T, Radulescu EG, Herzog D, Gharieb RR, Lacewell R, Thompson S, Mehta K, Stein A, Motamedi M. Fairway Medical Technologies, Houston, TX; Seno Medical Instruments, Houston, TX; University of Texas Medical Branch, Galveston, TX.

1116

Combination therapy with tetramethoxystilbene and phosphatidylinositol 3-kinase inhibitor is effective for killing hormone-resistant breast cancer. Park H, Aiyar SE, Kim S, Lee Y, Fan P, Santen RJ. Kyungpook National University Hospital, Daegu, Republic of Korea; University of Virginia, Charlottesville, VA; Seoul National University, Seoul, Republic of Korea.

1106

Variation of circulating angiogenic factor level and its potential value during chemotherapy in patients with metastatic breast cancer. Tang J, Zhao J, Qin J, Pan L, Xu Z. Jiangsu Tumor Hospital, Nanjing, Jiangsu, China; Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China.

1117

Inhibition of breast cancer growth with the combination of lapatinib and an ADAM protease inhibitor. Witters LM, Scherle PA, Friedman SM, Redman J, Fridman JS, Caulder E, Lipton A. Pennsylvania State University College of Medicine, Hershey, PA; Incyte Corporation, Wilmington, DE.

1118

1107

Association of genetic polymorphisms of VEGF and VEGFR-2 with outcome in E2100. Schneider B, Wang M, Radovich M, Sledge G, Badve S, Thor A, Flockhart D, Hancock B, Davidson N, Miller K. Indiana University School of Medicine, Indianapolis, IN; Harvard, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD.

uPAR gene amplification in breast cancer tissue: a rare event. Pintens S, Vanden Bempt I, Drijkoningen M, Van Belle V, Brouckaert O, Christiaens M-R, Neven P, Peeters C. UZ Leuven, Leuven, Belgium; ESAT KULeuven, Leuven, Belgium.

1119

Targeting of mTOR is associated with decreased VEGF expression and secretion in cancer cells. Lackner EM, Krauth MT, Kondo R, Rebuzzi L, Eigenberger K, Vales A, Kornek GV, Zielinski CC, Valent P. Medical University Vienna, Internal Medicine I, Division of Oncology, Vienna, Austria; Medical University Vienna, Internal Medicine I, Division of Hematology and Hemostaseology, Vienna, Austria; Clinic for Int. Medicine and Infectious Disease, Vienna, Austria; Hanusch Krankenhaus, Vienna, Austria.

1108

A novel assay to assess the antiangiogenic potential of cytotoxic drugs in human breast cancer. Lyons, III JM, Anthony CT, Woltering EA. Louisiana State University Health Science Center, New Orleans, LA.

1109

Comparing serum levels of vascular endothelial growth factor in premenopausic women with breast cancer according to menstrual cycle phase. Rios Zaragoza S, Martinez Chequer J, Mainero Ratchelous F. Hospital “Luis Castelazo Ayala” IMSS, Mexico, DF, Mexico.

7:00-10:00

Tumor Cell Biology: Antigens and Markers 1110-1112 1110

Labeling pattern of breast cancer stem phenotype in invasive breast carcinomas: an immunohistochemical analysis. Shaye AN, Sahin AA, Huo L, Woodward WA. UT M.D. Anderson Cancer Center, Houston, TX.

1112

Differential proteomic profiles observed in FFPE breast tissue specimens of several pathologic states. Izbicka E, Streeper R, West FB, Yeh I-T. CTRC, San Antonio, TX; UTHSCSA, San Antonio, TX.

Tumor Cell Biology: Growth Factors / Inhibitors 1113-1119 1113

1114

1115

Susan G. Komen for the Cure proudly presents the 2007 Brinker Awards for Scientific Distinction featuring special guest and keynote speaker Ambassador Nancy G. Brinker.

Nuclear FoxO3a expression is associated with lymph node negative, ER+ invasive ductal carcinomas. Turashvili G, Fridman E, Romanska H, Lam E, Skarda J, Murray P, Kolar Z, Lalani E-N. Institute of Pathology, University Olomouc, Palacky, Czech Republic; Tel Aviv University, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv, Israel; Division of Cancer Studies, University of Birmingham, Birmingham, United Kingdom; Imperial College, London, United Kingdom.

1111

Insulin-like growth factor I activates gene transcription programs strongly associated with ER – breast cancer and poor patient prognosis. Creighton CJ, Casa A, Lazard ZW, Tsimelzon A, Hilsenbeck SG, Lee AV. Baylor College of Medicine, Houston, TX. HER-1 overexpression is found only in oestrogen receptor negative breast cancer and is rarely associated with HER-1 gene amplification. Pintens S, Vanden Bempt I, Drijkoningen M, Van Belle V, Brouckaert O, Christiaens M-R, Neven P, De Wolf-Peeters C. UZ Leuven, Leuven, Belgium; ESAT, Leuven, Belgium. Effectiveness of RAD001 (everolimus) in combination with endocrine therapy varies with cell phenotype. Farmer I, Pancholi S, Thornhill A, Evans DB, Lane HA, Dowsett M, Martin L-A. Institute of Cancer Research, London, United Kingdom; Novartis Institute for BioMedical Research-Basel, Basel, Switzerland.

SUSAN G. KOMEN FOR THE CURE BRINKER AWARDS FOR SCIENTIFIC DISTINCTION DINNER - Henry B. Gonzalez Convention Center Ballroom C

“Towards a Culture of Discovery: Progress and Passion in the Search for the Cures” will be an evening to remember as we celebrate Susan G. Komen for the Cure’s 25th anniversary, congratulate the 2007 Brinker Award Recipients, Joe W. Gray, PhD and Leslie Bernstein, PhD and honor the great achievements of our past Brinker Laureates – Henry B. Gonzalez Convention Center – Ballroom C. Please purchase your tickets to the 2007 Brinker Dinner when registering at www.sabcs.org. You may also purchase your tickets onsite at the Susan G. Komen for the Cure booth. Tickets will be awarded on a first-come, first-served basis. If you have additional questions, please contact [email protected] org.

Friday, December  7:00-9:00

POSTER DISCUSSION 2 & CONTINENTAL BREAKFAST – Ballroom B

Metastasis 201-210 201

A unique model of estrogen receptor (ER) Ĝ-positive breast cancer metastasis. Fuqua SA, Beyer A, Selever J, Hilsenbeck SG, Tsimelzon A, Cui Y. Baylor College of Medicine, Houston, TX.

202

Primary tumor heterogeneity and sentinel lymph node metastases: understanding molecular processes of breast cancer metastasis. Ellsworth DL, Ellsworth RE, Patney HL, Becker TE, Deyarmin B, Jordan RM, Hooke JA, Shriver CD. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC.

203

Identification of genetic predisposition to development of lymph node metastasis in breast cancer patients. Callaghan KA, Weyandt JD, Ellsworth RE, Shriver CD. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC.

204

Identification of new candidate breast cancer metastasis genes. Geradts J, Desouki MM, Liao S. Duke University Medical Center, Durham, NC; Medical University of South Carolina, Charleston, SC.

205

ALDH1 positive stem cells in inflammatory breast cancer mediate metastasis and are associated with a poor clinical outcome. Charafe-Jauffret E, Ginestier C, Tarpin C, Iovino F, Esterni B, Jacquemier J, Xerri L, Merajver S, Dontu G, Birnbaum D, Wicha M, Viens P. Institut Paoli-Calmettes, Marseille, France; Comprehensive Cancer Center, University of Michigan Medical Center, Ann Arbor, MI.

206

Programmed cell death 4, a novel inhibitor of breast cancer invasion. Nieves-Alicea R, Simeone AM, Colburn NH, Tari AM. The University of Texas M.D. Anderson Cancer Center, Houston, TX; National Cancer Institute, Frederick, MD.

207

TROP2 is a novel, major determinant in breast cancer growth and metastatization. Alberti S, Trerotola M, Vacca G, Zappacosta R, Rossi C, Guerra E, Bonasera V, Lasorda R, Lattanzio R, Piantelli M. Foundation University of Chieti, Chieti Scalo, Chieti, Italy.

208

Osteoblasts and their progenitors stimulate breast cancer cell migration through chemokine secretion. Molloy AP, Dwyer RM, Kerin MJ. National University of Ireland, Galway, Ireland.

209

Significance of PELP1/MNAR-mediated ER-nongenotropic actions in cytoskeleton signaling. Chakravarty D, Chandrasekharan Nair B, Rajhans R, Cortez V, Nair SS, Tekmal RR, deGraffenried LA, Sun LZ, Vadlamudi RK. UTHSCSA, San Antonio, TX.

210

2003

17ß-hydroxysteroid dehydrogenase type 1 is a predictive factor in premenopausal hormone receptor positive breast cancer treated with tamoxifen. Kallstrom A-C, Salme R, Ryden L, Gunnarsson C, Nordenskjold B, Stal O. Helsingborg Hospital, Helsingborg, Sweden; University Hospital, Linkoping, Sweden; University Hospital, Lund, Sweden.

2004

A high ratio of 17HSD1/17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer. Jansson A, Gunnarsson C, Persson L, Fornander T, Skoog L, Nordenskjöld B, Stål O. Linköping University, Linköping, Sweden; Karolinska University Hospital, Stockholm, Sweden.

2005

TOP2A gene amplification and response to adriamycin based therapy. Tubbs R, Barlow W, Budd GT, Swain E, Porter P, Yeh I-T, Sledge G, Shapiro C, Ingle J, Haskell C, Albain K, Livingston R, Hayes D. Cleveland Clinic, Cleveland, OH; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Texas Health Science Center at San Antonio, San Antonio, TX; Indiana University Medical Center, Indianapolis, IN; Arthur James Cancer Center Hospital, Columbus, OH; Mayo Clinic, Rochester, MN; UCLA Medical Center, Santa Monica, CA; Loyola University Medical Center, Maywood, IL; Arizona Cancer Center, Tucson, AZ; University of Michigan Medical Center, Ann Arbor, MI.

2006

Double staining chromogenic in situ hybridization is a useful alternative to fluorescent in situ hybridization: first comparative study of HER2 and TOP2A gene amplification in breast cancer. Lacroix-Triki M, Mounie E, Charafe-Jauffret E, Jacquemier J. Institut Claudius Regaud, Toulouse, France; Institut PaoliCalmettes, Marseille, France.

2007

Quantitative measurements of HER2 expression and HER2:HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment. Huang W, Lipton A, Leitzel K, Ali SM, Fuchs EM, Weidler J, Chappey C, Sperinde J, Tan Y, Jin X, Paquet A, Winslow J, Petropoulos C, Kostler WJ, Bates M. Monogram Biosciences, Inc., So San Francisco, CA; Penn State/Hershey Medical Center, Hershey, PA; Medical University of Vienna, Vienna, Austria.

2008

Inter-observer interpretative reproducibility of HER2 genotyping of a consecutive series of primary breast carcinomas by Silver In Situ Hybridization (SISH). Tubbs R, Myles J, Papouchado B, Lloyd R, Oliveira A, McElhinny A, Vladich F, Pestic-Dragovich L, Downs-Kelly E, Prescott N, Pettay J, Loftus M, Roberts C, Grogan T, Roche P. Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine, Cleveland, OH; Mayo Clinic, Rochester, MN; Ventana Medical Systems International, Tucson, AZ.

2009

HER2 tumors are heterogeneous, clinically, molecularly, and in response to preoperative trastuzumab: pathway analysis of gene expression profiles from three breast cancer datasets. Harris LN, Eklund AC, Carter S, Li X, Winer EP, Hilsenbeck S, Esteva FJ, Symmans WF, Pusztai L, Szallasi Z, Chang J. Yale University, New Haven, CT; Childrens Informatics Program, Boston, MA; Dana Farber Cancer Institute, Boston, MA; Baylor University, Houston, TX; MD Anderson Cancer Center, Houston, TX.

2010

Comparison of ERBB2 evaluation by immuno-histochemistry and a quantitative RT-PCR method in primary breast cancers. Giacchetti S, Lehmann-Che J, De Roquancourt A, Cuvier C, Hocini H, Bertheau P, De The H, Espié M, Turpin E. Hopital Saint-Louis, Assistance Publique-Hopitaux de Paris, Paris, France; Hopital Saint-Louis, APHP, Paris, France.

Lapatinib prevents the metastatic colonization of EGFR+ and Her-2+ breast cancer cells in the brain. Palmieri D, Gril BM, Herring J, Vega-Valle E, Hua EK, Leiwehr D, Steinberg SM, Gilmer TM, Rubin SD, Steeg PS. National Cancer Institute, Bethesda, MD; SAIC-NCI, Fredrick, MD; GlaxoSmithKline, Collegeville, PA.

7:00-9:00

POSTER SESSION 2 & CONTINENTAL BREAKFAST - Exhibit Hall B

(#2001-2121) Prognosis and Response Predictions: Predictive Factors I 2001-2026 2001

2002

Elevated serum TIMP-1/HER-2 predicts decreased response and survival in metastatic breast cancer. Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Guar V, Carney W. Penn State University/Hershey Medical Center, Hershey, PA; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for BioMedical Research Basel, Basel, Switzerland; Penn State/Hershey Medical Center; Lebanon VAMC, Lebanon, PA; Oncogene Science Biomarker Group/Siemens Medical Solutions Diagnostics, Cambridge, MA. Plasminogen activator inhibitor-1 and tissue inhibitor of metalloproteinases-1 are additive in predicting response to chemotherapy in metastatic breast cancer. Schrohl Rasmussen A-S, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Foekens JA, Brünner N. University of Copenhagen, Faculty of Life Sciences, Copenhagen, Denmark; Erasmus MC, Josephine Nefkens Institute, Rotterdam, Netherlands; Hvidovre Hospital, Hvidovre, Denmark; Rigshospitalet, Copenhagen, Denmark.

2011

Development of novel proximity-based immunoassays for the detection of HER heterodimerization in breast cancer cell line lysates and formalin-fixed, paraffin-embedded tissue. Eli* L, Shi* Y, Dao-Pick T, Bose J, Frankson K, Penuel E, Weston J, Pidaprthi S, Mukherjee A, Nguyen X-T, Williams S, Goodman L, Winslow J. Monogram Biosciences, South San Francisco, CA.

2019

Adding the estimation of cyclin D1 gene amplification to the standard panel of predictors in breast carcinoma can significantly improve identification of tumors resistant to tamoxifen. Petrakova K, Nenutil R, Vyskocil J, Fabian P, Palacova M, Hanzelkova Z, Knoflickova D. Masaryk Memorial Cancer Institute, Brno, Czech Republic.

2012

Characterization of a novel proximity immunoassay for the quantitative determination of HER2 protein expression and HER2 homodimerization in formalin-fixed, paraffinembedded breast cancer tissue. Winslow J, Shi Y, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidiparthi S, Chen L, Williams S, Larson J, Goodman L, Whitcomb J, Petropoulos C, Huang W. Monogram Biosciences, Inc., South San Francisco, CA.

2020

Single agent in vitro drug sensitivity of molecular breast cancer subtypes defined by gene expression analysis. Brase J, Schmidt M, Hengstler J, von Törne C, Kölbl H, Gehrmann M. University of Luebeck, Luebeck, Germany; University of Mainz, Mainz, Germany; University of Dortmund, Dortmund, Germany.

2021

Tumour volume analysis. A better way than RECIST? Gordon AB, Stebbing J, Coombes C. Charing Cross Hospital, London, United Kingdom.

2022

Association of an extracellular matrix gene cluster with breast cancer prognosis and response to tamoxifen. Helleman J, Jansen MPHM, Sieuwerts AM, van Staveren IL, Ritstier K, Look MP, Meijer-van Gelder ME, Klijn JGM, Foekens JA, Berns EMJJ. Erasmus MC, Rotterdam, Netherlands.

2023

Increased b1 integrin expression is a predictor of trastuzumab resistance in HER-2 overexpressing metastatic breast cancer patients. Thoms J, Sabri S, Lesniak D, Lai R, Deschennes J, Mackey J, Murray D, Abdulkarim B. University of Alberta, Edmonton, AB, Canada.

2024

Preliminary results from I-SPY trial: tumor patterns on pre-treatment MRI predict breast conservation therapy eligibility. Gomez R, Hylton N, Madhavan S, Leung E, Broadwater G, Herman B, Esserman L, ISPY Radiology, Clinical & Pathology Investigators. UCSF, San Francisco, CA; NCI, Bethesda, MD; CALGB, Durham, NC; ACRIN, Providence, RI.

2025

Molecular markers as predictors of breast cancer response to adjuvant epirubicin-CMF chemotherapy in the BR9601 trial. Bartlett JM, Munro AF, Cameron DA, Thomas J, Prescott R, Twelves C. University of Edinburgh, Edinburgh, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Bradford, Bradford, United Kingdom.

2026

Identification of molecular predictors of response of advanced breast cancer patients to aromatase inhibition. Haynes B, Ghazoui Z, Anderson H, Dunbier A, Dexter T, Mackay A, Smith IE, Dowsett M. Royal Marsden Hospital, London, United Kingdom; The Breakthrough Toby Robins Breast Cancer Research Centre, London, United Kingdom.

2013

HER2 and SPARC status in tumors play an important role in the relative effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel. Desai N, Trieu V, Hwang L, Wu R, Hawkins M, Soon-Shiong P, Gradishar W. Abraxis BioScience, Inc., Los Angeles, CA; Northwestern University, Chicago, IL.

2014

HER2 immunohistochemistry: comparison of image analysis based interpretation of CB11 and 4B5 clones using reference fluorescence in-situ hybridization. Fine JL, Bhargava R, Surti U, Dabbs DJ. Magee-Womens Hospital of UPMC, Pittsburgh, PA.

2015

Expression of the microtubule-associated protein, tau, predicts improved survival, but not response, to a combination of docetaxel and vinorelbine in HER-2 negative metastatic breast cancer. Gralow JR, Barlow WE, Gown AM, Goldstein LC, Porter PL, Yeh I-T, Livingston RB, Hayes DF. University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Phenopath, Seattle, WA; UT San Antonio, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; University of Michigan, Ann Arbor, MI.

2016

2017

2018

Microtubule-associated protein tau is a marker of pathological complete response in Her-2/neu positive neoadjuvant treated breast cancer patients. Rueckert S, Wirtz R, Lenhard M, Hasmueller S, Ditsch N, Ruehl I, Kahlert S, Bauerfeind I, Untch M. LMU, Universtity of Munich, Munich, Germany; Siemens Medical Solutions Diagnostics GmbH, Leverkusen, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany. Cyclin-dependent kinase 2 to 1 specific activity ratio predicts response to epirubicin and paclitaxel in human breast cancer. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S, Tsukamoto F, Akazawa K, Nakayama S, Matsushima T, Torikoshi Y, Ishihara H. Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; Osaka Koseinenkin Hospital, Osaka, Japan; Sysmex Corporation, Kobe, Hyogo, Japan. High pretreatment cyclin E levels may define a higher risk subset of basal-like breast cancers: in depth immunohistochemical analysis and clinical outcome of neoadjuvantly treated basal-like breast cancers. Osborne CR, Tripathy D, Allada N, Bian A, Xie X-J, Ashfaq R. UT Southwestern Medical Center, Dallas, TX; Baylor University Medical Center, Dallas, TX.

Risk and Prevention: Diet and Nutrition 2027-2031 2027

Diet, lifestyle, and BRCA-related breast cancer risk among French-Canadian. Ghadirian P, Nkondjock A, Robidoux A, Narod S. University of Montreal, Epidemiology Research Unit, Research Centre CHUM, Hôtel-Dieu, Montreal, QC, Canada; CHUM, Hôtel-Dieu, Montreal, QC, Canada; Women’s College Hospital - University of Toronto, Toronto, ON, Canada.

2028

Milk products are a source of dietary progesterone. Goodson III WH, Handagama P, Moore II DH, Dairkee S. California Pacific Medical Center Research Institute, San Francisco, CA.

2029

Cardioprotective effects of oral dietary glutamine in tumorbearing rats treated with doxorubicin. Todorova VK, Kaufmann Y, Klimberg VS. University of Arkansas for Medical Sciences, Little Rock, AR; Central Arkansas Veterans Healthcare System, Little Rock, AR.

2030

Effects of Korean red ginseng on the concentration of blood estrogen, leptin and urinary excretion of estrogen metabolites in postmenopausal women. Kang SH, Lee SJ, Baek NW, Kim EM. Yeungnam University Medical Center, Daegu, Korea.

2031

Breast cancer survivors who use selected herbal supplements have lower circulating estradiol and free estradiol: the Health, Eating, Activity and Lifestyle study. Wayne SJ, Koprowski C, Neuhouser ML, Ulrich CM, Bernstein L, Gilliland F, Wiggins C, Baumgartner K, Baumgartner R, McTiernan A, Ballard-Barbash R. University of New Mexico, Albuquerque, NM; University of Southern California, Los Angeles, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; National Cancer Institute, Bethesda, MD.

Risk and Prevention: Familial Breast Cancer / Genetic Testing 2032-2051 2032

2033

2034

Toward individualized risk prediction: the clinical benefit of risk reduction mastectomy and oophorectomy in BRCA carriers with breast cancer. Burke HB, Hoang A, Metcalfe K, Culver JO, MacDonald DJ, Grant M, Thornton A, Robson M, Narod S, Weitzel JN. George Washington University, Washington, DC; University of Toronto, Toronto, ON, Canada; Memorial Sloan Kettering CA Ctr, New York, NY; City of Hope, Duarte, CA. A BRCA1 or BRCA2 mutation and young age predict fast breast cancer growth. Implications for screening? Tilanus-Linthorst MM, Obdeijn I-M, Hop WC, Causer P, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, Gilbert FJ. Erasmus University MC, Rotterdam, Netherlands; Sunnnybrook & Women’s Health Sciences Centre, Toronto, Canada; Institute of Cancer Research and Royal Marsden NHS, Sutton, Surrey, United Kingdom; Addenbrooke’s Hospital and University, Cambridge, United Kingdom; University of Aberdeen, Aberdeen, United Kingdom. Breast carcinoma in situ and the prevalence of BRCA1 and BRCA2 mutations in a large commercial database. Hall MJ, Reid JE, Noll WW, Frye CA, Burbidge LA, Wenstrup RJ. Herbert Irving Comprehensive Cancer Center, New York, NY; Myriad Genetic Laboratories, Inc., Salt Lake City, UT.

2035

Lifetime risk for breast and ovarian cancer in postmenopausal BRCA carriers: cause for concern? Tice JA, Crawford B, Ziegler J, McLennan J, Beattie M. UCSF, San Francisco, CA.

2036

BRCA1- and BRCA2-associated breast cancer is more sensitive to standard chemotherapy for metastatic disease in comparison with sporadic breast cancer. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee M, MenkePluymers MBE, Bartels CCM, van den Ouweland A, van Geel B, Hooning M, Brekelmans CTM, Klijn JGM. ErasmusMC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands.

2037

BRCA mutation in Chinese population: preliminary results from the Hong Kong hereditary and high risk breast cancer programme. Kwong A, Wong CLP, Ma E, Ford JM. The University of Hong Kong; Hong Kong Santorium and Hospital, Hong Kong; Stanford University, CA.

2038

The CHEK2*1100delC variant: present in the west of Ireland breast cancer population. Colleran GC, Rowan A, Miller N, Sawyer E, Curran C, Kerin M, Tomlinson I. National University of Ireland Galway, Galway, Ireland; London Research Institute, Cancer Research UK, London, England, United Kingdom.

2039

Addressing the needs of men in BRCA1/2 families. Daly MB. Fox Chase Cancer Center, Philadelphia, PA.

2040

Identification of a recurring BRCA1 mutation in Bahamian women with breast cancer. Donenberg T, Turnquest T, Lunn J, Curling D, Krill-Jackson E, Hurley J. University of Miami/Jackson Memorial Hospital, Miami, FL; Doctor’s Hospital, Nassau, Bahamas; Princess Margaret Hospital, Nassau, Bahamas; Mount Sinai Comprehensive Cancer Center, Miami Beach, FL.

2041

BRCA1 and BRCA2 mutation carrier predictions using the BRCAPRO model in clinic-based minority families. Huo D, Senie RT, Terry MB, Daly MB, Buys SS, Ogutha J, Hope K, Olopade OI. University of Chicago, Chicago, IL; Columbia University, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; University of Utah Health Sciences Center, Salt Lake City, UT.

2042

Outcome in BRCA2 mutation carriers is superior to that of high-risk women with sporadic breast cancer. McLennan JL, Hwang ES, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. University of California, San Francisco, CA.

2043

BRCA mutations among women with bilateral breast cancer: mutation carrier rate and sensitivity of the BRCAPRO model based on age at first diagnosis. Ready K, Vogel K, Atchley D, Amos C, Solomon K, Lu K, Arun B. The University of Texas M.D. Anderson Cancer Center, Houston, TX.

2044

Large genomic alterations in BRCA1 in young women with breast cancer participating in the breast cancer family registry. Smith LD. Genetic Epidemiology Laboratory, The University of Melbourne, Parkville, VIC, Australia.

2045

Clinical characteristics and choices regarding prophylactic surgery in BRCA mutation carriers. Stuckey A, Dizon D, Legare R, Wilbur J, Kent J, Tejada-Berges T, Gass J. Women and Infants’ Hospital/Warren Alpert Medical School of Brown University, Providence, RI.

2046

Cancer-predictive methylation patterns in hereditary breast cancer. Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, Vooijs M, van der Wall E, van Diest PJ. University Medical Center Utrecht, Utrecht, Netherlands; Johns Hopkins, Baltimore, MD.

2047

BRCA testing in underserved women: 5 years of follow-up. Wilcox C, Lee R, Chan S, Crawford B, Luce J, Ziegler J, Beattie MS. San Francisco General Hospital, San Francisco, CA; University of California, San Francisco, San Francisco, CA.

2048

Prophylactic surgeries among BRCA1/2 mutation carriers in the Netherlands. Hooning MJ. The Collaborative Group on Hereditary Breast and Ovarian Cancer in the Netherlands (HEBON).

2049

Breast cancer outcomes in an ethnically diverse clinic-based cohort of high-risk individuals. Nanda R, Spyrka S, Huo D, Cook M, Chen L, Hope K, Cummings S, Olopade O. University of Chicago, Chicago, IL.

2050

Different rate of BRCA1/BRCA2 predisposing mutations according to family history and clinical criteria of breast/ ovarian cancer risk. Sidoni T, De Marchis L, Midulla C, Capalbo C, Giusti R, Paris I, Assalone P, Rocchi A, Ronzino G, Di seri M, Scambia G, Ficorella C, Marchetti P, Cortesi E, Frati L, Gulino A, Giannini G, Ricevuto E. University of L’Aquila, Medical Oncology, L’Aquila, Italy; University “La Sapienza”, Service of Molecular and Ultrastructural Pathology, Rome, Italy; University “La Sapienza”, Medical Oncology, Rome, Italy; UCSC, Campobasso, Italy; S. Carlo Hospital, Rome, Italy; S. Andrea Hospital, Rome, Italy.

2051

Endogenous sex hormones and family history of breast cancer in Chinese women. Zhou L, Yin W, Lu J, Di G, Wu J. Cancer Hospital, Shanghai, China.

2061

A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. Liang H, Brufsky AM, Lembersky BB, Rastogi P, Vogel VG. University of Pittsburgh Cancer Institute, Pittsburgh, PA.

2062

A cohort study of the total health care costs for modern treatment of disseminated breast cancer. Dahlberg L, Lindman H, Lundkvist J. Uppsala University, Uppsala, Sweden; European Health Economics, Stockholm, Sweden.

2063

Halved pegfilgrastim doses in adjuvant breast cancer patients associated with similar efficacy but reduced toxicity. Bartelt ME, Harman S, Lower EE. University of Cincinnati, Cincinnati, OH.

2064

Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil. Vernaglia PR, Cunha FM, Correa M, Perdicaris MR, Saggia MG, Santos EAV, Nasciben VD, Pelizon C. Brazilian Institute for Cancer Control, São Paulo, SP, Brazil; Campinas Medical Center, Campinas, SP, Brazil; A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil; Beneficência Portuguesa Hospital, Santos, SP, Brazil; Roche Pharmaceuticals, São Paulo, SP, Brazil.

2065

Cost comparison of capecitabine in the treatment of patients with breast cancer: an analysis from a claims database. Rugo HS, Schulman KL, Zelt S. University of California San Francisco, San Francisco, CA; Thomson Healthcare, Cambridge, MA; Roche Labs Inc., Nutley, NJ.

Treatment: Bone Metastases 2052-2057 2052

2053

Systemic treatment of transforming growth factor-beta (TGFĝ) antagonists inhibited osteolytic bone metastasis induced by human breast cancer cells. Bandyopadhyay A, Wang L, Agyin JJ, Lopez-Casillas F, Tang Y, Sun LZ. University of Texas Health Science Center, San Antonio, TX; Universidad Nacional Autónoma de México, Mexico DF, Mexico. Bone-derived IGF-1 enhances bone pain through activation of acid-sensing nociceptors in bone metastases of breast cancer. Sakurai T, Umemura T, Yono H, Williams P, Farias A, Yoneda T. Wakayama Medical University Kihoku Hospital, Ito, Wakayama, Japan; University of Texas Health Center San Antonio, San Antonio, TX.

2054

Patients’ disease and treatment parameters significantly affect survival in metastatic breast cancer. Major P, Cook R. Juravinski Cancer Centre, Hamilton, ON, Canada; University of Waterloo, Waterloo, ON, Canada.

2055

Natural history of skeletal complications in patients receiving chemotherapy for breast cancer metastatic to bone. Major P, Cook R. Juravinski Cancer Centre, Hamilton, ON, Canada; University of Waterloo, Waterloo, ON, Canada.

2056

Application of preventive measures minimizes the occurrence of the osteonecrosis of the jaw (ONJ) in solid tumors patients (pts) with bone metastases treated with bisphosphonates (BPs): a single Institution series. Ripamonti C, Maniezzo M, Cislaghi E, Campa T, Fagnoni E, Saibene G, Bareggi C, Ascani L, Pigni A, Brunelli C. National Cancer Institute, IRCCS Foundation, Milano, Italy.

2057

Treatment: Endocrine Therapy 2066-2106 2066

Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Dixon JM, Jonat W, Rugo HS. Hospital Vall d’Hebron, Barcelona, Spain; NN Petrov Research Inst of Oncology, St. Petersburg, Russian Federation; Onc Centrum St Augustinus, Wilrijk, Belgium; City Oncological Dispensary, St. Petersburg, Russian Federation; Hospital Clinico Univ Lozana Blesa, Zaragoza, Spain; Centre Rene Gauducheau, Nantes, France; General Hospital, Vienna, Austria; Univ Hospital, Salzburg, Austria; Novartis Pharma AG, Basel, Switzerland; Istituto Nazionale Tumori, Milan, Italy; Western General Hospital, Edinburgh, United Kingdom; Univ-Frauenklinik, Kiel, Germany; Univ of CA SF, San Francisco, CA.

2067

Randomized Phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Osborne K, Neven P, Dirix L, Mackey J, Robert J, Underhill C, Gutierrez C, Magill P, Hargreaves L. Baylor College of Medicine, Houston, TX; Gasthuisberg, Leuven, Belgium; Sint Augustinus Oncologisch, Wilrijk, Belgium; Cross Cancer Institute, Edmonton, Canada; CHAUQ Hospital du St-Sacrement, Quebec, Canada; Murray Valley Private Hospital, Wondonga, Australia; AstraZeneca, Macclesfield, United Kingdom.

2068

Withdrawn.

Bone pain effectiveness and renal safety of ibandronate in breast cancer patients - are results of controlled clinical trials consistent with daily clinical practice? Interim analysis of a non-interventional post marketing surveillance trial in Germany. Meden H, Kuehnle H, Seraphin J, Soeling U, Luhn B. Diakoniekrankenhaus Rotenburg, Germany; Medizinische Hochschule Hannover, Hannover, Germany; Haematological and Oncological Practice, Northeim, Germany; Kassel, Germany; Hamburg, Germany.

Treatment: Cost Effectiveness 2058-2065 2058

Cost-effectiveness of late extended adjuvant letrozole following a prolonged therapy break from tamoxifen MA-17 post-unblinding analysis. Karnon J, DiTrapani F, Kaura S. University of Sheffield, Sheffield, Yorkshire, United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ.

2059

Comparison of cost of distant disease-free year gained of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective. El Ouagari K, Karnon J, Kaura S. Novartis, Dorval, QC, Canada; University of Sheffield, Sheffield, United Kingdom; Novartis, East Hanover, NJ.

2060

Surgical follow-up for low to average risk breast cancer patients: too much too soon? Khokhotva V, George RL, Khokhotva M. Kingston General Hospital, Queen’s University, Kingston, ON, Canada.

2069

Hot flushes and the risk of recurrence - retrospective, exploratory results from the ATAC trial.

2080

Increased prevalence of retinal hemorrhages among anastrozole users. Eisner A, Falardeau J, Toomey MD, Vetto JT. Oregon Health & Science University, Beaverton, OR; Oregon Health & Science University, Portland, OR.

2081

New treatment strategies using aromatase inhibitors: a preclinical study. Chen S, Phung S, Masri S. Beckman Research Institute of the City of Hope, Duarte, CA.

2082

A placebo-controlled trial examining the effects of letrozole on mammographic breast density and bone and lipid metabolism. Cigler T, Yaffe MJ, Johnston D, Verma S, Findlay B, Wadden N, Pater JL, Richardson H, Tu D, Shangle Q, Goss PE. Massachusetts General Hospital, Boston, MA; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Niagara Health System, St. Catharines, ON, Canada; Memorial University of Newfoundland, St. John’s, NL, Canada; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; (NCIC CTG) MAP.1.

2083

Survival analysis of first-line tamoxifen versus aromatase inhibitors for estrogen-positive metastatic breast cancer in postmenopausal women - a BC perspective. Kyritsis V, De Lemos M, Walker B, Kennecke H, Nakashima L. BC Cancer Agency, Vancouver, BC, Canada; Queens University Belfast, Belfast, Ireland.

2084

Impact of CYP2A6 genotype on pharmacokinetics, safety and efficacy of letrozole treatment in Japanese postmenopausal women with metastatic breast cancer. Minami H, Ohsumi S, Nakamura S, Inaji H, Takenoshita S, Fujiwara Y, Iino Y, Woo M, Tanii H, Tominaga T, Takashima S. CGS20267 Collaborate Study Group, Tokyo, Japan.

2085

Bone health and anastrozole adverse events in Japan. Sagara Y, Rai Y. Hakuaikai Sagara Hospital, Kagoshima City, Kagoshima Prefecture, Japan.

2086

The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: preliminary results of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study. Aihara T, Hozumi Y, Suemasu K, Takei H, Takehara M, Osumi S, Saito T, Masuda N, Ohashi Y. Aihara Hospital, Minoo, Osaka, Japan; Jichi Medical University, Shimono, Tochigi, Japan; Saitama Cancer Center, Kitaadachi, Saitama, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shikoku Cancer Center, Matsuyama, Ehime, Japan; Saitama Red Cross Hospital, Saitama, Saitama, Japan; Osaka National Hospital, Osaka, Japan; The University of Tokyo, Tokyo, Japan.

2087

LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breast cancer. Preliminary report of activity and cardiac tolerability. Frassoldati A, Guarneri V, Cagossi K, Bottini A, Cavanna L, Jovic G, Piacentini F, Oliva C, Conte P. University of Modena, Modena, Italy; Ramazzini Hospital, Carpi, Modena, Italy; Azienda Ospedaliera, Cremona, Italy; General Hospital, Piacenza, Italy; Glaxo SmithKline, Greenford, United Kingdom.

Cuzick J. Wolfson Institute of Preventive Medicine, London, United Kingdom. 2070

Withdrawn.

2071

Risk factors for joint symptoms in the ATAC trial. Sestak I, on Behalf of the ATAC Trialists’ Group. Wolfson Institute of Preventive Medicine, London, United Kingdom.

2072

Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. Renshaw L, McHugh M, Williams L, Dixon OM, Fallowfield LJ, Evans DB, Dixon JM. Western General Hospital, Edinburgh, Scotland, United Kingdom; University of Edinburgh, Edinburgh, Scotland, United Kingdom; Brighton & Sussex Medical School, Falmer, Sussex, United Kingdom; Novartis Institutes for BioMedical Research Basel, Basel, Switzerland.

2073

The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial. Eastell R, Coleman R, Mansel R, Bianco A, Nagykalnai T, Cuzick J, on Behalf of the ATAC Trialists’ Group. Academic Unit of Bone Metabolism, Sheffield, United Kingdom; Cancer Research Centre, Sheffield, United Kingdom; University of Wales College of Medicine, Cardiff, United Kingdom; Universita Degli Studi De Napoli Federico II, Naples, Italy; Uzsoki H Hospital, Budapest, Hungary; Cancer Research UK, London, United Kingdom.

2074

A randomised study of the effects of letrozole and anastrozole on bone turnover. McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM. Western General Hospital, Edinburgh, Scotland, United Kingdom; Medical School, University of Edinburgh, Edinburgh, Scotland, United Kingdom; Northern General Hospital, Sheffield, England, United Kingdom.

2075

Increased efficacy and combination therapy: targeted letrozole/estrogen receptor-ĝ specific ligand nanoparticles homing to mammary tumors in HER-2/aromatase double transgenic mice. Nair HB, Santhamma B, Agyin JK, Perla RP, Rossini G, Kirma NB, Liu Y-G, Evans DB, Tekmal RR. University of Texas Health Science Center at San Antonio, San Antonio, TX; Southwest Research Institute, San Antonio, TX; Novartis Pharma AG, Basel, Switzerland.

2076

Molecular characterization of aromatase inhibitor resistance: a genome-based approach. Masri S, Phung S, Wang X, Wu X, Yuan Y-C, Chen S. Beckman Research Institute of the City of Hope, Duarte, CA.

2077

Therapeutic strategies using aromatase inhibitors and tamoxifen in a post-menopausal breast cancer model. Alami N, Li Z, Macedo LF, Brodie A, Leyland-Jones B. VM Institute of Research, Montreal, QC, Canada; U. of Maryland, Baltimore, MA; McGill University, Montreal, QC, Canada.

2078

Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment. Bertelli G, Hall E, Ireland E, Jassem J, Bliss JM, Snowdon CF, Coombes RC. Singleton Hospital, Swansea, United Kingdom; Institute of Cancer Research, Sutton, United Kingdom; Medical University of Gdansk, Poland; Imperial College London, United Kingdom; on behalf of the IES Group.

2079

Adjuvant aromatase inhibitors in early breast cancer toxicity and adherence. Important observations in clinical practice. Dent SF, Hopkins S, Di Valentin T, Verreault J, Vandermeer L, Verma S. The Ottawa Hospital Regional Cancer Centre (TOHRCC), Ottawa, ON, Canada.

2088

2089

Health-related quality of life and psychological distress in Japanese patients with breast cancer treated with tamoxifen, exemestane or anastrozole for adjuvant therapy: a phase III randomized study of National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04. Takehara M, Ohsumi S, Takei H, Shimozuma K, Ohashi Y, Suemasu K, Hozumi Y. Jichi Medical University, Shimotsuke, Tochigi, Japan; National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan; Saitama Cancer Center, KitaAdachi, Saitama, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; University of Tokyo, Bunkyo, Tokyo, Japan; Arche Clinic Breast Center, Omiya, Saitama, Japan. The lipid metabolism of SERMs and AI with primary breast cancer: combined results of Multi 01 and 02 trial. Kusama M, Mitsuyama S, Yanagita Y, Doihara H, Komaki K, Ikeda T, Kimura M, Sano M, Miyauchi K, Anan K. Shinjuku Breast Center, Tokyo, Japan; Kitakyushu Municipal Medical Center, Fukuoka, Japan; Gunma Cancer Center, Gunma, Japan; Okayama University Medical School, Okayama, Japan; Breastopia NAMBA Hospital, Miyazaki, Japan; Teikyo University School of Medicine, Tokyo, Japan; Ota General Hospital, Gunma, Japan; Niigata Association of Occupational Health Inc., Niigata, Japan; Miyauchi Clinic, Hyogo, Japan.

2090

Estrogen deprivation is crucial for the antitumor effect of fulvestrant and adding the HER inhibitor gefitinib delays acquired resistance in a xenograft model of ER-positive breast cancer. Massarweh S, Osborne K, Heidi W, Schiff R. University of Kentucky and Markey Cancer Center, Lexington, KY; Baylor College of Medicine and Dan L. Duncan Cancer Center, Houston, TX.

2091

Fulvestrant vs exemestane following non-steroidal aromatase inhibitor failure: first overall survival data from the EFECT trial. Chia S, Piccart M, Gradishar W, on Behalf of the EFECT Writing Committee. British Columbia Cancer Agency, Vancouver, BC, Canada; Jules Bordet Institute, Brussels, Belgium; Robert H. Lurie Comprehensive Cancer Centre of Northwestern University, Chicago, IL.

2092

Pharmacokinetic profile of the fulvestrant (Fasolodex™) loading-dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. McCormack PJ, Sapunar F. AstraZeneca, Macclesfield, Cheshire, United Kingdom.

2093

Fulvestrant does not stimulate endometrial growth in postmenopausal breast cancer patients. Morales L, Neven P, Timmerman D, Wildiers H, Konstantinovic ML, Tan PN, Christiaens M-R, Paridaens R. University Hospitals KULeuven; Faculty of Medicine, KULeuven, Belgium.

2094

Fulvestrant in pretreated postmenopausal patients with metastatic breast cancer: analysis from the French multicentre compassionate use programme. Gligorov J, Antoine EC, Dalenc F, Namer M, Chollet P, Spielmann M, Campone M, Zelek L, Debled M. APHP Tenon, Paris, France; Clinique Hartmann, Neuilly, France; APHP H Mondor, Creteil, France; Centre Antoine Lacassagne, Nice, France; Institut Gustave Roussy, Villejuif, France; Centre Claudius Regaud, Toulouse, France; Centre Bergonie, Bordeaux, France; Centre Rene Gauducheau, Nantes, France; Centre Jean Perrin, Clermont Ferrand, France.

2095

Plasma immunoreactive estradiol is increased during therapy with fulvestrant in menopausal breast cancer patients. Illarramendi JJ, Salgado E, Vera R, Rivero A, Tirapu B, Del Rio L, Lainez N, Martinez M. Hospital de Navarra, Pamplona, Spain.

2096

HDAC inhibitors sensitize ER negative breast cancer cells to AIs. Sabnis GJ, Gediya LK, Njar VCO, Brodie AMH. University of Maryland, School of Medicine, Baltimore, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD.

2097

Phase II trial of the HDAC inhibitor, vorinostat, in combination with tamoxifen for patients with advanced breast cancer who have failed prior anti-hormonal therapy. Lacevic M, Minton SE, Schmitt ML, Bicaku E, Marchion DC, Munster PN. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

2098

Tamoxifen resistance and tumor initiation mediated by Dicer overexpression in breast cancer progenitor cells - role of BCRP. Selever J, Lewis MT, Corona-Rodriguez A, Tsimelzon A, Fuqua SA. Baylor College of Medicine, Houston, TX.

2099

Co-prescription rates of tamoxifen and CYP2D6 inhibitors: are we compromising breast cancer outcome? Connolly RM, Barron TI, Feely J, Kennedy MJ. Mater Misericordiae Hospital, Dublin, Ireland; Trinity College Dublin, Dublin, Ireland; Trinity College Dublin & St James’s Hospital, Dublin, Ireland.

2100

Association of chemotherapy and estrogen receptor genotype with change in bone mineral density after one year of tamoxifen therapy. Henry NL, Nguyen A, Robarge J, Li L, Hayden J, Lemler S, Schott A, Skaar TC, Flockhart DA, Hayes DF, Stearns V, Consortium on Breast Cancer Pharmacogenomics (COBRA) Investigators. University of Michigan, Ann Arbor, MI; Indiana University, Indianapolis, IN; Johns Hopkins University, Baltimore, MD.

2101

Late tamoxifen treatment in patients previously operated for breast cancer without postoperative tamoxifen: interim analysis. La Mura N, Magri MD, Scalone S, Da Ronch L, Miolo G, Freschi A, Veronesi A. Centro di Riferimento Oncologico, Aviano, PN, Italy.

2102

Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer. Chernozemsky I, Kalinov K, Tzekov H, Racheva M, Hristova S, Tomova A, Koynova T, Taskova V, Boideva L, Eniu A, Krasteva E. National Oncology Centre, Sofia, Bulgaria; New Bulgarian University, Sofia, Bulgaria; University Hospital “Sv. Marina”, Varna, Bulgaria; Dispensary of Oncological Diseases, Veliko Tarnovo, Bulgaria; Dispensary of Oncological Diseases, Plovdiv, Bulgaria; Dispensary of Oncological Diseases, Sofia, Bulgaria; Dispensary of Oncological Diseases, Varna, Bulgaria; Dispensary of Oncological Diseases, Haskovo, Bulgaria; Institute of Oncology, Cluj Napoca, Romania.

2103

Tamoxifen withdrawal syndrome. Sedlacek SM, Sedlacek JE. Rocky Mountain Cancer Centers, Denver, CO; Dartmouth College, Hanover, NH.

2104

Downregulated expression of SIAH2, an ubiquitin E3 ligase, is associated with endocrine therapy failure. Jansen MP, Ritstier K, Dorssers LC, van Staveren IL, Helleman J, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Klijn JG, Foekens JA, Berns EM. Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, Netherlands.

2105

PET FES measures uterine and tumor in vivo pharmacodynamics of endocrine therapy. Linden HM, Peterson LM, Schubert EK, Sandarajan L, Mankoff DA. University of Washington, Seattle, WA.

2106

Adjuvant hormonal therapy choice in women with early stage breast cancer. Song X, Nicholas G, Dent S, Verma S. The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada.

2117

Lentivirus-mediated oncogene delivery to initiate tumors in mouse mammary epithelial cells. Siwko S, Lewis B, Gutierrez C, Li Y. Baylor College of Medicine, Houston, TX; University of Massachusetts Medical Center, Worcester, MA.

2118

FGFR1 amplification is a breast cancer treatment target and is associated with endocrine therapy resistance. Turner NC, Iorns E, Smith A, Lambros MB, Reis-Filho JS, Ashworth A. The Institute of Cancer Research, London, United Kingdom.

2119

Identification of proline-, glutamic acid-, leucine, rich protein (PELP1) as a novel CDK4 substrate and characterizing its role in breast cancer cell proliferation. Chandrasekharan Nair B, Nair SS, Chakravarty D, Rajhans R, Cortez V, Yew RP, Tekmal R, Vadlamudi RK. UTHSCSA, San Antonio, TX.

2120

The regulation of LKB1 by hormones and its implications for post-menopausal breast cancer. Brown KA, McInnes KJ, Simpson ER. Prince Henry’s Institute, Clayton, Victoria, Australia; Monash University, Clayton, Victoria, Australia.

2121

Androgen receptor CAG repeats, haplotypes, non-random X chromosome inactivation, and LOH at Xq25 in relation to breast cancer risk. Chien H-T, Tsai H-C, Chen S-T, Chien Y-C. National Changhua University, Changhua, Taiwan, Taiwan; Changhua Christian Hospital, Changhua, Taiwan, Taiwan.

Tumor Cell Biology: Imunology / Immunotherapy 2107-2114 2107

A systematic review of the role of adjuvant ovarian ablation in the treatment of women with early stage breast cancer. Eisen A, Messersmith H, Trudeau M. Cancer Care Ontario, ON, Canada; McMaster University, Hamilton, ON, Canada.

2108

Trilostane (modrenal) as a hormonal treatment for postmenopausal women with breast cancer. Sabine VS, Speirs V, Macaskill JE, Shaaban AM, Campbell F, Renshaw L, Faratian D, Bartlett JM, Dixon MJ. University of Edinburgh, Edinburgh, United Kingdom; University of Leeds, Leeds, United Kingdom.

2109

Characterization of anti-MUC1 immune response in patients with in situ, early and locally-advanced breast cancer. Geller BA, Lepisto AJ, McKolanis JR, Ahrendt GM, Potter DM, Finn OJ, Brufsky AM. University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Pittsburgh School of Medicine, Pittsburgh, PA; University of Pittsburgh Cancer Institute; MageeWomens Hosptial of UPMC, Pittsburgh, PA.

2110

2111

Relation of intratumoral B-cells and response to neoadjuvant chemotherapy. Lenhard MS, Wirtz RM, Hasmueller S, Rueckert S, Ditsch N, Ruehl I, Kahlert S, Bauerfeind I, Untch M, on Behalf of the Participating Centers. Ludwig-Maximilians-University of Munich, Munich, Germany; Molecular Research, Leverkusen, Germany; Helios Hospital, Berlin-Buch, Germany. Decreased accumulation of CD163-positive macrophages is associated with nodal metastases in patients with breast cancer. Mansfield AS, Heikkila P, Vakkila J, von Smitten K, Leidenius M. Helsinki University Central Hospital, Helsinki, Finland; University of Helsinki, Helsinki, Finland.

2112

Immunological status of micrometastasis-positive sentinel nodes in breast cancer patients. Matsuura K, Osaki A, Saeki T, Ohara M, Murakami S, Arihiro K. International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Research Institute for Radiation Biology and Medicine, Hiroshima, Japan; Hiroshima University, Hiroshima, Japan.

2113

Clinicopathological significance of regulatory T cells in breast cancer. Ohara M, Murakami S, Yamaguchi Y, Arihiro K. Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; Kawasaki Medical School, Kurashiki, Okayama, Japan; Hiroshima University, Hiroshima, Japan.

2114

Alternatively activated macrophages promote the invasiveness of breast cancer cells. Gong C, Zhang X, Liu S, Yu F, Su F, Song E. Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China.

9:00-9:30

Energy balance, insulin, and breast cancer Michael Pollak, MD McGill University Montreal, CANADA

9:30-11:15

Mechanism of action of herceptin killing of HER-2+ breast cancer cells under “in vitro” and “in vivo” conditions. Kute TE, Savage L, Wood J, Vaughn J. Wake Forest University Medical Center, Winston-Salem, NC; Wake Forest University, Winston-Salem, NC.

2116

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I clinical trial. Patil R, Holmes JP, Amin A, Carmichael M, Jama YH, McNeill A, Hueman MT, Craig D, Ponniah S, Peoples GE. Windber Medical Center, Windber, PA; National Naval Medical Center, Bethesda, MD; USUHS, Bethesda, MD; Brooke Army Medical Center, Ft. Sam Houston, TX.

GENERAL SESSION 3 – Exhibit Hall D

9:30

31. Genomic approaches to breast cancer subset identification and treatment. Albertson D, Chin K, Devries S, Feiler H, Pinkel D, Spellman P, Waldman F, Wang N, Hennessy B, Mills G, Barcellos Hoff MH, Bissell M, Guan Y, Hu Z, Kuo W-L, McCormick F, Neve R, Stampfer M, Wooster R, Yaswen P, Das D, Fridlyand J, Correll E, Jin J, Nordmeyer B, Sudar D, Chew K, Dairkee S, Ljung BM, Hwang S, Esserman L, Arbushites M, Benz C, Koehler M, Marks JD, Zhou Y, Park J, Weber B, Gray J. University of California, San Francisco, CA; Lawrence Berkeley National Laboratory, Berkeley, CA; MD Anderson Cancer Center, Houston, TX; GlaxoSmithKline, King of Prussia, PA; California Pacific Medical Center, San Francisco, CA; Buck Institute for Age Research, Novato, CA; Genentech, South San Francisco, CA.

9:45

32. Genome-wide analysis of DNA copy number alterations in conjunction with gene expression profiling identifies DNA amplification loci that predict distant recurrence in lymph node-negative (LNN) primary breast cancer patients. Zhang Y, Klijn J, Yu J, Jiang J, Jatkoe T, Sieuwerts A, Martens J, Wang Y, Foekens J. Johnson & Johnson, San Diego, CA; Erasmus MC, Rotterdam, Netherlands.

10:00

33. Gene expression profiles of ER+/PR-breast cancer are associated with genomic instability and Akt/mTOR signaling, and predict poor patient outcome better than clinically assigned PR status. Creighton CJ, Osborne CK, van de Vijver M, Foekens JA, Wang Y, Zhang Y, Klijn JGM, Horlings HM, Hilsenbeck SG, Lee AV, Schiff R. Baylor College of Medicine, Houston, TX; Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus MC-Daniel den Hoed, Rotterdam, Netherlands; Veridex LLC, a Johnson & Johnson Company, San Diego, CA.

Tumor Cell Biology: Oncogenes/Tumor Suppressor Genes 2115-2121 2115

PLENARY LECTURE 3 – Exhibit Hall D

10:15

10:30

10:45

11:00

34. Expression of alphavbeta6 supersedes Her2 and triplenegative/basal classification of breast cancer and defines novel subgroups with poor survival: implications for breast cancer classification and treatment. Jones JL, Thomas GJ, Duffy SW, Chou P, Gabe R, Ellis I, Green A, Saha A, Mulligan KT, Ryder K, Gillet C, Violette S, Weinreb P, Hart IR, Marshall JF. Bart’s and the London, Queen Mary’s School of Medicine and Dentistry, London, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; Guy’s Hospital, London, United Kingdom; Biogen Idec, Cambridge, MA. 35. A stroma-related gene signature predicts resistance to epirubicin-containing neoadjuvant chemotherapy in breast cancer. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Tubiana-Hulin M, MacGrogan G, Petit T, Jassem J, Rouanet P, Blot E, Bogaerts J, Bergh J, Iggo R, Delorenzi M. National Centre of Competence in Research (NCCR) Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland; European Organisation for Research and Treatment of Cancer (EORTC), Breast Cancer Group, Brussels, Belgium; The Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; The Anglo-Celtic Cooperative Oncology Group (ACCOG), Edinburgh University, Edinburgh, United Kingdom; The Swedish Breast Cancer Group (SweBCG), Karolinska Institute, Stockholm, Sweden. 36. The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trastuzumab trial. Reinholz MM, Jenkins RB, Hillman D, Lingle WL, Davidson N, Martino S, Kaufman P, Kutteh L, Perez EA. Mayo Clinic College of Medicine, Rochester, MN; John Hopkins, Baltimore, MD; The Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Mayo Clinic College of Medicine, Jacksonville, FL.

2:00

The women’s health initiative randomized trials of menopausal hormone therapy: Results and impact on clinical practice Rowan Chlebowski, MD, PhD LA Biomedical Research Institute Torrance, CA

2:30

A review of HRT and breast cancer in other epidemiologic studies Jack Cuzick, PhD Wolfson Institute of Preventive Medicine London, UNITED KINGDOM

3:00

Understanding changes in breast cancer incidence. Interactions between epidemiological and clinical trial evidence. Peter Ravdin, MD, PhD MD Anderson Cancer Center Houston, TX

3:30-5:00 3:30

41. ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion. Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M on behalf of the ATAC Trialists’ Group. University of Newcastle, Calgary Mater Hospital, NSW, Australia; Cancer Research UK, UK; M.D. Anderson Cancer Center, USA; Christie Hospital, UK; Portland Hospital, UK.

3:45

42. Mid-term efficacy of a breast cancer screening program for women with a familial or genetic susceptibility: update of the Dutch MRI screening study (MRISC). Rijnsburger AJ, Obdeijn I-M, Kriege M, Boetes C, Oosterwijk JC, Tollenaar RAEM, Peterse H, Bergers E, Tilanus-Linthorst MMA, de Koning HJ, Rutgers EJT, Klijn JGM, on behalf of the MRISC Study Group. Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; University Medical Center Nijmegen, Nijmegen, Netherlands; Groningen University Medical Center, Groningen, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands; Free University Medical Center, Amsterdam, Netherlands.

4:00

43. Detection of enhancing lesions on contrast-enhanced MRI of the breast using real-time virtual sonography: fusion of MRI and sonography data. Nakano S, Yorozuya K, Takasugi M, Mouri Y, Fukutomi T, Arai O, Mitake T. Aichi Medical University, Aichi-gun, Aichi, Japan; Hitachi Medical Corporation, Kashiwa-city, Chiba, Japan.

4:15

44. MRI for diagnosing pure ductal carcinoma in-situ. Kuhl CK, Schrading S, Wardelmann E, Braun M, Kuhn W, Schild HH. University of Bonn, Bonn, Germany.

4:30

45. Noninvasive monitoring of neoadjuvant chemotherapy using optical tomography with ultrasound localization: initial experience. Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman S, Baccaro N, Iyer M, Wilson L, Deckers P, Zhu Q. University of Connecticut, Farmington, CT; University of Connecticut, Storrs, CT.

4:45

46. Tomosynthesis for the detection of breast cancer in a clinical setting. Ikeda DM, Ruschin M, Timberg P, Svahn T, Zackrisson S, Andersson I. Radiology, Lund University, Malmoe University Hospital, Malmoe, Sweden; Radiology, Stanford University School of Medicine, Stanford, CA.

37. Multidrug resistance and breast cancer: a meta-analysis of MDR1 and its clinical significance. Trock B, Leonessa F, Clarke R. Johns Hopkins, Baltimore, MD; Uniformed Services University of Health Sciences, Bethesda, MD; Georgetown University, Washington, DC.

11:15-12:00

WILLIAM L. MCGUIRE MEMORIAL LECTURE – Exhibit Hall D Sponsored by GlaxoSmithKline.

Biomarking the oestrogen dependence of breast cancer Mitchell Dowsett, PhD Institute of Cancer Research/Royal Marsden NHS Trust London, UNITED KINGDOM

12:00-1:00

LUNCH [Ticket Required] – Exhibit Hall A

12:30-1:45

CASE DISCUSSION 1 – Ballroom A

2:00-3:30 MINI-SYMPOSIUM 2 – Exhibit Hall D WOMEN’S HEALTH INITIATIVE: HRT AND OTHER ISSUES Peter Ravdin, MD, PhD, Moderator MD Anderson Cancer Center Houston, TX 2:00

Introduction

GENERAL SESSION 4 – Exhibit Hall D

5:00-7:00

POSTER DISCUSSION 3 & RECEPTION – Ballroom B

309

Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. Wardley A, Antón-Torres A, Pivot X, Morales-Vasquez F, Zetina L, Dias Gaui M, Otero Reyes D, Jassem J, Button P, Bell R. Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; Hospital Universitario Miguel Servet, Zaragoza, Spain; CHU Jean Minjoz, Besançon, France; Instituto Nacional de Cancerología, Mexico City, Mexico; Hospital Roosevelt, Guatemala City, Guatemala; Instituto Nacional do Câncer, Rio de Janeiro, Brazil; Hospital CIMA, San José, Costa Rica; Akademia Medyczna, Gdansk, Poland; Roche Products Pty Ltd, Dee Why, New South Wales, Australia; Andrew Love Cancer Centre, Geelong Hospital, Geelong, Victoria, Australia.

310

A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer. Krop IE, Beeram M, Modi S, Rabbee N, Girish S, Tibbitts J, Holden SN, Lutzker SG, Burris HA. Dana-Farber Cancer Institute, Boston, MA; Institute for Drug Development, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech, South San Francisco, CA; Sarah Cannon Research Institute, Nashville, TN.

Antibodies and Immunotherapy 301-310 301

Optimal dose and schedule of a HER2/neu peptide (E75) vaccine in disease-free breast cancer patients: results from two phase I/II clinical trials. Holmes JP, Patil R, Amin A, Jama YH, McNeill A, Hueman MT, Craig D, Ponniah S, Peoples GE. National Naval Medical Center, Bethesda, MD; Windber Medical Center, Windber, PA; USUHS, Bethesda, MD; Brooke Army Medical Center, Ft. Sam Houston, TX.

302

Clinical results of a phase I trial of a HER2/neu-derived peptide (GP2) vaccine in disease-free, node-negative breast cancer patients. Carmichael M, Holmes JP, Mittendorf EA, Amin A, Hueman MT, Ponniah S, Peoples GE. USUHS, Bethesda, MD; National Naval Medical Center, Bethesda, MD; UTMD Anderson Cancer Center, Houston, TX; Brooke Army Medical Center, Ft. Sam Houston, TX.

303

Immunotherapy against metastatic breast cancer with a twist. Demaria S, Wang B, Yang AM, Santori F, Kawashima N, Matsumura S. New York University School of Medicine, New York, NY.

304

10 years follow up of pilot phase III immunotherapy study in early stage breast cancer patients using oxidized mannanMUC1. Vassilaros S, Tsibanis A, Tsikkinhs A, McKenzie IF, Apostolopoulos V. PROLIPSIS – Diagnostic Breast Center, Athens, Greece; Burnet Institute at Austin, Heidelberg, Victoria, Australia.

POSTER SESSION 3 & RECEPTION – Exhibit Hall B

(#3001-3120) Detection and Diagnosis: Axillary/Sentinel Nodes 3001-3027 3001

Is intraoperative cytology of sentinel nodes useful and predictive for non-sentinel axillary nodes? NSABP B-32. Julian TB, Anderson SJ, Fourchotte V, Brown AM, Boudros E, Mamounas EP, Costantino JP, Wolmark N. NSABP Medical Affairs, NSABP Investigators & NSABP Operation & Biostatistical Centers, Pittsburgh, PA.

Targeting of the chemokine receptor CXCR4 in acquired trastuzumab resistance. Tripathy D, Mukhopadhyay P, Verma U, Mukhopadhyay C, Shelton J, Story M, Ding L. University of Texas Southwestern Medical Center, Dallas, TX.

3002

First clinical results on the potential of intraoperative imaging for sentinel lymph node biopsy in breast cancer. Barranger E, Kerrou K, Pitre S, Duval M-A, Charon Y, Uzan S. Tenon Hospital, Paris, France; Lariboisiere Hospital, Paris, France; CNRS Paris 7- Paris 11, Orsay, France.

TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Carey LA, Mayer E, Marcom PK, Rugo H, Liu M, Ma C, Rimawi M, Storniolo A, Forero A, Esteva F, Wolff A, Ingle J, Ferraro M, Sawyer L, Davidson N, Perou CM, Winer EP. University of North Carolina; Dana Farber; Duke; UCSF; Georgetown; Washington University; Baylor; Indiana University; University of Alabama-Birmingham; M.D. Anderson; Johns Hopkins; Mayo.

3003

Optical biopsy scanner utilising elastic scattering spectroscopy for rapid intra-operative diagnosis of sentinel node metastases in breast cancer. Somasundaram SK, Chicken DW, Austwick MR, Bown SG, Keshtgar MR. University College London, London, United Kingdom.

3004

Sentinel lymph node biopsy for advanced breast cancer after neoadjuvant chemotherapy: results of the French multicenter prospective trial GANEA. Classe J-M, Giard S, Mignotte H, Rodier J-F, Leveque J, Ferron G, Marchal F, Alran S, Ladonne J-M, Cuisenier J, Dupre P-F, Body G, Andrieux N, Campion L. Cancer Center, Nantes, France; Cancer Center, Lille, France; Cancer Center, Lyon, France; Cancer Center, Strasbourg, France; University Hospital, Rennes, France; Cancer Center, Toulouse, France; Cancer Center, Nancy, France; Cancer Center, Paris, France; Cancer Center, Rouen, France; Cancer Center, Dijon, France; University Hospital, Brest, France; University Hospital, Tours, France.

3005

The basal breast cancer molecular subtype predicts for a lower incidence of axillary lymph node involvement in primary breast cancer. Crabb SJ, Immonen T, Bajdik CD, Cheang MC, Leung S, Speers CH, Huntsman D, Nielsen TO, Chia SK. BC Cancer Agency, Vancouver, BC, Canada.

305

Circulating immature myeloid cells in breast cancer patients correlate with clinical cancer stage and cyclophosphamide treatment: implications for cancer immunotherapy. Montero AJ, Dewaay DJ, Salem M, Cole DJ, Diaz-Montero CM. Medical University of South Carolina, Charleston, SC.

306

307

308

5:00-7:00

Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. O’Shaughnessy J, Weckstein DJ, Vukelja SJ, McIntyre K, Krekow L, Holmes FA, Asmar L, Blum JL. US Oncology Research, Inc., Houston, TX; Baylor-Charles A. Sammons Cancer Center, Dallas, TX; Texas Oncology, P.A. – Dallas Presbyterian, Dallas, TX; New Hampshire Oncology-Hematology, Hookset, NH; Tyler Cancer Center, Tyler, TX; The Breast Care Center of North Texas, Bedford, TX; Texas Oncology, P.A., Houston, TX.

3006

Axillary staging is more accurate today than ever before: no increase in the false negative rate with wide-spread adoption of sentinel node technique. Helyer LK, Coburn NG, Law CH, McCready DR. Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

3007

Rapid detection of lymph node metastasis in breast cancer patients by “One-step Nucleic Acid Amplification (OSNA)”: results from a multi-institutional clinical study. Kaneko T, Akiyama F, Tsujimoto M, Noguchi S, Inaji H, Nakamura S, Otomo Y, Kato Y, Matsuura N. The Cancer Institute Ariake Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Police Hospital, Osaka, Japan; Osaka University, Osaka, Japan; Osaka Medical Center of Cancer and Cardiovascular Diseases, Osaka, Japan; St Luke’s International Hospital, Tokyo, Japan; SYSMEX Corp, Kobe, Japan.

3008

Clinical significance of occult axillary lymph node metastases in breast cancer patients without adjuvant systemic therapy: a long-term retrospective study. Kelten C, Mittendorf EA, Broglio K, Vo T, Middleton LP, Ueno N, Hunt KK, Sahin AA. UT M.D. Anderson Cancer Center, Houston, TX.

3009

Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor-2 (HER2) overexpression in breast cancer. Sevick-Muraca EM, Sampath L, Kwon S, Ke S, Schiff R, Mawad ME. Baylor College of Medicine, Houston, TX.

3010

Peripheral blood microarray data may aid in predicting lymph node status of breast cancer patients. Jordan RM, Hu H, Heckman CM, Kvecher L, Shriver CD, Mural R, Yang Y-C. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC.

3011

Magnetic nanoparticles for detecting cancer spread. Joshi T, Pankhurst QA, Hattersley S, Brazdeikis A, Hall-Craggs M, De Vita E, Bainbridge A, Sainsbury R, Sharma A, Douek M. Royal Free and University College Medical School, London, United Kingdom; London Centre for Nanotechnology, London, United Kingdom; Texas Center for Superconductivity, Houston, TX; University College London Hospital, London, United Kingdom.

3012

Intra-operative assessment of sentinel lymph node using real time quantitative PCR versus delayed assessment of sentinel lymph node: a cost-effectiveness model. Goyal A, Douglas-Jones A, Woods V, Jasani B, Mansel RE. School of Medicine, Cardiff University, Cardiff, United Kingdom.

3013

Discriminating between sentinel node micrometastases and sub micrometastases is not contributive to omit axillary lymph node dissection. Gilles HG, Sylvia GS, Herve MH, Max BM, Jean Marc CJM, Monique CM, Claude NC, GCFCC. Institut Paoli Calmettes, Marseille, Bouches du Rhone, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Centre Rene Gauducheau, Nantes, France; Casamance, Marseille, France; Hopital G Pompidou, Paris, France; Groupe des Chirurgiens de Federation des CLCC, France.

3014

3015

Scoring system to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: comparison with other scoring systems and nomogram. Cho J, Han W, Ko E, Lee JW, Chung SY, Kim E-K, Hwang K-T, Kim S-W, Noh D-Y. Seoul National University College of Medicine, Seoul, Korea. Detailed pathologic evaluation of non-sentinel axillary lymph nodes following identification of sentinel lymph node metastases by cytokeratin immunohistochemistry and/or permanent section H&E levels. Lillemoe TJ, Dunn D, Bretzke M, Johnson E, O’Leary J, Stoller D, Fraki S, Pearson S, Diaz LK. Abbott Northwestern Hospital, Minneapolis, MN.

3016

“One Step Nucleic Acid Amplification” for rapid molecular analysis of breast cancer lymph nodes: the way towards one stop sentinel node surgery? Snook KL, Kissin MW, Layer GT, Jackson P, de Vries CS, Shousha S, Sinnett HD, Nigar E, Singhal H, Chia Y, Cunnick G. Royal Surrey Hospital, Guildford, Surrey, United Kingdom; The University of Surrey, Guildford, Surrey, United Kingdom; Charing Cross Hospital & Imperial College, London, United Kingdom; Northwick Park Hospital, Harrow, Middlesex, United Kingdom; Wycombe General Hospital, High Wycombe, Buckinghamshire, United Kingdom.

3017

Rapid detection of sentinel lymph node metastasis in breast cancer by OSNA assay. Beitsch P, Taylor W, Jordan J, Garcia M, Kocian L. Dallas Surgical Group, Dallas, TX.

3018

Preoperative axillary ultrasound and fine needle aspiration cytology of the axillary nodes in the diagnosis of axillary nodal involvement in breast cancer. Swinson C, Ravichandran D, Nayagam M, McLaggan S, Wilkie J, Wright D, Yanny L, Allen S. Luton & Dunstable NHS Foundation Trust, Luton, United Kingdom.

3019

Metastatic pattern of axillary lymph nodes after sentinel lymph node on 3D-CT lymphography. Yamashita K, Shimizu K. Musashikosugi Hospital, Nippon Medical School, Kawasaki, Kanagawa, Japan; Nippon Medical School, Bunkyo-ku, Tokyo, Japan.

3020

The necessity of two gene markers for accurate detection of lymph node micrometastasis using an investigational real time RT-PCR assay confirmed by 0.2 mm interval frozen section analysis in breast cancer. Kurosumi M, Kobayashi Y, Takei H, Kitsugi K, Ueno M, Green G, Vargo J. Saitama Cancer Center, Saitama, Japan; Veridex LLC, Japan; Veridex LLC, NJ.

3021

Navigation surgery using a dye and fluorescence for detecting sentinel lymph nodes in breast cancer. Hojo T, Kinoshita T, Yoshida M, Shien T, Iwamoto E, AkashiTakana S. National Canver Center Hospital, Tokyo, Japan.

3022

Real time reverse transcriptase-polymerase chain reaction assay as an adjuvant tool in evaluation of breast cancer sentinel lymph nodes. Tafe LJ, Schwab MC, Rizzo EJ, Joel LA, Wells WA, Tsongalis GJ. Dartmouth Medical School, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH.

3023

Sentinel node excision after neoadjuvant chemotherapy - a multicentric analysis. Bauerfeind IGP, Kuehn T, Himsl I, Ruehl IM, Kahlert S, Lebeau A, Untch M, Hoess C. Ludwig-Maximilians-University of Munich, Grosshadern, Munich, Germany; Klinikum Esslingen, Esslingen, Germany; University Eppendorf, Hamburg, Germany; Klinikum Berlin Buch, Berlin, Germany; Krankenhaus, Ebersberg, Germany.

3024

Clinicopathologic factors associated with microinvasion in ductal carcinoma in situ: possible utility in planning sentinel lymph node biopsy. Mahtani R, Ying B, Rescigno J, Aziz M, Bernik S, Klein P. St. Vincents Cancer Care Center, New York, NY.

3025

Utility of internal mammary lymph node biopsy in breast cancer. Ozmen V, Cabioglu N, Ozcinar B, Ozgen G, Tihan D, Mudun A, Ozmen T, Igci A, Muslumanoglu M, Kecer M, Dagoglu T. Istanbul Medical Faculty, University of Istanbul, Istanbul, Capa Fatih, Turkey.

3026

3027

Long term follow up after 664 sentinel node biopsies: local axillary failure and overall survival. Soler C, Bouteille C, Chol R, Reynaud R, Gremillet E, Bousserolles AM. Centre Hospitalier Privé de la Loire, Saint-Etienne, France; Centre Hospitalier Universitaire, Saint-Etienne, France; Centre Hospitalier General, Firminy, France; Centre Hospitalier General, Le Puy en Velay, France. Patterns of cellular distribution within the sentinel node positive for breast cancer. Tsiapali E, Dizon D, Steinhoff M, Gass J. Women and Infants Hospital, Providence, RI; Brown University Medical School, Providence, RI.

3037

Fine needle aspiration cytology material is highly suitable for mRNA extraction and subsequent molecular analysis of breast cancer. Uzan C, Andre F, Veronique S, Suzette D, Philippe V. Institut Gustave Roussy, Villejuif, France; UPRESS EA 3535, France.

3038

The borderline amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Striebel JM, Bhargava R, Surti U, Brufsky A, Dabbs DJ. Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA.

3039

Core biopsy following neoadjuvant chemotherapy in breast cancer - a tool to predict both residual disease and plan axillary treatment. Balasubramanian R, Aref F, Sivagurunathan S, Riddle P, Ahmad R, Vashisht R. West Middlesex University Hospital, London, United Kingdom.

3040

Medico-economic evaluation of the rapid diagnosis of breast lesions using fine-needle aspiration in a one stop breast clinic. Delaloge S, Noel E, Andre F, Benhamou E, Larue C, Balleyguier C, Vielh P, de Pouvourville G. Institut Gustave Roussy, Villejuif, France; ESSEC Business School, Cergy Pontoise, France.

3041

Equivocal triple assessment summary scores - do they mean anything? Parmeshwar R, Harland RN. Royal Albert Edward Infirmary, Wigan, Lancashire, United Kingdom.

Detection and Diagnosis: Diagnostic Pathology 3028-3041 3028

3029

3030

Gene expression by standardized quantitative RT-PCR in the special histologic subtypes of estrogen receptor positive invasive breast cancer. Baehner FL, Watson D, Ballard JT, Palmer G, Shak S. Genomic Health, Inc., Redwood City, CA. One-step nucleic acid amplification for intra-operative detection of lymph node metastases in breast cancer patients. Schem C, Maass N, Bauerschlag DO, Jonat W, Carstensen M, Löning T, Tiemann K. University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany; Albertinen Krankenhaus, Hamburg, Germany; University Clinic of Hamburg Eppendorf, Hamburg, Germany. Discrepancy between triple negative phenotype and basallike tumor: an immunohistochemical analysis based on 150 “triple-negative” breast cancers. Conforti R, Bidard F-C, Michiels S, Boulet T, Tomasic G, Mathieu M-C, Delaloge S, Andre F. Institut Gustave Roussy; Breast Cancer Business Unit; Institut Gustave Roussy, Villejuif, France.

3031

Prophylactic mastectomy - trends in pathology findings. Wen YH, Roses DF, Axelrod DM, Guth AA, Shapiro RL, Cangiarella J, Ziguridis N, Darvishian F, Singh B. New York University School of Medicine, New York, NY.

3032

Multiplexed immunohistochemical quantitative molecular phenotyping via multispectral imaging and automated segmentation. Hoyt CC, Gossage K, Levenson RM, Bandaru R, Gardner H. Cambridge Research and Instrumentation, Inc., Woburn, MA; Novartis Institutes for BioMedical Research Inc., Cambridge, MA.

3033

3034

3035

3036

Assessment of ErbB2 gene amplification with quantitative real time PCR. Gunnarsson C, Olsson H, Nilsson J, Holmlund B, Jansson A. Linkoping University Hospital, Linkoping, Sweden; Faculty of Health Science Linkoping, Linkoping, Sweden. Scoring system to predict malignancy in patients diagnosed as atypical ductal or lobular hyperplasia on ultrasoundguided core needle biopsy. Ko E, Han W, Lee JW, Cho J, Kim E, Jung S-Y, Moon WK, Park IAe, Kim S-W, Lee ES, Noh D-Y. Seoul National University Hospital, Seoul, Korea; Bundang Seoul National University Hospital, Sungnam-si, Korea; National Cancer Center, Goyang-si, Korea. Identification of commonly aberrant genomic regions using high-resolution array CGH on paraffin-embedded breast cancer samples. Davis R, Poirier B, De Witte A, Lin E, Borowsky A, Gosh J, Gao J, Giles S, LeProust E, Amorese D, Roberts D, Shams S, Carmack C, Gregg JP. UC Davis, Sacramento, CA; Agilent Technologies, Santa Clara, CA; BioDisovery, Manhattan Beach, CA. Correlation between breast core biopsies of uncertain malignant potential and subsequent excision biopsies. Fazel MZ, Rothnie ND, Payne S. Southend University Hospital, Southend-on-Sea, Essex, United Kingdom.

Detection and Diagnosis: Biopsy Techniques 3042-3044 3042

Is diathermy excision of gynaecomastia superior to saline adrenaline and sharp dissection technique? Parmeshwar R, Harland RNL, Prasad R. Royal Albert Edward Infirmary, Wigan, Lancashire, United Kingdom.

3043

The accuracy of preoperative core biopsy in patients with ductal carcinoma in situ. Halliday M, Bruce E, Marshall, Thompson C, Shokuhi S, Jones L, Harries S, Clarke D. Warwick Hospital, Warwick, Warwickshire, United Kingdom.

3044

Breast biopsy for mammographically detected nonpalpable lesions using a vacuum-assisted biopsy device (Mammotome) and an upright-type stereotactic mammography unit. Ohsumi S, Taira N, Aogi K, Takashima S, Nishimura R. National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.

Epidemiology and Outreach: Racial Aspects 3045-3052 3045

Racial differences in frequency and spectrum of BRCA1/2 mutations in young women with breast cancer. Haffty BG, Choi DH, Moran MS, Silber A, Matloff E, Lee MH, Ranieri K, Toppmeyer D. UMDNJ-RWJMS and Cancer Institute of New Jersey, New Brunswick, NJ; Soonchunhyang Hospital, Seoul, Korea; Yale University, New Haven, CT.

3046

A transcription factor-centric computational analysis of genes differentially expressed in healthy breast tissues from African American and Caucasian women. Hu H, Stegmaier P, Field LA, Kel A, Shriver CD, Liebman MN, Mural RJ. Windber Research Institute, Windber, PA; BIOBASE GmbH, Wolfenbüttel, Germany; Walter Reed Army Medical Center, Washington, DC.

3047

Identification of protein expression differences in invasive breast tumors from African American compared to Caucasian women. Ellsworth RE, Seeley EH, Ellsworth DL, Sanders M, Hooke JA, Caprioli RM, Shriver CD. Windber Research Institute, Windber, PA; Vanderbilt University, Nashville, TN; Walter Reed Army Medical Center, Washington, DC.

3048

NCIC CTG MAP.3: enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial. Moy B, Richardson H, Johnston D, Pater JL, Chlebowski R, AlésMartínez JE, Ingle J, Goss PE. Massachusetts General Hospital, Boston, MA; Queen’s University, Kingston, ON, Canada; HarborUCLA, Torrance, CA; Hospital Ruber Internacional, Madrid, Spain; Mayo Clinic, Rochester, MN.

3049

Ethnicity and breast cancer: risk and predictors in a pre-paid health plan. Shim VC, Li Y, Baer D, Udaltsova N, Klatsky AL. Kaiser Permanente Medical Center, Oakland, CA; Kaiser Permanente Medical Care Program, Oakland, CA.

3050

Identification of trends in large breast cancers in an ethnically diverse population. Bailey L, Mendelsohn MA, Bishop S. Alta Bates Summit Medical Center, Berkeley-Oakland, CA.

3051

Patterns of therapy and adherence to established treatment guidelines in caucasian versus African-American newepisode breast cancer patients. Short L, Fisher M, Wahl P, White S, Rodriguez N, Kelly M. HealthCore, Inc., Wilmington, DE; Blue Cross Blue Shield of Georgia, Atlanta, GA; University of Pittsburgh School of Medicine, Pittsburgh, PA.

3052

Multiethnic comparisons of genome-wide alterations in breast cancer using paraffin embedded samples. Baumbach LL, Ahearn ME, Jorda M, Gomez C, Halsey TA, Ellison K, Farragher SM, Jellema GL, Gluck S. Miller School of Medicine, Univ of Miami, Miami, FL; Almac Diagnostics, Durham, NC.

3056

Multicenter phase II randomized trial evaluating toxicities of concurrent and sequential radiotherapy and letrozole (COHORT) as adjuvant therapy after conservative surgery in postmenopausal women with hormone receptor positive tumors: preliminary results. Azria D, Ozsahin M, Rosenstein B, Romieu G, Gutowski M, Zaman K, Llacer Moscardo C, Lemanski C, Jeanneret-Sozzi W, Gligorov J, Gourgou S, Larbouret C, Pelegrin A, Dubois J-B, Belkacemi Y. CRLC Val d’Aurelle, Montpellier, France; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; NYU School of Medicine, New York, NY; AP-HP CancerEst Tenon, Paris, France; CLCC Oscar Lambret, Lille, France.

3057

Distant metastasis: the most common type of early recurrence with adjuvant tamoxifen therapy. Doughty JC, Wilson CR, Monypenny IJ, Skene AI, Abram P, Gattuso J, Carpenter R, Angerson WJ, Mansell J. Western Infirmary, Glasgow, Scotland, United Kingdom; University of Wales College of Medicine, Cardiff, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Northern Ireland Cancer Centre, Ulster, United Kingdom; St. Bartholomew’s Hospital, London, United Kingdom.

3058

Acceptance of extended hormonal therapy with letrozole after 5 years of adjuvant tamoxifen in post menopausal breast cancer patients in Calgary, Alberta. Trotter T, Railton C, Webster M, Paterson AHG. Tom Baker Cancer Centre, Calgary, AB, Canada.

3059

Chronological changes of side effect profile of anastrozole compared with tamoxifen in Japanese women: findings from N-SAS BC03 trial every 3 months after one year of the randomization. Hozumi Y, Aihara T, Takatsuka Y, Osumi S, Aogi K, Imoto S, Iwata H, Watanabe T, Nakagami K, Ohashi Y. Jichi Medical University, Shimotsuke, Tochigi, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center East, Kashiwa, Chiba, Japan; Aichi Cancer Center Central, Nagoya, Aichi, Japan; Hamamatsu Oncology Center, Hamamatsu, Shizuoka, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo University, Bunkyo-ku, Tokyo, Japan.

3060

First results of the prospective Hospital del Mar Bone Health Breast Cancer study (HMBHBC) in postmenopausal women receiving adjuvant aromatase inhibitors for early breast cancer. Nogues X, Servitja S, Velat M, Nadal R, Garces JM, Pena MJ, Albanell J, Diez-Perez A, Tusquets I. Hospital del Mar, Autonomous University Barcelona, Barcelona, Spain.

3061

Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer. Hadji P, Ziller V, Holzhauer W, Ziller M, Kalder M, Wagner U. Philipps-University of Marburg, Marburg, Germany.

3062

Risk of contralateral breast cancer in patients receiving adjuvant aromatase inhibitor - the rate of positive biopsies for cancer. Castaner MC, Elledge R, Tham YL. Baylor College of Medicine, Houston, TX.

3063

Phase II feasibility trial incorporating bevacizumab into dose dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). Miller KD, O’Neill A, Perez EA, Seidman AD, Sledge GW. Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institute; Mayo Clinic; Memorial Sloan Kettering Cancer Center.

Treatment: Adjuvant Therapy 3053-3082 3053

A prospective study comparing clinical rheumatological findings and tenosynovial and synovial changes on magnetic resonance imaging of breast cancer patients receiving adjuvant aromatase inhibitors or tamoxifen. Morales L, Pans S, Verschueren K, Paridaens R, Westhovens R, Timmerman D, Desmet L, Marie-Rose C, Neven P. University Hospitals KULeuven, Belgium.

3054

A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Gjerde J, Geisler J, Lundgren S, Ekse D, Breilid H, Hauglid M, Varhaug JE, Mellgren G, Steen VM, Lonning PE, Lien EA. Section for Endocrinology, Institute of Medicine, University of Bergen, Norway; Section of Oncology, University of Bergen, Norway; Norwegian University of Science and Technology, Department of Cancer Research and Molecular Medicine, Norway; Haukeland University Hospital, Norway; Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Norway; Institute of Medicine, University of Bergen, Norway; University of Bergen, Norway; Section of Oncology, University of Bergen, Bergen, Norway; Section for Endocrinology, University of Bergen, Norway.

3055

How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12). Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Robert J, Arnold A, Vandenberg TA, O’Reilly SE, Graham B, Shepeherd LE. National Cancer Institute of Canada Clinical Trials Group, Queen’s University, Kingston, ON, Canada.

3064

BCIRG 006: quality of life (QoL) of patients (pts) treated with docetaxel and trastuzumab-based regimens in node positive and high risk node negative HER2 positive early breast cancer. Au H-J, Robert N, Eiermann W, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Bee V, Slamon D. Breast Cancer International Research Group (BCIRG), Edmonton, AB, Canada.

3065

Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. McArthur HL, Rugo H, Paulson M, Rourke M, Traina T, Panageas K, Steingart R, Dang C, Fornier M, Park J, Moasser M, Melisko M, Sugarman S, Norton L, Hudis CA, Dickler MN. Memorial SloanKettering Cancer Center, New York, NY; UCSF Comprehensive Cancer Center, San Francisco, CA.

3066

3067

Preliminary results of a multicenter study of bevacizumab with 3 docetaxel-based adjuvant breast cancer regimens. Yardley DA, Hart L, Badarinath S, Waterhouse DM, Daniel B, Childs BH, Burris III HA. Tennessee Oncology, Nashville, TN; Florida Cancer Specialists, Fort Meyers, FL; Integrated Community Oncology Network, Jacksonville, FL; Oncology Hematology Care, Cincinnati, OH; Chattanooga Oncology & Hematology Associates, Chattanooga, TN; Sanofi-Aventis, Bridgewater, NJ. Pre-anthracycline and herceptin cardiac scanning for adjuvant breast carcinoma: a retrospective analysis of results in Scotland’s biggest cancer centre. Lindsay CR, McIlroy P, Stirling L, Canney PA. Gartnavel General Hospital, Glasgow, Scotland, United Kingdom.

3068

Adjuvant trastuzumab uptake outside of clinical trials. Snow SL, Rayson D, Barnes PJ, Sellon M, Skedgel C, Dewar R, Weber A, Younis T. Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Cancer Care Nova Scotia, Halifax, NS, Canada.

3069

Final toxicity analysis of the ADEBAR phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement. Janni W, Harbeck N, Sommer H, Rack B, Augustin D, Simon W, Jueckstock J, Wischnik A, Annecke K, Friese K, Kiechle-Bahat M. LMU, Munich, Germany; Frauenklinik, Deggendorf, Germany; Frauenklinik, Stuttgart, Germany; Frauenklinik, Augsburg, Germany; Klinikum Rechts der Isar TU, Munich, Germany.

3070

T1N0 triple negative breast cancer: adjuvant chemotherapy treatment and risk of recurrence. Kaplan HG, Malmgren JA, Atwood MK. Swedish Cancer Institute, Seattle, WA; HealthSTAT Consulting, Inc, Seattle, WA.

3071

The incidence of thromboembolism in patients receiving adjuvant anthracycline based chemotherapy for early stage breast cancer. Nolan L, Boleti E, Darby A, Simmonds PD. Southampton University Hospitals NHS Trust, Southampton, United Kingdom.

3072

Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose-dense FEC and docetaxel results of a randomized, open-label phase II study. Wildiers H, Dirix L, Neven P, Prové A, Clement P, Amant F, Skacel T, Paridaens R. University Hospital Gasthuisberg, Leuven, Belgium; St-Augustinus Hospital, Wilrijk, Belgium; Amgen (Europe) GmbH, Zug, Switzerland.

3073

A feasibility study of capecitabine monotherapy for elderly patients with high risk early breast cancer. Bernard-Marty C, Widakowich C, Demonty G, Personeni N, Lebrun F, Paesmans M, Veys I, Lieutenant F, Kabanga E, Biganzoli L, Nogaret J-M, Piccart MJ, Cardoso F. Jules Bordet Institute, Brussels, Belgium; Prato Hospital, Prato, Italy.

3074

Delivery of adjuvant dose dense doxorubicin+cyclophosph amide¢paclitaxel to early stage breast cancer patients with pegfilgrastim and darbepoetin alfa support - interim results from an Australian phase II study. De Boer RH, Patterson W, Beith J, Rocchi L, Beer F, Lewis C. Royal Melbourne Hospital, Melbourne, Victoria, Australia; Queen Elizabeth Hospital, Woodville, South Australia, Australia; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Amgen Australia Pty Ltd, Hawthorn, Victoria, Australia; Prince of Wales Hospital, Randwick, New South Wales, Australia.

3075

A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in elderly breast cancer patients. Wildiers H, Jurcut R, Denys H, de Backer J, Ganame J, Herbots L, Neven P, Cocquyt V, Rademakers F, Voigt J-u, Paridaens R. University Hospital Gasthuisberg, Leuven, Belgium; University Hospital Gent, Gent, Belgium.

3076

Adjuvant chemotherapy in breast cancer patients older than 70 years. Garg P, Rana F, Guthrie TH. University of Florida, Jacksonville, FL; Baptist Cancer Center, Jacksonville, FL.

3077

Annual hazard rates of recurrence for early breast cancer. What has changed in the last 10 years? Results from the NORA study. Cazzaniga ME, Mustacchi G, Pronzato P, De Matteis A, Di Costanzo F, Nardi M, Barberis G, D’Aprile M, Rulli E, Floriani I. Az Osp Treviglio-Caravaggio, Treviglio, Bergamo, Italy.

3078

Do patients with infiltrating lobular carcinoma (ILC) have an increased risk of contralateral, local, or distant recurrences compared with patients with infiltrating ductal carcinoma (IDC)? Pestalozzi BC, Zahrieh D, Mallon E, Gusterson B, Gelber R, Price K, Castiglione-Gertsch M, Coates A, Goldhirsch A. International Breast Cancer Study Group, Berne, Switzerland.

3079

Prognostic effect of amenorrhea and return of menses after adjuvant treatment of premenopausal patients with nodepositive breast cancer. Jonat W, Sauerbrei W, Kaufmann M, Schumacher M. UKSH Schleswig Holstein, Kiel, Germany; Universitätsklinikum Freiburg, Freiburg, Germany; University of Frankfurt, Frankfurt, Germany.

3080

Detection of minimal residual disease (MRD) in peripheral blood of primary breast cancer patients - translational research in the SUCCESS-study. Jueckstock JK, Rack B, Thurner-Hermanns E, Forstbauer H, Pantel K, Ulmer H-U, Beckmann MW, Lichtenegger W, Janni WJ, Friese K, Sommer HL. Frauenklinik, Klinikum Innenstadt, Munich University, Munich, Bavaria, Germany; Klinikum Rosenheim, Rosenheim, Bavaria, Germany; Oncologic Practice Dr. Forstbauer/ Dr. Ziske, Troisdorf, Nordrhein-Westfalen, Germany; University Hamburg-Eppendorf, Hamburg, Germany; Klinikum Karlsruhe, Karlsruhe, Baden-Wuerttemberg, Germany; Frauenklinik, University of Erlangen, Erlangen, Bavaria, Germany; Charite Universitaetsmedizin, Berlin, Germany.

3081

Biological risk assessment based on snap frozen tissue samples. Feasibility, qualitiy assuance and study progress of the multicenter trial NNBC 3-Europe. Thomssen C, Vetter M, Geurts-Moespot A, Persing M, Paepke D, Schmidt M, Meisner C, von Minckwitz G, Sweep F, Harbeck N. Martin-Luther Universitaet, Halle/Saale, Germany; Radboud Universiteit, Nijmegen, Netherlands; Technische Universitaet Muenchen, Muenchen, Germany; Johannes-Gutenberg Universitaet, Mainz, Germany; Eberhard-Karls Universitaet, Tuebingen, Germany; German Breast Group, Neu-Isenburg, Germany.

3082

Evaluation of practice patterns in the treatment of nodenegative, hormone-receptor positive breast cancer patients with the use of the oncotype DX assay at the University of Pennsylvania. Erb C, Fox KR, Patel M, Hook K, DeMichele A, Kaplan C, Domchek S. University of Pennsylvania, Philadelphia, PA.

3094

Targeting up-regulated notch signaling in the CD133+ stem cells within the protected niche of the lymphovascular embolus of inflammatory breast cancer. Barsky SH, Xiao Y, Ye Y. The Ohio State University College of Medicine, Columbus, OH.

3095

The overexpression of ERBB receptor tyrosine kinases and ABC transporters is associated with an increased side population in hormone resistant breast cancer cells. Chumsri S, Nakanishi T, Phatak P, Macedo LF, Sabnis G, Hamburger AW, Brodie AH, Burger AM. University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Maryland School of Medicine, Baltimore, MD.

3096

CTEN and LKB1: novel tumor biomarkers for breast cancer implications of resistance and response to tyrosine kinase inhibitor (TKI)-based therapies in breast cancer. Yarden Y, Shell SA, Spector NL, Bacus SS. Targeted Molecular Diagnostics, Westmont, IL; Duke University Medical Center, Durham, NC; Weizmann Institute of Science, Rehovot, Israel.

3097

HER2 increases the translational rates of acetyl-CoA carboxylase alpha and fatty acid synthase in breast cancer cells. Lee MJ, Park B-W, Yoon S, Lee M-Y, Kim K-S, Kim J-H, Park S-H. Yonsei University, College of Medicine, Seoul, Korea; Yonsei University, College of Medicine, Korea.

3098

The identification of proteins associated with radiotherapy resistance in breast cancer cells: screening 725 antibodies simultaneously using novel microarray technology. Smith L, Qutob O, Watson MB, Beavis AW, Lind MJ, Drew PJ, Cawkwell L. University of Hull, Hull, East Yorkshire, United Kingdom.

3099

A combined proteomic and microarray screening approach for the identification of proteins associated with radiotherapy resistance in breast cancer cells. Smith L, Qutob O, Watson MB, Beavis AW, Jameel JK, Welham KJ, Drew PJ, Lind MJ, Cawkwell L. University of Hull, Hull, East Yorkshire, United Kingdom.

3100

Genomic signature of invasive lobular cancer by DNA array hybridization. Hwang ES, Devries S, Roydasgupta R, Fridlyand J, Chin K, Chen Y-Y, Korkola J, Waldman FM. University of California, San Francisco, CA; Memorial Sloan Kettering Cancer Center, New York, NY.

3101

The genomic relationship between breast carcinomas and their paired lymph node metastases. Desouki MM, Gaile DP, Conroy J, McQuaid D, Nowak NJ, Shepherd L, Liao S, Geradts J. Medical University of South Carolina (MUSC), Charleston, SC; State University of New York, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY; Duke University Medical Center, Durham, NC.

3102

A Q-RT PCR profile for the cytological diagnosis of early breast lesions. Delaloge S, Laurent I, Scott V, Dessen P, Andre F, Suciu V, Saghatchian M, Lazar V, Lidereau R, Michiels S, Vielh P. Institut Gustave Roussy, Villejuif, France; Centre Rene Huguenin, Saint Cloud, France.

3103

Breast cancer classication according to “stem cell-like” features and its relevance for systemic adjuvant treatment decision. Rody A, Holtrich U, Gätje R, Engels K, von Minckwitz G, Loibl S, Gehrmann M, Ruckhäberle E, Ahr A, Solbach C, Karn T, Kaufmann M. J.W. Goethe-University, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Siemens Medical Solutions Diagnostics GmbH, Leverkusen, Germany.

Treatment: Hormone Replacement Therapy 3083-3087 3083

Reduced use of HRT by women in Victoria Australia in 2002 was not followed by a fall in breast cancer incidence. Bell R, Chappell G, Stagoll O, Maljevac S, Wilkinson J, Giles GG. The Geelong Hospital, Barwon Health, Geelong, Victoria, Australia; BreastScreen Victoria, Melbourne, Victoria, Australia; Victorian Cancer Registry, Melbourne, Victoria, Australia.

3085

The effects of vaginal estrogens on plasma estradiol levels in women taking aromatase inhibitors. Howard G, Wills S, Kresge C, McConnell D, Balasubramaniam M, Decker D. William Beaumont Hospital, Royal Oak, MI; School of Public Health, University of Michigan, Ann Arbor, MI.

3086

Use of hormonal therapies before and after diagnosis of a high risk breast lesion among 1,198 women in the community setting. Habel LA, Puligandla B, Jiang SF, Callahan ME, Kutner S, Shim V. Kaiser Permanente, Oakland, CA; Kaiser Permanente, Santa Teresa, CA.

3087

The multidisciplinary management of menopause symptoms after breast cancer. Saunders CM, Hickey M, Stuckey B. University of Western Australia, Perth, WA, Australia; Sir Charles Gairdner Hospital, Perth, WA, Australia.

Tumor Cell Biology: Apoptosis 3088-3089 3088

Protein kinase C-epsilon and -eta confers TRAIL resistance in breast cancer cells via distinct mechanisms. Persaud SD, Jain K, Shankar E, Basu A. University of North Texas Health Science Center, Fort Worth, TX.

3089

Naphthaquinones - Promising anticancer agents against breast and ovarian cancers. Thasni AK, Nair RS, Rojini G, Ratheeshkumar T, Gopal S, Banergji A, Srinivas P. Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala, India.

Tumor Cell Biology: Carcinogenesis 3090-3092 3090

Contribution of chromosomal alterations to the development of poorly-differentiated invasive breast carcinomas. Ellsworth RE, Hooke JA, Ellsworth DL, Shriver CD. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC.

3091

Mouse mammary tumor virus-related sequence expression in the patients with breast phyllodes tumors. Luschnikova AA, Parokonnaya AA, Lyubchenko LN, Polevaya EB, Peredereeva EV, Smirnova EG. N.Blochin Cancer Research Center RAMS, Moscow, Russian Federation.

3092

Interactions between breast cancer cells and their stromal component: an analysis of alterations in gene expression. Sotiriou C, El Ouriaghli F, Majjaj S, Haibe-Kains B, Desmedt C, Lallemand F, Larsimont D, Piccart M. Institut Jules Bordet, Brussels, Belgium; Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.

Tumor Cell Biology: Tumor Biology 3093-3112 3093

Insulin sensitivity gene expression and efficacy of systemic adjuvant therapy in women with early breast cancer. Gennari A, Sormani M, Bruzzi P, Pronzato P, Mirisola V, Ravera G, Pfeffer U. National Cancer Rsearch Institute, Genoa, Italy; University of Genoa, Genoa, Italy.

3104

DNA hypermethylation profile of inflammatory breast cancer. Van der Auwera I, Van den Bosch S, Van Laere SJ, Van den Eynden GG, van Dam P, Colpaert CC, van Engeland M, Van Marck EA, Vermeulen PB, Dirix LY. Translational Cancer Research Group (Laboratory of Pathology University of Antwerp/ University Hospital Antwerp, Edegem; Oncology Centre, General Hospital St-Augustinus, Wilrijk), Wilrijk, Antwerp, Belgium; Research Institute GROW, Maastricht, Netherlands.

3105

Changes of stromal protein expression after preoperative systemic therapy in breast cancer. Szasz AM, Tokes A-M, Toth AI, Farkas A, Dank M, Molnar IA, Harsanyi L, Kulka J. Semmelweis University, Budapest, Hungary.

3106

3107

Vitronectin in the tumor microenvironment promotes breast cancer cell proliferation and elevated protein synthesis despite hypoxia by integrin Ĝvĝ3 activation of the mTOR/4E-BP1 pathway. Pola C, Formenti SC, Schneider RJ. New York University School of Medicine, New York, NY. Caveolin-1 enhances the growth inhibitory effects of gefitinib in MCF-7 breast cancer cell line. Agelaki S, Spiliotaki M, Markomanolaki Ch, Kallergi G, Stournaras Ch, Georgoulias V. University General Hospital of Heraklion, Heraklion, Crete, Greece; School of Medicine, University of Crete, Heraklion, Crete, Greece.

6054

The breast cancer surveillance consortium: a platform for collaborative research stemming from breast cancer risk through survivorship research. Geller BM, Ballard-Barbash R, Buist DSM, Carney PA, Kerlikowske K, Miglioretti DL, Rosenberg RD, Taplin SH, Yankaskas B, Weaver DL. University of Vermont, Burlington, VT; National Cancer Institute, Bethesda, MD; Group Health Cooperative Center for Health Studies, Seattle, WA; Dartmouth College, Lebanon, NH; UCSF, San Francisco, CA; University of New Mexico, Albuquerque, NM; University of North Carolina, Chapel Hill, NC.

6093

Second nonbreast malignancies following breast cancer in the Japanese female population. Sato N, Kanbayashi C, Sano M. Niigata Cancer Center Hospital, Niigata, Japan; Niigata Breast Examination Center, Niigata, Japan.

Saturday, December  7:00-9:00

POSTER DISCUSSION 4 & CONTINENTAL BREAKFAST – Ballroom B

Estrogen Receptors 401-409 401

Patterns of estrogen receptor alpha (ER) protein expression and ESR1 gene amplification in primary and metastatic breast cancer. Holst F, Haas H, Nottbohm AK, Sauter G, Simon R. University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

402

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Ejlertsen B, Nielsen KV, Rasmussen BB, Balslev E, Müller S, Møller S, Mouridsen HT. Rigshospitalet, Copenhagen, Denmark; Dako A/S, Glostrup, Denmark.

403

Relationship between ESR1 copy number and ER expression in the DBCG 89D trial. Ejlertsen B, Nielsen KV, Rasmussen BB, Jensen M-B, Møller S, Balslev E, Müller S, Mouridsen HT. Rigshospitalet, Copenhagen, Denmark; Dako A/S, Glostrup, Denmark.

404

Gene copy number variability of oestrogen receptor-Ĝ in breast cancer. Drury S, Lambros, Marchio, Johnson, Salter J, Levey, Fletcher, Peto, Reis-Filho J, Dowsett M. The Breakthrough Breast Cancer Research Centre, London, United Kingdom; CR-UK Epidemiology & Genetics, LSHTM, London, United Kingdom.

405

Serine118 phosphorylation of estrogen receptor: correlation with kinase pathways and evolution after preoperative endocrine therapy. Zoubir M, Mathieu M-C, Simmans F, Bouaziz J, Geha S, Drusch F, Liedtke C, Spielmann M, Delaloge S, Andre F. Institut Gustave Roussy, Paris, France; MD Anderson Cancer Center, Houston, TX.

406

Induction of a novel estrogen receptor (ERĜ) phosphoserine (S154) in human breast cancer cells identified by mass spectrometry. Britton D, Scott G, Schilling B, Held J, Atsriku C, Baldwin M, Gibson B, Benz C. Buck Institute for Age Research, Novato, CA.

Rescheduled Posters

407

Withdrawn

1031

408

Mitogen activated protein kinase (MAPK) regulation of estrogen receptor (ER) Ĝ and tamoxifen resistance. Cui Y, Fuqua SAW. Baylor College of Medicine, Houston, TX.

3108

3109

The downregulation of cyclin B1 sensitizes the antiproliferative effect of chemotherapeutics in breast cancer cells. Yuan J, Androic I, Kramer A, Kaufmann M, Strebhardt K. Medical School, J.W. Goethe-University, Frankfurt, Hessen, Germany. ER dependent regulation of sphingolipid metabolism in the context of apoptosis and proliferation in breast cancer. Ruckhäberle E, Karn T, Schiffmann S, Grösch S, Geisslinger G, Gätje R, Holtrich U, Rody A, Kaufmann M. J.W. Goethe University, Frankfurt, Germany.

3110

Studies on the role of nicotinic receptors-mediated cell proliferative effects in human breast cancer cells. Wu C-H, Ho Y-S. Taipei Medical University, Taipei, Taiwan.

3111

Osteocalcin as a prognostic indicator in ductal mammary carcinoma. Davies SR, Mansel RE, Jiang WG. College of Medicine, Caridiff University, Cardiff, South Glamorgan, United Kingdom.

3112

Expression and activity of core binding factor (CBF) in human breast cancer cells. Yong T, Fowler M, Davis N, Meyers S, Sun A. Louisiana State University Health Sciences Center, Shreveport, LA.

Prognosis and Response Predictions: Prognostic Factors I 3113 3113

Immunohistochemical expression of YKL-40 is not a prognostic marker in patients with high-risk primary breast cancer. Roslind A, Knoop AS, Jensen M-B, Johansen JS, Nielsen DL, Price PA, Balslev E. Herlev University Hospital, Copenhagen, Denmark; Odense University Hospital, Odense, Denmark; Copenhagen, Denmark; University of California San Diego, La Jolla, CA.

Why women with breast cancer do not return for surveillance mammography. Geller B, Skelly J, Muss H. University of Vermont, Burlington, VT; Vermont Cancer Center, Burlington, VT.

409

Single nucleotide polymorphism 3814 C>T (P1272S) in steroid receptor coactivator-1 alters its coactivation activity. Richter AS, Hartmaier RJ, Lee AV, Skaar T, Rae J, Li L, Flockhart D, Tchatchou S, Hemminki K, Schmutzler RK, Meindl A, Bartram CR, Burwinkel B, Oesterreich S. Baylor College of Medicine, Houston, TX; Indiana University, Indianapolis, IN; University of Michigan, Ann Arbor, MI; DKFZ, Heidelberg, Germany; University of Cologne, Cologne, Germany; Klinikum Rechts der Isar TU, Munich, Germany; University of Heidelberg, Heidelberg, Germany.

7:00-9:00

4007

Risk categorisation of node positive tamoxifen treated breast cancer patients based on genetically defined subtypes. Schmidt M, Span P, Müller V, Rody A, von Törne C, Sweep F, Gehrmann M. University of Mainz, Mainz, Germany; Radboud University Nijmegen, Nijmegen, Netherlands; University of Hamburg-Eppendorf, Hamburg, Germany; Goethe-University Frankfurt, Frankfurt, Germany; Siemens Medical Solutions, Leverkusen, Germany.

4008

ABCB1 MDR1) inherited polymorphisms in relation to doxorubicin and docetaxel pharmacokinetics in patients with breast cancer. Gligorov J, Selle F, Lévy E, Beerblock K, Saintigny P, Avenin D, Rezai K, Bernaudin J-F, Uzan S, Antoine M, Lévy P, Lokiec F, Fajac A. Hôpital Tenon, Paris, France; HEGP, Paris, France; Hôpital Avicenne, Bobigny, France; Centre René Huguenin, Saint-Cloud, France.

4009

Breast cancer proteomic profiles of tumor susceptibility to neoadjuvant chemotherapy. He J, Shen D, Chung D, Saxton R, Faull KF, Whitelegge JP, Chang HR. School of Medicine, UCLA, Los Angeles, CA.

4010

47% pathologic complete response rate to anthracyclinesbased associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients. Le Tourneau C, Dettwiler S, Laurence V, Alran S, Beuzeboc P, Pierga J-Y, Frenaux P, Sigal-Zafrani B, Dieras V, Vincent-Salomon A. Institut Curie, Paris, France.

4011

Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer. Lee JS, Verrill MW, Sludden J, Griffin MJ, Erb S, Sumpter KA, Cole M, Calvert AH, Boddy AV. Newcastle University, Newcastle upon Tyne, Tyne & Wear, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, Tyne & Wear, United Kingdom.

4012

COX-2 over-expression and sensitivity to celecoxib and capecitabine in metastatic breast cancer patients. Metro G, Melucci E, Sperduti I, Mottolese M, Papaldo P, Milella M, Carlini P, Ferretti G, Cognetti F, Fabi A. Regina Elena National Cancer Institute, Rome, Italy.

4013

Thymidine phosphorylase expression is associated with time to progression in patients receiving docetaxel-modulated capecitabine for metastatic breast cancer. Puglisi F, Cardellino GG, Di Loreto C, Lombardi D, Perin T, Puppin C, Andreetta C, Russo S, Minisini AM, Mansutti M, Pizzolitto S, Adami G, Dipasquale M, Veronesi A. Azienda OspedalieroUniversitaria, Udine, Italy; CRO di Aviano, Aviano (PN), Italy; General Hospital, San Daniele del Friuli, Italy.

4014

The presence of the FRA12E/SMRT fragile site in the genome of breast cancer (BC) patients is a predictor of metastatic development. O’Connor T, Houde C, Dolce J, Bundy B, Nesline M, Davis W, Ambrosone C, Levine E, Edge SB, Coignet LJ. Roswell Park Cancer Institute, Buffalo, NY.

4015

Correlation of IGF1R gene expression and mutations with the risk of local recurrence in early breast carcinoma treated with conservative surgery and radiation therapy. Adrover E, Peiró G, Benlloch S, Sánchez-Tejada L, Lerma E, Peiró FM, Aranda FI. Universitary General Hospital, Alicante, Spain; Sant Paús Hospital, Barcelona, Spain.

4016

A retrospective clinical correlation study of the breast cancer patients’ responses to anticancer drugs with the expression level of drug response indicators (DRI) measured in patient’s archival tumor tissue. Rak Tkaczuk KH, Tait NS, Rogers WH, Tan M, Ioffe O, Lesko SA, Deamond S, Lum Z-P, Ts’o PO. University of Maryland Greenebaum Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD.

POSTER SESSION 4 & CONTINENTAL BREAKFAST– Exhibit Hall B

(#4001-4117) Prognosis and Response Prediction: Predictive Factors II 4001-4025 4001

4002

4003

4004

4005

4006

Early changes in expression of oestrogen-regulated and proliferation genes illustrate heterogeneity in primary resistance to letrozole. Miller WR, Larionov A, Evans DB, Dixon M. University of Edinburgh, Edinburgh, United Kingdom; Novartis Institutes for BioMedical Research, Basel, Switzerland. Radiation-induced CD8 T-lymphocyte apoptosis yield predicts toxicities after adjuvant treatment with concurrent and sequential radiotherapy and letrozole in postmenopausal women with hormone receptor positive breast cancers: preliminary results of the multicenter phase II randomized trial (COHORT). Ozsahin M, Belkacemi Y, Rosenstein B, Llacer Moscardo C, Lemanski C, Romieu G, Gutowski M, Zaman K, Jeannerat-Sozzi W, Gourgou S, Gligorov J, Larbouret C, Pèlegrin A, Dubois J-B, Azria D. Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Centre Oscar Lambret, Lille, France; Mount Sinai School of Medicine and NYU School of Medicine, NY, NY; CRLC Val d’Aurelle, Montpellier, France; AP-HP CancerEst Tenon, Paris, France; Centre de Recherche en Cancérologie de Montpellier, Montpellier, France. Signal pathway profiling of primary breast tumors identifies potential phosphoprotein biomarkers that are predictive for tamoxifen response following recurrence. Wulfkuhle J, Umar A, Deng J, Timmermans M, Liotta L, Foekens J, Petricoin E. George Mason University, Manassas, VA; Erasmus Medical Center, Rotterdam, Netherlands. Selective serotonin reuptake inhibitors and modification of tamoxifen effectiveness in Danish breast cancer patients. Lash T, Cronin-Fenton D, Pedersen L, Ahern T, Sorensen HT, Lunetta K, Rosenberg C, Silliman R, Hamilton-Dutoit S, Garner JP, Ewertz M. Boston University, Boston, MA; Aarhus University Hospital, Aarhus, Denmark; Aalborg Hospital, Aalborg, Denmark. Predictive gene expression profile of breast cancer patients treated with tamoxifen. Lyng MB, Laenkholm AV, Vach W, Pallisgaard N, Knoop A, Ditzel HJ. Odense University Hospital (OUH); University of Southern Denmark (SDU); SDU; OUH, Odense, Denmark. Biomarker analysis of a phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole or placebo plus letrozole as neoadjuvant therapy for patients with estrogen receptor positive breast cancer. Gardner H, Bandaru R, Barrett C, Calcaterra M, Crowell T, Decker J, Dixon M, Fisch R, Fuchs M, Gelb A, Hanoteau N, Jonat W, Lane H, Lebwohl D, Liu W-H, Molloy B, Pena C, Phillips P, Rheinhardt J, Rugo H, Salesky S, Steinseifer J, Stumm M, Tokaji E, Voelker F, Yarbrough G, Yateman N, Yu Y, Zuber E, Baselga J. Novartis Institutes for Biomedical Research, Cambridge, MA; Novartis Pharmaceuticals, East Hanover, NJ; Hospital Vall d’Hebron, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; UnivFrauenklinik, Kiel, Germany; UCSF, San Francisco; Western General Hospital, Edinburgh, United Kingdom.

4017

4028

Withdrawn

4029

Traditional breast cancer risk factors and common breast pathologies in post-menopausal women. Maskery SM, Hu H, Liebman M, Hooke J, Shriver CD, Taioli E. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC; University of Pittsburgh, Pittsburgh, PA.

4030

Validation of the Gail model for breast cancer risk in postmenopausal women with osteoporosis. Goldstein S, Yeo A, Qu Y, Wong M, Mitchell B, Mershon J. NYU, New York, NY; Eli Lilly and Company, Indianapolis, IN.

4031

A pilot study of known or controversial breast cancer risk factors using the Clinical Breast Care Project database as a research environment. Bekash A, Maskery SM, Kvecher L, Hooke J, Liebman MN, Shriver CD, Mural RJ, Hu H. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC.

4032

Prognostic determinants in patients with breast cancer who are staged using sentinel lymph node biopsy. Rosman M, Cheng Z, Sawyer K, Verbanac K, Tafra L. Anne Arundel Medical Center, Annapolis, MD; East Carolina University, Greenville, NC.

Absolute breast fibroglandular volume strongly associated with breast cancer risk. Shepherd JA, Kerlikowske K, Malkov S, Ma L, Margolin F, Cummings S. University of California at San Francisco, San Francisco, CA; California Pacific Medical Center, San Francisco, CA.

4033

Significance of Akt activation and compartmentalization for prediction of outcome in Her-2 positive breast cancer patients treated with trastuzumab. Svoboda M, Grell P, Fabian P, Radova L, Palacova M, Nenutil R, Vyzula R. Masaryk Memorial Cancer Institute, Brno, Czech Republic; Tomas Bata University in Zlin, Zlin, Czech Republic.

Large errors in volumetric fibroglandular density occur if breast thickness and paddle tilt are not measured. Shepherd JA, Malkov S, Cummings S. University of California at San Francisco, San Francisco, CA; California Pacific Medical Center, San Francisco, CA.

4034

The ratio of the estradiol metabolites 2-hydroxyestrone (2OHE1) and 16a-hydroxyestrone (16aOHE1) predicts breast cancer risk in postmenopausal but not in premenopausal women - a case-control study. Huober J, Zimmermann B, Brunner S, Mueck AO, Wallwiener D, Seeger H. Kantonsspital St. Gallen, St. Gallen, Switzerland; University Womens Hospital, Tuebingen, Germany.

4035

Type II diabetes and breast cancer; a potentially modifiable risk factor? Jones K, George RL. Kingston General Hospital, Queen’s University, Kingston, ON, Canada.

4036

Reproductive risk factors and breast tumor characteristics in African American and non-Hispanic White women with early onset breast cancer. Ogutha J, Huo D, Olopade OI. The University of Chicago Medical Center, Chicago, IL.

4037

Sub epithelial impedance: a new biomarker of breast cancer risk. Greene T, Brumfield MK, Pierce M, Davies RJ. Hackensack University Medical Center, Hackensack, NJ.

4038

The OncoVue® model for predicting breast cancer risk. Jupe ER, Ralph DA, Manjeshwar S, Knowlton NS, Pugh TW, DeFreese DC, Gramling BA, Shimasaki CD. InterGenetics Incorporated, Oklahoma City, OK; NSK Statistical Solutions, LLC, Choctaw, OK.

Estrogen receptor status: a prognostic predictor of outcome in HER-2 positive breast cancer with brain metastases. Vallow L, Hines S, Jain A, Tan W, Buskirk S, Perez EA. Mayo Clinic, Jacksonville, FL.

4018

The potential prognostic value of osteoprotegrin in ductal carcinoma of the breast. Davies SR, Mansel RE, Jiang WG. College of Medicine, Cardiff University, Cardiff, South Glamorgan, United Kingdom.

4019

The initial response of circulating epithelial tumor cells to primary systemic chemotherapy in breast cancer is highly predictive for final tumor reduction and outcome. Camara O, Kavallaris A, Rengsberger M, Koch A, Schneider U, Egbe A, Untch M, Pachmann K. Friedrich Schiller-Universität Jena, Jena, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany; Transfusionsmedizinisches Zentrum Bayreuth, Bayreuth, Germany.

4020

4021

4022

Predictors of response to neoadjuvant chemotherapy in women with locally advanced breast cancer. Parmar V, Nadkarni MS, Hawaldar R, Shet T, Nair R, Gupta S, Chinoy R, Badwe R. Tata Memorial Hospital, Mumbai, Maharashtra, India.

4023

Use of flow cytometry to identify breast cancer patients likely to benefit from specific targeted therapies. Visram H, Sangrar W, George R, Greer P. Queen’s University, Kingston, ON, Canada.

4024

Is pathologic complete response related to level of hormonal receptor positivity in hormonal-sensitive breast cancer treated with anthracycline-based neo-adjuvant chemotherapy? Petit T, Wilt M, Velten M, Rodier J-F, Fricker J-P, Dufour P, Ghnassia J-P. CLCC Paul Strauss, Strasbourg, France.

4025

Serum markers predictive of chemotherapy-induced premature ovarian failure among premenopausal women with early stage breast cancer. Anders CK, Snyder SA, Gu L, Unruhe SP, Welch RA, Lyons PS, Kimmick GG, Marcom KP, Shaw HS, Antenos M, Woodruff TK, Blackwell KL. Duke University, Durham, NC; Northwestern University, Chicago, IL.

Risk and Prevention: Risk Factors 4026-4038 4026

4027

Women with elevated body mass index at increased risk of breast cancer with a poor prognosis. Kerlikowske K, Desai A, Miglioretti DL, Walker R, Ballard-Barbash RSM, Buist DSM. UCSF, San Francisco, CA; John Hopkins, Baltimore, MD; Group Health, Seattle, WA; National Cancer Institute, Bethesda, MD. Risk factors for developing breast cancer following benign breast disease: a 25-year follow-up of a nationwide cohort. Papa MZ, Chetrit A, Oberman B, Feldman D, Lubin F, Sadetzki S. Chaim Sheba Medical Center, Ramat-Gan, Israel; Gertner Institute for Epidemiology and Health Policy Research, RamatGan, Israel; Tel-Aviv University, Tel-Aviv, Israel.

Risk and Prevention: Prevention 4039-4055 4039

A study of relationship between lipophilic statin use and estrogen receptor negative breast cancers. Gupta S, Desai A. Albert Einstein Medical Center, Philadelphia, PA.

4040

4041

4042

Phase II tissue-based biomarker prevention trial of celecoxib in premenopausal women at high risk for development of breast cancer. Fabian CJ, Kimler BF, Mayo MS, Zalles CM, Khan SA, Dooley WC, Krontiras H, Browne D. University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; Northwestern University Medical Center, Chicago, IL; University of Oklahoma Health Science Center, Oklahoma City, OK; University of Alabama Birmingham, Birmingham, AL; National Cancer Institute, Bethesda, MD. Immunomodulatory effects of celecoxib in patients at increased risk for breast cancer. Arun B, Vuskovic M, Vasiliu D, Xu HY, Atchley D, Chambers J, Bovin N, Sneige N, Hortobagyi GN, Huflejt M. The University of Texas M.D. Anderson Cancer Center, Houston, TX; Cellexicon, Inc, La Jolla, CA; Shemyakin Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation. Cumulative effects of raloxifene on the incidence of breast cancer over 8 years in postmenopausal women with osteoporosis. Mershon J, Yeo A, Qu Y, Wong M, Mitchell B, Vogel V. Eli Lilly and Company, Indianapolis, IN; University of Pittsburgh, Pittsburgh, PA.

4043

Incidence of breast cancer in postmenopausal women after discontinuation of long-term raloxifene use. Vogel V, Qu Y, Wong M, Mitchell B, Mershon J. University of Pittsburgh, Pittsburgh, PA; Eli Lilly and Company, Indianapolis, IN.

4044

Relative cost-effectiveness of raloxifene and tamoxifen in chemo-prevention of breast cancer with less thromboembolic events than no chemoprevention. Bishop JF, Glass P, Taylor PS, Pezzullo ML, Moore PT, Parkinson BT, Cotter TF, Tracey EA. Cancer Institute NSW, Sydney, Australia; Access Economics Pty Ltd, Canberra, Australia.

4045

Tamoxifen for the prevention of breast cancer development: an updated meta-analysis. Dahabreh IJ, Economopoulos KP. National University of Athens, Medical School, Athens, Greece.

4046

Prevention of breast cancer using rexinoids: results of a phase II biomarker modulation trial using bexarotene in women at high risk of breast cancer. Brown P, Arun B, Miller A, Isaacs C, Gutierrez C, Huang J, Mohsin S, Sneige N, Kim H, Sexton K, Weiss H, Hilsenbeck S, Lamph W, Negro-Vilar A, Johnson K, Elledge R. Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; Cancer Therapy and Research Center, San Antonio, TX; Georgetown University, Washington, DC; Ligand Pharmaceuticals, San Diego, CA; National Cancer Institute, Bethesda, MD.

4047

Chemoprevention in a mouse model for ductal carcinoma in situ: targeting the mTOR pathway. Liu SY, Namba R, Enriquez RJ, Tepper CG, Young LJT, Abbey CK, Borowsky AD, Cardiff RD, Gregg JP. University of California, Davis, Sacramento, CA; University of California, Davis, CA; University of California, Santa Barbara, CA.

4048

A strong association between body fat mass and proteomes of nipple aspirate fluids. Huang Y, Nagamani M, Anderson KE, Kurosky A, Haag AM, Lu L-JW. University of Texas Medical Branch, Galveston, TX.

4049

Prophylactic mastectomy: pathological findings in high risk women. Sedlacek SM, Sedlacek JE. Rocky Mountain Cancer Centers, Denver, CO; Dartmouth College, Hanover, NH.

4050

A pilot study to increase physical activity in sedentary women at risk for breast cancer. Korde L, Venzon D, Smith AW, Nehrebecky M, Calhoun T, Sebring N, Drinkard B, Smith M, Prindiville S, Zujewski J, EngWong J. NCI; NIH Clinical Center.

4051

Improving informed consent in clinical trials: a randomised controlled trial of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II). Juraskova I, Butow P, Lopez A-L, Seccombe M, Smith B, Coates A, Boyle F, McCarthy N, Reaby L, Forbes JF. University of Sydney, NSW, Australia; University of Newcastle, NSW, Australia; Royal Brisbane Hospital, QLD, Australia.

4052

Effect of green tea extract and tamoxifen on mammary carcinogenesis of C3H/OuJ mouse. Sakata M, Ikeda T, Imoto S, Jinno H, Kitagawa Y. Keio University School of Medicine, Shinjuku, Tokyo, Japan; Teikyo University School of Medicine, Itabashi, Tokyo, Japan; Kyorin University School of Medicine, Mitaka, Tokyo, Japan.

4053

Lyophilized aqueous extract of American ginseng (AG) abrogates induced COX-2 expression in human breast cancer cells. Minnis J, Louis S, Peralta E. Southern Illinois University School of Medicine, Springfield, IL.

4054

Conjugated linoleic acid synergizes with the CYP1B1 inhibitor 2,3’,4,5’-tetramethoxystilbene in suppressing breast cancer cell growth. Kirma NB, Nair HB, Liu Y-g, Tekmal RR. University of Texas Health Science Center @ San Antonio, San Antonio, TX.

4055

Serving the high risk patient in community practice: development and managment of a high risk clinic. Prill SJ, Vogel W. Blue Ridge Medical Specialists, Bristol, TN.

Treatment: Antibody-Based Regimens 4056-4064 4056

Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer - the TBP study (GBG 26/BIG 3-05). von Minckwitz G, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Maartense E, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S. University Hospital Frankfurt, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Gynäkologie und Gynäkologische Onkologie, Wiesbaden, Germany; University Hospital Mainz, Mainz, Germany; Studienzentrale Gynäkologische Onkologie (SGO) Kiel, Kiel, Germany; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Ikazia Zickenhuis, Rotterdam, Netherlands; Reinier de Graaf Gasthuies, Delft, Netherlands; University Hospital and Cancer Centre, Wien, Austria; Rigshospitalet University Hospital, Kopenhagen, Denmark; University College London Hospital, London, United Kingdom.

4057

Retrospective evaluation of clinical outcomes in HER2positive advanced breast cancer patients progressing on trastuzumab-based therapy in the pre-lapatinib era. Montemurro F, Viale G, Donadio M, Bottini A, Sanna G, Botti G, dei Tos AP, Marchiò C, Danese S, Clavarezza M, Del Curto B, Sapino A, Aglietta M. Institute for Cancer Research and Treatment, Candiolo, Italy; European Institute of Oncology, Milano, Italy; Centro Onco Ematologico Subalpino, Torino, Italy; Breast Unit Istituti Ospitalieri, Cremona, Italy; Istituto Nazionale Tumori (IST) Fondazione Senatore Pascale, Napoli, Italy; Ospedale Regionale, Trevisio, Italy; Ospedale S. Anna, Torino, Italy; Istituto Nazionale per la Ricerca sul Cancro (IST), Genova, Italy; Ospedale San Giovanni Battista- Molinette, Torino, Italy.

4058

4059

4060

4061

Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2positive metastatic breast cancer. Untch M, Tjulandin S, Jonat W, Meerpohl H, Lichinitser M, Manikhas GM, Jänicke F, Muscholl M, Pauschinger M, Thomssen C, Lehle M. Frauenheilkunde mit Geburtshilfe, Berlin, Germany; Russian Cancer Research Center, Moscow, Russian Federation; Christian-Albrechts-Universität, Kiel, Germany; Frauenklinik der St-Vincentius-Krankenhäuser, Karlsruhe, Germany; St Petersburg City Oncology Hospital, Russian Federation; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Ludwig-MaximiliansUniversität, Munich, Germany; Charité - Universitätsmedizin Benjamin Franklin, Berlin, Germany; Martin-Luther-Universität Halle-Wittenberg, Halle, Germany; F Hoffmann-La Roche, Basel, Switzerland. Clinical use of trastuzumab (Herceptin®) in metastatic breast cancer (MBC) in Germany from 2001 to 2006. Jackisch C, Eustermann H, Schoenegg W, Soelling U, Stauch M, Goehler T, Kuehn W, Krieger G, Reichert D. Klinikum Offenbach, Offenbach, Germany; Research Institute, Langen, Germany; Gynaekologische Praxis, Berlin, Germany; Gynaekologische Praxis, Kassel, Germany; Praxis, Kronach, Germany; Praxis, Dresden, Germany; Charité, Berlin, Germany; Hegau Klinikum, Singen, Germany; Klinikum Oldenburg, Germany. HER-2 positive inflammatory breast cancer: high pathological response rate with trastuzumab-based neoadjuvant therapy. Dawood S, Gonzalez-Angulo AM, Broglio K, Gong Y, Resetkova E, Yang WT, Barnett CM, Islam R, Ueno NT, Hortobagyi GN, Cristofanilli M. UT M.D. Anderson Cancer Center, Houston, TX. Survival gain by trastuzumab therapy after the onset of intracranial metastasis in metastatic breast cancer. Nam BH, Kim SY, Han HS, Lee KS, Ro J. National Cancer Center, Goyang, Korea.

4062

A phase II trial of docetaxel with bevacizumab as first line therapy for Her2/neu negative metastatic breast carcinoma. Hurvitz SA, Kabbinavar FF, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Reese D, Slamon DJ. UCLA, Los Angeles, CA; Translational Oncology Research International, Los Angeles, CA.

4063

Bevacizumab combined with chemo-endocrine preoperative therapy in locally advanced operable breast cancers. Ferrari B, Scarano E, Pietri E, Dellapasqua S, Colleoni M. European Institute of Oncology, Milan, Italy.

4064

Capecitabine + docetaxel + bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a phase II pilot study. Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B. Private Medical University Hospital Salzburg, Salzburg, Austria.

4067

Breast-conserving therapy: balancing surgery and radiation. Indelicato D, Galloway T, Morris CG, Mendenhall NP. University of Florida, Gainesville, FL.

4068

Cosmetic effect of breast radiotherapy in older women. Kunkler IH, Prescott RJ, Williams L, King CC, Jack WJL, Dixon MJ, van der Pol M. Edinburgh University, Edinburgh, United Kingdom; Aberdeen University.

4069

Breast conservative therapy results of triple negative breast cancer. Tulusan AH, Popovich M, Bühner M, Keilholz L, Volkholz H, Lex B. Klinikum Bayreuth GmbH, Bayreuth, Germany.

4070

Does surgical closure technique affect early mammographic detection of tumor recurrence following breast-conserving therapy? Newlin HE, Indelicato DJ, Abbitt P, Marshall J, Wymer D, Grobmyer S, Haigh L, Copeland E, Morris CG, Mendenhall NP. University of Florida, Gainesville, FL.

4071

Stem cell augmented reconstruction: a new hope for reconstruction after breast conservation therapy. Kitamura K, Kajitani K, Hedrick M, Sugimachi K. Kyushu Central Hospital, Fukuoka, Japan; Cytori Therapeutics, San Diego, CA.

4072

Co-transplantation of adipose tissue-derived regenerative cells improves long-term retention of fat graft. Zhu M, Zhou Z, Chen Y, Schreiber R, Fraser JK, Hedrick MH, Ransom JT, Kuo H-C. Cytori Therapeutics Inc, San Diego, CA; UCLA, Los Angeles, CA.

4073

Radiofrequency ablation therapy for breast cancer. Oura S, Tamaki T, Yoshimasu T, Ohta F. Wakayama Medical University, Wakayama, Japan.

Treatment: Radiation Therapy 4074-4097 4074

Concurrent chemoradiation with capecitabine achieves meritable response and local control for inoperable and recurrent neoadjuvant chemotherapy refractory breast cancer. Perkins GH, Middleton LP, Tran R, Garcia SM, Cristofanilli M, Pusztai L, Singletary SE, Strom EA, Woodward WA, Yu T-K, Oh JL, Tereffe W, Whitman GJ, Huang E, Allen PK, Buchholz TA. The University of Texas M. D. Anderson Cancer Center, Houston, TX.

4075

The late radiotherapy normal tissue phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependant causes. Symonds P, Giotopoulos G, Peat I, Foweraker K, Plumb M. University of Leicester, Leicester, Leicestershire, United Kingdom; University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom.

4076

Increased use of regional radiotherapy is associated with improved outcome in a population-based cohort of women with breast cancer and 1-3 positive nodes. Wai ES, Tyldesley S, Speers CH, Truong PT, Kyle K, Olivotto IA. BC Cancer Agency - Vancouver Island Centre, Victoria, BC, Canada; BC Cancer Agency - Vancouver Centre, Vancouver, BC, Canada; BC Cancer Agency - Vancouver, Vancouver, BC, Canada.

4077

Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. Hooning MJ, Aleman BMP, Hauptmann M, Klijn JGM, Noyon R, Stovall M, van Leeuwen FE. Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, Netherlands; University of Texas, M.D. Anderson Cancer Center, Houston, TX.

Treatment: Breast Conservation 4065-4073 4065

4066

Increased use of breast-conserving surgery: preferred treatment or failure to provide adequate local therapy? Virnig B, Habermann E, Al-Refaie W, Jensen E, Tuttle T. University of Minnesota, Minneapolis, MN. Impact of the interval between breast conserving surgery and adjuvant radiotherapy on clinical outcomes in early stage breast cancer. Campbell SAM, Kerr GR, Kunkler IH. Edinburgh Cancer Centre on Behalf of the Edinburgh Breast Group, Edinburgh, United Kingdom.

4078

4079

4080

4081

4082

4083

4084

4085

4086

Toxicity and cosmesis from RTOG 95-17: a phase I/II trial to evaluate brachytherapy as the sole method of radiation therapy for stage I and II breast carcinoma. Rabinovitch R, Winter K, Taylor M, Kuske R, Bolton J, Arthur D, White J, Hanson W, Wilenzick R, McCormick B. U of CO, Aurora, CO; RTOG, Philadelphia, PA; Washington U, Saint Louis, MO; AZ Onc Services, Scottsdale, AZ; Ochsner Clinic, New Orleans, LA; Med Coll VA, Richmond, VA; Med Coll WI, Milwaukee, WI; MDACC, Houston, TX; MSKCC, New York, NY. Update of the phase II MammoSite® brachytherapy trial for DCIS. Streeter, Jr OE, Benitez P, Vicini F, Mehta V, Quiet C, Kuske R, Hayes M, Arthur D, Kuerer H, Strom E, Freedman G, Keisch M, DiPetrillo T, Khan D, Hudes R, Groshen S, Silverstein MJ. USC/Norris Cancer Center, Los Angeles, CA; William Beaumont Hospital, Royal Oak, MI; Swedish Cancer Institute, Seattle, WA; Arizona Oncology Services, Scottsdale, AZ; New York Presbyterian Hospital, NY, NY; Virgnia Commenwealth University, Richmond, VA; M.D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Cedars Medical Center, Miami, FL; Rhode Island Hospital, Providence, RI; Centinela Freeman Medical Center, Inglewood, CA; St. Agnes Healthcare, Baltimore, MD. Partial breast irradiation using the MammoSite® device for low risk breast carcinoma in patients aged ≥ 60 years: toxicity, cosmesis and quality of life results of a phase II study. Belkacemi Y, Chauvet MP, Giard S, Lacornerie T, Bonodeau F, Baranzelli MC, Bonneterre J, Lartigau E. Centre Oscar Lambret, Lille, France. Intra-fraction motion during tangential treatment of the left breast: how consistently is the heart actually blocked? Wang Z, Yin F-F, Maurer J, Wu QJ, Hubbs J, Marks LB. Duke University Medical Center, Durham, NC. Prospective trial of individual optimal positioning (prone versus supine) for whole breast radiotherapy: results of 194 patients. Formenti SC, Guth AA, Axelrod DM, Goldberg JD, DeWyngaert JK. New York University School of Medicine, New York, NY. Relative importance of posterior and upper borders of tangential radiation portals in axillary lymph node coverage after breast conserving surgery. Gross E, Padovani L, Badinand D, George L, Muracciole X, Cowen D. Hôpital Timone, Marseille, France. Post-operative radiotherapy does not adversely affect the outcome of autologous free abdominal flap breast reconstruction. Chatterjee J, Lee A, Baker L, Anderson W, Dewar JA, Stevenson JH, Thompson AM. University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom. Linear accelerator-based intraoperative radiotherapy in limited stage breast cancer - results of an ISIORT pooled analysis in 1131 patients. Reitsamer R, Fastner G, Merz F, Menzel C, Kopp M, Hager E, Ciabattoni A, Willich N, Orecchia R, Valentini V, Sedlmayer F. Paracelsus Private Medical School Salzburg, Salzburg, Austria; General Hospital Klagenfurt, Klagenfurt, Austria; San Francisco Neri Hospital, Rome, Italy; University Hospital Münster, Münster, Germany; European Institute of Oncology, Milan, Italy; Gemelli University Clinic, Rome, Italy; on behalf of the ISIORT. The Cambridge breast intensity modulated radiotherapy trial: dosimetry results for 1089 patients. Coles CE, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Hoole ACF, Burnet NG. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

4087

Utilization of fiducial markers in accelerated partial breast irradiation with intensity modulated radiotherapy (IMRT). Page BR, Gibbons SK. Albany Medical College, Albany, NY; Albany Medical Center, Albany, NY.

4088

Intervals longer than 20 weeks from breast conserving surgery to radiation therapy are associated with inferior outcome for women with early stage breast cancer not receiving chemotherapy. Olivotto I, Lesperance M, Berrang T, Speers C, Nichol A, Tyldesley S, Germain F, Wai E, Holloway C, Kwan W, Truong P. BC Cancer Agency, Victoria, Vancouver, Kelowna, Surrey, BC, Canada; University of Victoria, Victoria, BC, Canada; BC Cancer Agency, Vancouver, BC, Canada.

4089

Are patients with T1-2 breast cancer with 1-3 positive nodes suitable candidates for partial breast radiotherapy trial enrolment? Truong PT, Jones S, Alexander A, Speers C, Kader H, Wai E, Olivotto IA. BC Cancer Agency, Vancouver Island Centre, Victoria, BC, Canada.

4090

Lumpectomy and accelerated partial breast irradiation as an alternative to mastectomy following prior mantle field radiation or breast irradiation. Adkison JB, Palazzi-Churas K, Kuske RR, Patel RR. University of Wisconsin Hospital and Clinics, Madison, WI; Arizona Oncology Services, Phoenix, AZ.

4091

Surgeon characteristics and receipt of adjuvant radiotherapy following breast conservation surgery in elderly women with breast cancer. Hershman DL, Buono D, Jacobson JS, Tsai WY, Joseph KA, Grann VR, Neugut AI. Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY.

4092

Non-invasive imaging techniques quantify radiation induced vascular changes in the breast. Klifa CS, Hattangadi J, Hwang J, Watkins M, Sakata T, Tromberg B, Hylton N, Park C. University of California, San Francisco, CA; University of California, Irvine, CA.

4093

The identification of patients for postmastectomy radiotherapy using the Cambridge index: audit of a prospective series. Wilson CB, Haba Y, Wishart GC. Addenbrookes Hospital, Cambridge, United Kingdom.

4094

Postmastectomy locoregional recurrence in Hong Kong: low risk patients without radiotherapy have more failures than intermediate risk patients with radiotherapy. Yau TK, Chang TY, Soong S, Chan K, Sze H, Yeung MW, Lee WM. Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.

4095

Thyroid dysfunction following modern three-dimensional conformal radiation therapy to low neck in women with breast cancer — a dosimetric, volumetric, and biochemical assessment. Albuquerque K, Beall N, Bova D. Loyola University Medical Center, Maywood, IL.

4096

Oesophageal carcinoma as second malignancy after irradiation for breast cancer. From meta-analysis and large epidemiological studies to patients’ records and dosimetric questions: where is the truth? Large scale single institutional experience. Kirova YM, Asselain B, Fourquet A. Institut Curie, Paris, France.

4097

Patient rated breast symptoms and body image in early breast cancer: first results of the UK standardisation of breast radiotherapy (START) trials. Hopwood P, Haviland J, Sumo G, Mills J, Bliss JM, Yarnold J. Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; The Institute of Cancer Research, Sutton, United Kingdom; Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; on behalf of the START Trial Management Group.

4108

Profiling HER-family receptor dimerization in HER2 overexpressing cells that coexpress mutated EGFR receptors. Dua R, Nhonthachit P, Petropoulos C. Monogram Biosciences, Inc, South San Francisco, CA.

4109

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen resistant MCF-7 cells leading to the activation of AKT and p90RSK. Pancholi S, Lykkesfeldt A, Dowsett M, Martin L-A. Institute of Cancer Research, London, United Kingdom; Danish Institute of Cancer Research, Copenhagen, Denmark.

4110

Reverse phase protein array analysis of an ER-positive/ HER2-positive breast cancer xenograft model reveals distinct resistance mechanisms to HER2 targeted therapy. Wang Y-C, Hennessy B, Huang C, Wiechmann LS, Rimawi M, Mills GB, Osborne CK, Schiff R. Baylor College of Medicine; M.D. Anderson, Houston, TX.

4111

Carcinoembryonic antigen cell adhesion molecule 6 has a functional role in endocrine resistance. Cummings M, Maraqa L, Speirs V. University of Leeds, Leeds, West Yorks, United Kingdom.

4112

Distinct chemokines mediate tumourigenicity of breast cancer cells. Potter SM, Dwyer RM, Kerin MJ. National University of Ireland, Galway, Ireland.

The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Wang X, Masri S, Phung S, Chen S. City of Hope/Beckman Research Institute, Duarte, CA.

4113

BRCA1 transcriptionally regulates the genes associated with the basal phenotype in breast cancer. James CR, Quinn JE, Gorski JJ, Stewart G, Harkin P. Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom.

Ĝ6ĝ1 and Ĝ6ĝ4 integrins and their critical role in promoting resistance to multiple treatment strategies for breast cancer. Huang C, Osborne CK, Schiff R. Baylor College of Medicine, Houston, TX.

4114

Kinome survey of molecular pathways lead to tamoxifenresistant breast cancer cell growth. Gonzalez LG, Park J, Geistlinger TR, Pearlberg J, Endege W, Degot S, Sawyer J, Hu Y, Harlow E, Labaer J. Harvard Institute of Proteomics, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA.

4115

On the role of calpain in regulation of HER2 and resistance to trastuzumab in breast cancer cells. Kulkarni S, Reddy KB, Esteva FJ, Budd TG, Moore HCF, Tubbs RR. Cleveland Clinic, Cleveland, OH; M.D. Anderson Cancer Center, Houston, TX.

4116

P450 aromatase regulation by autocrine human growth hormone confers resistance to aromatase inhibitors in a human mammary carcinoma cell line. Perry JK, Yang W-S, Grandison P, Lobie PE. University of Auckland, Auckland, New Zealand.

4117

Tissue inhibitor of metalloproteinases-1 influences sensitivity to etoposide in MCF-7 S1 breast cancer cells. Schrohl Rasmussen A-S, Würtz SØ, Brünner N, Lademann U. University of Copenhagen, Faculty of Life Sciences, Copenhagen, Denmark.

Tumor Cell Biology: Cell Biology 4098-4105 4098

4099

4100

4101

4102

4103

4104

4105

Distinct cancer stem cells may mediate heterogeneity among the human breast premalignant lesions. Behbod F, Kittrell FS, Allred DC, Eaves C, Kuperwasser C, Perou CM, Rosen JM, Medina D. Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; BC Breast Cancer Research Center, Vancouver, Canada; Tufts Univeristy School of Medicine, Boston, MA; University of North Carolina at Chapel Hill, Chapel Hill, NC. Preliminary characterization and in vitro propagation of putative stem/progenitor cells from human inflammatory breast cancer. Woodward WA, Reuben J, Gao H, Krishnamurthy S, Lucci A, Singh B, Li L, Cristofanilli M. The University of Texas M.D. Anderson Cancer Center, Houston, TX. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and proliferation through MMPdependant and -independant mechanisms. Alcock RA, Allen MD, Holliday DL, Edwards DR, Pennington CL, Shaw JA, Walker RA, Pringle JH, Jones JL. University of Leicester, Leicester, United Kingdom; Bart’s and the London, Queen Mary’s School of Medicine and Dentistry, London, United Kingdom; University of East Anglia, Norwich, United Kingdom.

Development of in vitro models to study microenvironmental influences on breast cancer progression. Holliday DL, Mulligan KT, Jones JL. Barts and the London, Queen Marys School of Medicine and Dentistry, London, United Kingdom. MCF7 and MDA-MB-231 cells cultured on Poly-HEMAcoated dish are more invasive, yet show less tumourigenicity, than cells cultured on the tissue culture dish. Kim JB, Lee K-M, Ko E, Han W, Lee JE, Shin I, Lee JW, Cho J, Noh D-Y. Seoul National University College of Medicine, Seoul, Korea; College of Natural Sciences, Hanyang University, Seoul, Korea. The anti-aromatase effect of the natural metabolites of progesterone: 20Ĝ-dihydroprogesterone and 5Ĝ dihydroprogesterone in MCF-7aro breast cancer cells. Pasqualini JR, Chetrite GS. Hormones and Cancer Research Unit, Paris, France.

Tumor Cell Biology: Drug Resistance 4106-4117 4106

4107

Development of resistance to targeted therapy strategies transforms the clinically-defined molecular profile subtype of breast tumors. Creighton CJ, Massarweh S, Tsimelzon A, Huang S, Hilsenbeck SG, Osborne CK, Schiff R. Baylor College of Medicine, Houston, TX; University of Kentucky, Lexington, KY. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell-cycle progression in-vitro and in-vivo. Martin L-A, Head JE, Pancholi S, Salter J, Quin E, Detre S, Kaye S, Howes A, Dowsett M, Johnston SR. Institute of Cancer Research, London, United Kingdom; Johnson & Johnson PRD, High Wycombe, United Kingdom; Royal Marsden Hospital, London, United Kingdom.

9:00-9:30

PLENARY LECTURE 4 – Exhibit Hall D Multidisciplinary guidelines across the continuum of care: the NCCN experience Robert Carlson, MD Stanford University Stanford, CAS

9:30-10:00

PLENARY LECTURE 5 – Exhibit Hall D Symptom management in breast cancer survivors Charles Loprinzi, MD Mayo Clinic Rochester, MN

10:00-11:00 10:00

10:15

10:30

10:45

GENERAL SESSION 5– Exhibit Hall D

2:00-3:30

51. Is completion axillary dissection always required after a positive sentinel node biopsy? NSABP B-32. Julian TB, Anderson SJ, Fourchotte V, Brown AM, Boudros E, Mamounas EP, Bear H, Costantino JP, Wolmark N. NSABP Medical Affairs, NSABP Investigators & NSABP Operation & Biostatistical Centers, Pittsburgh, PA. 52. The impact of micrometastases in the sentinel nodes of patients with invasive breast cancer. Hansen NM, Grube BL, Ye C, Turner R, Brennan M, Brenner J, Giuliano AE. John Wayne Cancer Institute, Santa Monica, CA; Saint John’s Hospital and Health Center, Santa Monica, CA. 53. High sensitivity of a molecular assay for breast metastases in sentinel lymph nodes that are difficult to detect by frozen section. Blumencranz P, Deck KB, Whitworth PW, McCue P, Reintgen DS, Chagpar AS, Beitsch P, Julian TB, Mamounas M, Saha S, Giuliano A, Simmons R. Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Weill-Cornell Breast Center, New York, NY. 54. Increased sentinel lymph node lymphangiogenesis predicts non-sentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Van den Eynden GG, Vandenberghe MK, van Dam P-JH, Colpaert CG, van Dam P, van Marck EA, Vermeulen PB, Dirix LY. (Lab Pathology University of Antwerp/University Hospital Antwerp, Wilrijk; Oncology Center, GH St-Augustinus, Wilrijk, Belgium), Antwerp, Belgium.

SYSTEMS BIOLOGY AND TARGETING THE HER NETWORK IN THE TREATMENT OF BREAST CANCER C. Kent Osborne, MD, Co-Moderator Baylor College of Medicine, Houston, TX and Rachel Schiff, PhD, Co-Moderator Baylor College of Medicine, Houston, TX 2:00

Introduction

2:00

HER pathways in the context of systems biology and integrating networks Yosef Yarden, PhD The Weizmann Institute of Science Rehovat, ISRAEL

2:30

3:00

3:30-5:00

Development of non-invasive optical methods for breast cancer detection and clinical management Bruce J. Tromberg, PhD Beckman Laser Institute Irvine, CA

11:30

61. The influence of a very high vegetable-fruit-fiber, lowfat diet on prognosis following treatment for breast cancer: results from the Women’s Healthy Eating and Living (WHEL) randomized trial. Pierce JP, Natarajan L, Cann BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, Carlson R, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML. Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Kaiser Permanente Northern California, Oakland, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA; University of California, San Diego; University of California, Davis, CA; M.D. Anderson Cancer Center, The University of Texas, Houston, TX; Center for Health Research, Portland, OR; Roswell Park Cancer Institute, Buffalo, NY; University of Arizona, Tucson, AZ; Arizona Cancer Center, Arizona Prevention Center, University of Arizona, Tucson, AZ; Stanford Prevention Research Center, Stanford University, Stanford, CA.

3:45

62. Outcome prediction for Clinical Stage II and III ER+ breast cancer based on treatment response, pathological stage, tumor grade, Ki67 proliferation index, and estrogen receptor status after neoadjuvant endocrine therapy. Ellis MJ, Tao Y, Luo, Evans DB, Bhatnagar, Chaudri-Ross HA, von Kameke, Miller WR, Eiermann W. Washington University, St Louis, MO; Novartis Pharma AG, Basel, Switzerland; Edinburgh University, Scotland; Red Cross Women’s Hospital, Munich, Germany.

4:00

63. Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of intergroup trial E2197. Goldstein L, Ravdin P, Gray R, Yoshizawa C, Childs B, Rowley S, Shak S, Badve S, Baehner FL, Davidson N, Sledge GW, Sparano JA. Eastern Cooperative Oncology Group, Brookline, MA; MD Anderson Cancer Center, Houston, TX; Genomic Health, Inc., Redwood City, CA; sanofi aventis, Bridgewater, NJ.

Functional breast imaging: State of the PET Eric L. Rosen, MD Seattle Cancer Care Alliance Seattle, WA

12:00-1:00

LUNCH [Ticket Required] – Exhibit Hall A

12:30-1:45

CASE DISCUSSION 2 – Ballroom A

GENERAL SESSION 6 – Exhibit Hall D

3:30

Susan Hilsenbeck, PhD, Co-Moderator Baylor College of Medicine, Houston, TX and Eva Sevick-Muraca, PhD, Co-Moderator Baylor College of Medicine, Houston, TX Introduction

Novel experimental global approaches in studies of signaling networks and therapy resistance René Bernards, PhD The Netherlands Cancer Institute Amsterdam, NETHERLANDS

MOLECULAR IMAGING FOR BREAST CANCER DIAGNOSTICS

11:00

Novel strategies for HER-targeted therapy and mechanisms of resistance C. Kent Osborne, MD Baylor College of Medicine Houston, TX

11:00-12:00 MINI-SYMPOSIUM 3 – Exhibit Hall D

11:00

MINI-SYMPOSIUM 4 – Exhibit Hall D

4:15

64. Value of centrally-assessed Ki-67 labeling index as a marker of prognosis and predictor of response to adjuvant endocrine therapy in the BIG 1-98 trial of postmenopausal women with estrogen receptor-positive breast cancer. Viale G, Giobbie-Hurder A. BIG 1-98 Collaborative Group and International Breast Cancer Study Group (IBCSG), Bern, Switzerland.

4:30

65. Erythropoietin receptor expression in breast cancer and correlation to tamoxifen response. Larsson A-M, Jirstrom K, Rydén L, Landberg G, Pahlman S. Lund University, University Hospital MAS, Malmo, Sweden.

4:45

66. Inflammatory breast cancer pathogenesis is mediated in significant part by translation initiation factor eIF4G amplification and unorthodox protein synthesis. Silvera D, Arju R, Darvishian F, Levine PH, Formenti SC, Schneider RJ. New York University School of Medicine, New York, NY; The George Washington University School of Public Health and Health Services, Washington, DC.

5:00-7:00

507

Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo. Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P, Holen I. University of Sheffield, Sheffield, Yorkshire, United Kingdom; Faculte de Medicine Laennec, Lyon, France.

508

Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment. Lipton A, Cook R, Major P, Smith M, Coleman R. Milton S. Hershey Medical Center, Hershey, PA; University of Waterloo, Waterloo, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Massachusetts General Hospital Cancer Center, Boston, MA; University of Sheffield, Sheffield, United Kingdom.

509

Effects of zoledronic acid on wnt inhibition by dickkopf1 and frizzled-related protein in patients with bone metastases. Helsten TL, Mortimer JE, Corr M. Moores UCSD Cancer Center, La Jolla, CA; University of California, San Diego, CA.

510

Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Lin A, Park J, Melisko M, Goga A, Moasser M, Moore D, Brissaud C, Rugo H. University of California-San Francisco, Comprehensive Cancer Center, San Francisco, CA.

511

Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Rack BK, Jueckstock J, Genss E-M, Schoberth A, Schindlbeck C, Strobl B, Heinrigs M, Rammel G, Zwingers T, Sommer H, Friese K, Janni W. Ludwig-Maximilians-University, Munich, Germany; Laboratory Drs. Tiller and Partners, Munich, Germany; Estimate GmbH, Augsburg, Germany.

POSTER DISCUSSION 5 & RECEPTION Ballroom B

Bisphosphonates for Bone Loss and Bone Metastases 501-511 501

502

503

504

505

506

The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. De Boer R, Eidtmann H, Lluch A, Pinotti G, Miller J, Schenk N, Dias R, Coleman R. Royal Melbourne Hospital, Parkville, Victoria, Australia; Universitaetsklinikum, Kiel, Germany; Hospital Clinico Universitario de Valencia, Valcenia, Spain; Ospedale di Circolo Fondazione Macchi, Varese, Italy; Novartis, East Hanover, NJ; Weston Park Hospital, Sheffield, United Kingdom. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. Van Poznak C, Hannon RA, Clack G, Campone M, Mackey JR, Apffelstaedt J, Eastell R. University of Michigan, Ann Arbor, MI; University of Sheffield, Sheffield, United Kingdom; AstraZeneca, Macclesfield, Cheshire, United Kingdom; Site Hospitalier Nord de Nantes, Nantes, France; University of Alberta, Edmonton, AB, Canada; University of Stellenbosch, Tygerberg, South Africa. The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women on SERMS versus aromatase inhibitors: a 2 year trial. van Londen G, Perera S, Vujevich K, Sereika S, Bhattacharya R, Vogel V, Brufsky A, Lembersky B, Greenspan S. University of Pittsburgh, Pittsburgh, PA; University of Kansas, Kansas City, KS. Practical guidance for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer. Hadji P, Appro M, Brufsky A, Tubiana-Hulin M, Guise T, Body JJ. Philipps-University of Marburg, Marburg, Germany; Institut Multidisciplinaire d’Oncology, Genolier, Switzerland; University of Pittsburgh, Pittsburgh, PA; Centre René Huguenin, St. Cloud, France; University of Virginia, Charlottesville, Virginia; Université Libre de Bruxelles, Brussels, Belgium. Effect of zoledronic acid on bone loss in women undergoing chemotherapy for breast cancer. Aft R, Chavez-MacGregor M, Trinkaus K, Naughton M, Weilbaecher K. Washington University, Siteman Cancer Center, St. Louis, MO; John Cochran Veterans Administration Hospital, St. Louis, MO. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer. Hershman DL, McMahon D, Crew K, Cremers S, Irani D, Cucchiara G, Brafman L, Siarra A, Shane E. Columbia University Medical Center, New York, NY.

5:00-7:00

POSTER SESSION 5 & RECEPTION Exhibit Hall B

(#5001-5119) Detection and Diagnosis: Detection 5001-5012 5001

Molecular etiology of breast cancer: potential biomarkers of risk and for use in prevention. Cavalieri E, Gaikwad N, Rogan E, Pruthi S, Ingle J. University of Nebraska Medical Center, Omaha, NE; Mayo Clinic College of Medicine, Rochester, MN.

5002

Increased detection of breast cancer markers human epidermal growth factor receptor dimer and downstream signaling proteins utilizing the VeraTag technology with dextran modified antibodies. Wallweber J, Dang T, Gupta S, Winslow J, Petropoulos C. Monogram Biosciences, Inc., South San Francisco, CA.

5003

Changing pattern of the detection of loco-regional relapse in breast cancer: the Edinburgh experience. Montgomery DA, Krupa K, Kerr G, Jack W, Dixon M. Royal Infirmary, Glasgow, United Kingdom; Royal Alexandra Hospital, Paisley, United Kingdom; Western General Hospital, Edinburgh, United Kingdom.

5004

Value of clinical follow-up following breast conserving treatment for breast cancer. Hamed H, Kontos M, Jones G, Allen D. Guy’s Hospital, London, United Kingdom.

5005

Estrogen plus progestin and breast cancer detection with mammography and breast biopsy. Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gillian MA, Walsh BW, Chen C, McTiernan A. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; The State University of New York, Stony Brook, NY; Geisinger Healthcare, Danville, PA; Medical College of Wisconsin, Milwaukee, WI; Bringham & Womens Hospital, Boston, MA.

5006

Galactose oxidase Schiff’s reactivity is higher in nipple aspirate fluid from cancerous breasts than from healthy patients. Chagpar AB, Evelegh M. University of Louisville, Louisville, KY; McMaster University, Hamilton, ON, Canada.

5007

Hormonal attributes of breast ductal lavage fluid in pre- and post-menopausal women. Effect of tamoxifen. Chatterton RT, Avram MJ, Helenowski IB, Khan SA. Northwestern University, Chicago, IL.

5008

Novel impedance device to detect breast cancer in younger women. Boolbol SK, Ironstone JS, Feldman SM. Beth Israel Medical Center, New York, NY.

5009

Intraoperative in vivo reflectance spectroscopy for discrimination of normal, benign, and malignant breast tissues. Brown JQ, Wilke LG, Kennedy S, Palmer GM, Geradts J, Ramanujam N. Duke University, Durham, NC; Duke University Medical Center, Durham, NC.

5010

5011

5012

Water state changes in malignant and benign breast tumors measured by diffuse optical spectroscopy in vivo. Chung SH, Cerussi AE, Merritt SI, Hsiang D, Mehta R, Tromberg BJ. University of California, Irvine, CA; Masimo Corporation, Irvine, CA; UCI Medical Center, Orange. Sonopheresis and ductal epithelial impedance spectroscopy as a non-invasive technique for breast cancer diagnosis. Davies RJ, Brumfield MK, Pierce M, Greene T. Hackensack University Medical Center, Hackensack, NJ; UMD-New Jersey Medical School, Newark, NJ. Combination of mammogram BI-RADS data and serum mass spectrometry proteomic profiles in improving breast cancer diagnosis. Sun M, Sun M, Lokshin AE, Modugno FM, Bigbee WL. University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA.

5019

Serum HER2 compared with CA153 for the monitoring of advanced breast cancer. Briscoe T, Thompson D, Bosomworth M, Dodwell DJ, Adlard JW. St James’s University Hospital, Leeds, United Kingdom.

5020

Liquid FISH-like assay for detection of HER-2 gene amplification in the serum of patients with breast cancer. Yeh C-H, Whitmire III WA, Albitar M. Quest Diagnostics Nichols Institute, San Juan Capistrano, CA.

5021

CA 15-3 level at time of metastatic relapse of breast cancer strongly correlates with hormone receptor but not with Her2 expression. Bensouda Y, Andre F, Boulet T, Mathieu MC, Conforti R, Ponzio-Prion A, de la Motte Rouge T, Zoubir M, El Masmoudi Y, Spielmann M, Delaloge S. Institut Gustave Roussy, Villejuif, France.

5022

Differential gene expression in circulating tumor cells between primary and metastatic breast cancer patients. Reinholz MM, Kitzmann KK, Hillman D, Lingle WL, Hobday T, Moreno A, Vivek R, Perez EA. Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic College of Medicine, Jacksonville, FL.

5023

Metastasis in blood of breast cancer patients. Lu J, Zeng W, Zhao Q, Zaslavsky E, Fan T, O’Hea B, Burk M, Merriam L, Pameijer C, Chen W-T. Stony Brook University Medical Center, Stony Brook, NY; Vitatex, Inc., Stony Brook, NY.

Detection and Diagnosis: Marrow and Blood Micrometastases 5024-5025 5024

RASSF1A DNA methylation in bone marrow (mRASSF1ABM) or peripheral blood plasma (mRASSF1APB) of primary breast cancer (BC) patients. Braun S, Auer D, Vogl FD, Schneitter A, Egle D, Taucher S, Daxenbichler G, Marth C. Innsbruck Medical University, Innsbruck, Austria; Medical Services, Meran, Italy.

5025

Incidence and kinetics of circulating tumor cells in breast cancer patients treated with primary systemic therapy including trastuzumab for patients with HER2positive tumors - a translational project within the study “GeparQuattro”. Riethdorf S, Loibl S, Komor M, Huober J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K, Mueller V. University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Goethe University Frankfurt, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center Tuebingen, Tuebingen, Germany; Henriettenstiftung Hannover, Hannover, Germany; St. Barbara Klinik Hamm Heessen, Hamm Heessen, Germany; Heliosklinik Berlin-Buch, Berlin, Germany.

Detection and Diagnosis: Circulating Markers 5013-5023 5013

Identification of a metabolic fingerprinting for metastatic breast cancer by proton nuclear magnetic resonance spectroscopy-metabolomic analysis. Claudino WM, Colangiuli D, Biganzoli L, Nepi S, Cappadona S, Ciarlo A, Luchinat C, Vinci E, Bertini I, Di Leo A. Hospital of Prato; Istituto Toscano Tumori-Prato, Prato, Italy; Scientific Pole, University of Florence, Sesto Fiorentino, Florence, Italy; Sesto Fiorentino, Florence, Italy.

5014

Identification of blood-based biomarkers for the detection of breast cancer and lymph node status. Field LA, Love BJ, Hadix JA, Ellsworth RE, Shriver CD. Windber Research Institute, Windber, PA; Invitrogen Informatics, Carlsbad, CA; Walter Reed Army Medical Center, Washington, DC.

5016

Discovery of serum biomarkers for breast cancer detection. Sheta EA, Bryson JK, Meyers GL, Hollingsworth A. Power3 Medical Products, Inc., The Woodlands, TX; Mercy Women’s Center, Oklahoma City, OK.

5017

Protein markers for the stratification of breast cancer patients. Quong JN, Rosenberg AL, Farooqi S, Yeow W-S, Brill KL, Minkeau A, Sabherwal Y, Quong AA. Thomas Jefferson University and Hospital, Philadelphia, PA.

5018

Detection of oligometastases in breast cancer by using tumor markers. Ertl I, Heinemann V, Bauerfeind I, Laessig D, Nagel D, Seidel D, Stieber P. Institute of Clinical Chemistry, Munich, Germany; Medical Department III, Munich, Germany; Gynecological Department, Munich, Germany.

Prognosis and Response Predictions: Prognostic Factors – Methods 5026-5040 5026

Web calculators for estimating the risk of breast cancer death and the impact of adjuvant treatment on that risk. Michaelson JS, Chen L, Martei Y, Smith B, Younger J. Massachusetts General Hospital, Boston, MA.

5027

Nodal ratios as an alternative to pN-staging in node-positive breast cancer: a validation study. Vinh-Hung V, Vlastos G, Fioretta G, Usel M, Neyroud-Caspar I, Rapiti E, Verkooijen L, Bouchardy C. Institute for Social and Preventive Medicine, Geneva University, Geneva, Switzerland; UZ Brussel, Jette, Brussels, Belgium; International Nodal Ratio Working Group; Geneva University Hospitals, Geneva, Switzerland.

5028

Automated image analysis for high-throughput quantitative detection of ER and PgR expression levels in large-scale clinical studies: the TEAM trial experience. Faratian D, Kay C, Campbell F, Robson T, Grant M, Rea D, Bartlett J. Edinburgh Cancer Research Centre, Edinburgh, Scotland, United Kingdom; University of Birmingham, Birmingham, United Kingdom.

5029

Estrogen receptor and breast cancer survival in a Kaiser permanente population-based study: comparison of quantitative reverse transcriptase polymerase chain reaction and immunohistochemistry. Habel LA, Achacoso N, Maddala T, Alexander C, Baehner FL, Shak S, Quesenberry C, Gown AM, Goldstein LC. Kaiser Permanente, Oakland, CA; Genomic Health Inc, Redwood City, CA; PhenoPath Laboratories, Seattle, CA.

5030

Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis. Søiland H, Skaland I, Van Diermen B, Janssen EAM, Kørner H, Varhaug JE, Søreide JA, Baak JPA. Stavanger University Hospital, Stavanger, Norway; Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway; Free University, Amsterdam, Netherlands.

5031

Human epidermal growth factor receptor 2 (Her-2/Neu), immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing at McGill University Health Centre: a comparison of absolute FISH copies (FISH-ABS abs) with Her-2 COPY/chromosome 17 ratio (FISH-17 RATIO) in 198 consecutive early breast cancer cases. Sade S, Momta P, Quenneville L, Mihalcioiu C, Omeroglu A, Ragaz J. McGill University Health Centre, Montreal, QC, Canada; McGill University, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada.

5032

Quality control procedures are essential in accurate HER2 FISH testing using automated morphometric image analysis. Barry TS, Tse C, Goldstein LC, Kim PM, Kussick SJ, Kandalaft P, Gown AM. Phenopath Labs, Seattle, WA.

5033

Impact of ERBB2 on prognosis and microarray data. Koscielny S. Institut Gustave Roussy, Villejuif, France.

5034

Reproducibility of HER2-analysis in a national survey performed at 24 routine pathology departments in Sweden. Ferno M, Haglund M, Bendahl P-O, Hatschek T, Kolaric A, Kovacs A, Olsson A, Olsson H, Ryden L, Strand C. University Hospital, Lund, Sweden; University Hospital, Malmo, Sweden; Karolinska University Hospital, Stockholm, Sweden; University Hospital, Orebro, Sweden; University Hospital, Gothenburg, Sweden; University Hospital, Linkoping, Sweden.

5035

Assessing HER-2 status via virtual microscopy. Bloom KJ, Kyshtoobayeva A, Chen S, Hii A. CLARiENT, Aliso Viejo, CA.

5036

Intrinsic near-infrared spectroscopic biomarkers applied for evaluation of final pathological response to neaoadjuvant chemotherapy. Kukreti S, Cerussi AE, Tanamai VW, Tromberg BJ, Rita M, David H, Gratton E. University of California, Irvine, CA; University of Illinois, Urbana-Champaign, IL.

5037

Prognosis-prediction model using multimarker in lymph node negative breast cancer by decision tree analysis. Jung S-Y, Han W, Han M-R, Park IA, Ko E, Kim E, Lee JW, Cho J, Kim S-W, Hwang K-T, Noh D-Y. Seoul National University Hospital, Seoul, Republic of Korea.

5038

Bayesian analysis of recurrence in lymph node positive and lymph node negative breast cancer patients. Maskery S, Hu H, Liebman M, Shriver C, Verbanac K, Tafra L, Rosman M. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC; East Carolina University, Greenville, NC; Ann Arundel Medical Center, Annapolis, MD.

5039

Stage migration of breast cancer using two techniques of tumor size assessment and its impact on projection for survival and treatment decision making. Phillips J, Staszewski H, Schuss A, Buyuk A. Winthrop University Hospital, Mineola, NY.

5040

Withdrawn

Treatment: DCIS 5041-5047 5041

Sentinel node biopsy in ductal carcinoma in situ of breast - a meta-analysis. Ansari B, Ogston SSA, Purdie CCA, Adamson DJA, Brown DC, Thompson AM. Dundee University, Dundee, Scotland, United Kingdom.

5042

Pathologic and radiographic response of ER-positive DCIS to neoadjuvant letrozole therapy. Hwang ES, Chen Y-Y, Wolverton DE, Lessing JN, Shim V, Devries S, Anderson J, Johnson LR, Hylton NM, Esserman LJ, Waldman FM. University of California, San Francisco, CA; Kaiser Permanente Oakland Medical Center, Oakland, CA; California Pacific Medical Center, St. Luke’s Hospital, San Francisco, CA; Emory University School of Medicine, Atlanta, GA; University of California, San Francisco, CA.

5043

ERISAC trial: evidence exemestane effects oestrogen receptor (ER) positive ductal carcinoma in situ (DCIS) proliferation. Bundred NJ, Cramer A, Cheung KL, Johnson RL, Flint P, Young O, Grassby S, Turner L, Baildam A, Barr L, Byrne GJ, Dixon JM. University Hospital of South Manchester, Manchester, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Western General Hospital, Edinburgh, United Kingdom.

5044

Genetic and phenotypic characteristics in pleomorphic lobular carcinoma in situ. Chen Y-Y, Roydasgupta R, DeVries S, Anderson J, Wa C, Fitzgibbons P, Jacobs T, MacGrogan G, Peterse H, VincentSalomon A, Tokuyasu T, Hwang ES, Schnitt S, Waldman FM. University of California, San Francisco, CA; St Jude Med Ctr, Fullerton, CA; Virginia Mason Med Ctr, Seattle, WA; Institute Bergonie, Bordeaux, France; Netherlands Cancer Institute, Amsterdam, Netherlands; Insititute Curie, Paris, France; Beth Israel Deaconess Med Ctr, Boston, MA.

5045

Molecular profiling of DCIS: identification of distinct subgroups of potential prognostic importance. Clark SE, Marshall JF, Hart IR, Carpenter R, Jones JL. St. Bartholomew’s Hospital, London, United Kingdom; Institute of Cancer, QMUL, London, United Kingdom.

5046

Suboptimal local control of ductal carcinoma in situ of the breast is associated with inferior 10-year breast cancer specific survival in a population-based cohort of women treated with breast conserving surgery. Wai ES, Alexander CS, Culp M, Moccia P, Mackinnon M, Moore S, Olivotto IA. BC Cancer Agency - Vancouver Island Centre, Victoria, BC, Canada; University of British Columbia, Victoria, BC, Canada.

5047

Can subcutaneous mastectomy be considered an alternative for ductal carcinoma in situ treatment, when breast conservation is not possible? Giménez Climent MJ, Merck B, LLopis Martínez F, Sancho Merle F, Vázquez Albaladejo C. Fundación Instituto Valenciano de Oncología, Valencia, Spain.

Treatment: Male Breast Cancer 5048-5051 5048

Male breast cancer (MBC): impact of early diagnosis and adjuvant treatments. Analysis of 983 cases. Cutuli B, Cohen-Solal-Le-Nir C, Serin D, Kirova Y, Belkacemi Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H, Tunon de Lara C, Edeline J, Penault-Llorca F, Romestaing P, Delva C. Polyclinique de Courlancy, Reims, France; Sylia-Stat, Bourg La Reine, France.

5049

Survivin and COX-2 expression in male breast cancer. Younis T, Dakin-Hache KA, Rayson D, Dewar R, Gray S, Barnes PJ. Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Cancer Care Nova Scotia, Halifax, NS, Canada; Dalhousie Medical School, Halifax, NS, Canada.

5050

Patterns of body size in male breast cancer and impact of obesity on disease outcome. Kulkarni S, Franssen E, Madarnas Y. Queen’s University, Kingston, ON, Canada.

5051

Expression of basal-like markers in male breast cancers. Flanagan MB, Bhargava R, Dabbs DJ, Thull D, Chivukula M. Magee-Womens Hospital, Pittsburgh, PA.

5056

Randomized placebo-controlled phase l l trial with preoperative epirubicin and cyclophosphamide +/- gefitinib in patients with operable and estrogen receptor negative breast cancer. Ejlertsen B, Bentzon N, Jacobsen E, Kromann N, Ottestad L, Ingvar C. University Hospital of Copenhagen, Copenhagen, Denmark; Herlev Hospital, Herlev, Denmark; Vejle Hospital, Vejle, Denmark; University Hosp. of Copenhagen Rigshospitalet, Copenhagen, Denmark; Norske Radiumhospital, Oslo, Norway; University Hospital Lund, Lund, Sweden.

5057

Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine + epirubicin + cyclophosphamide vs 5-FU + epirubicin + cyclophosphamide in operable breast cancer. Roché H, Penault-Llorca F, Berton Rigaud D, Tubiana Mathieu N, Ferrero J-M, Coudert B, Mousseau M, Monnier A, Orfeuvre H, Audhuy B, Rotarski M, Homokos H, Fumoleau P. Inst Claudius Régaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre René Gauducheau, St. Herblain, France; Hôpital Dupuytren, Limoges, France; Centre Antoine Lacassagne, Nice, France; Centre Georges François Leclerc, Dijon, France; CHU de Grenoble, La Tronche, France; CH de Montbeliard, Montbeliard, France; CH de Fleyriat, Bourg en Bresse, France; Hôpital Pasteur, Colmar, France; Centre Oncologie Du Pays Basque, Bayonne, France; Roche, Neuilly sur Seine, France.

Treatment: Neoadjuvant Therapy 5052-5076 5052

Significant improvement in disease free and overall survival with neoadjuvant, dose intensified two weekly treatment with anthracycline and taxane in primary breast cancer, including inflammatory disease. Fifty five months median follow up results of a multicenter prospective randomised phase III AGO-trial. Untch M, Konecny G, Moebus V, Bauerfeind I, Thomssen Ch, Harbeck N, Kuhn W, Bothmann G, Wallwiener D, Kreienberg R, Lueck HJ. Helios Klinikum Berlin Buch, Berlin, Germany; Mayo Clinic, Rochester, MN; Klinikum Frankfurt Hoechst, Frankfurt, Germany; University of Munich Grosshadern, Munich, Germany; University of Halle, Halle, Germany; Technical University of Munich, Munich, Germany; University of Bonn, Bonn, Germany; Städtisches Klinikum, Wolfsburg, Germany; University of Tuebingen, Tuebingen, Germany; University of Ulm, Ulm, Germany; Horst Schmitt Kliniken, Wiesbaden, Germany.

5053

Evaluating the efficacy and safety of trastuzumab given concomitantly to epirubicin/cyclophosphamide ¢ docetaxel±capecitabine as neoadjuvant treatment of HER2 overexpressing primary breast cancer. First analysis of the GBG/AGO intergroup-study “GeparQuattro”. Untch M, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, von Minckwitz G. Frauenklinik, Berlin, Germany; Senologie, Brustzentrum, Düsseldorf, Germany; University Hospital Frankfurt, Frankfurt, Germany; Neu-Isenburg, Germany; Frauenklinik mit Poliklinik, Erlangen, Germany; Senologiezentrum Ostschweiz SENZO, St. Gallen, Switzerland; Onkologie Bethanien, Frankfurt, Germany; Frauenklinik, München, Germany; Frauenklinik, Hannover, Germany.

5058

Sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients: results of the planned interim analysis and analysis of predictive parameters. Supported by PHRC AOM/2OO2/02117, Pfizer inc., Roche, sanofi-aventis. Marty M, Guinebretiere J-M, Mathieu M-C, Sigal-Zafrani B, de Roquancourt A, Spielmann M, Giacchetti S, Extra J-M, Spyratos F, de The H, Pierga J-y, Salmon R, Mefti-Lacheraf F, Asselain B. Saint Louis University Hospital, Paris, France; Centre Rene Huguenin, Saint Cloud, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France.

5054

Development of a genomic tool to predict pathologic complete remission in a community-based, preoperative, phase II trial of 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel-capecitabine for stage II, III breast cancer. Holmes FA, Hellerstedt B, Pippen J, Vukelja SJ, Kocs D, Collea R, Blum JL, McIntyre K, Ward FT, Pusztai L, Boehm KA, Asmar L, O’Shaughnessy J. US Oncology Research, Houston, TX; Texas Oncology, P.A., Houston, TX; Baylor-Charles A. Sammons Cancer Center, Dallas, TX; Texas Oncology Cancer Centers, Austin, TX; Tyler Cancer Center, Tyler, TX; Texas Cancer Center, Round Rock, TX; New York Hematology and Oncology, Albany, NY; Texas Oncology, P.A., Dallas, TX; M.D. Anderson Cancer Center, Houston, TX.

5059

Neoadjuvant capecitabine plus docetaxel ± trastuzumab therapy for recently diagnosed breast cancer: phase II results. Tripathy D, Moisa C, Gluck S. University of Texas Southwestern Medical Center, Dallas, TX; Roche Laboratories, Inc, Nutley, NJ; University of Miami, Miami, FL.

5060

Dose-dense docetaxel, carboplatinum and trastuzumab as neoadjuvant therapy for human epidermal growth factor receptor-2 - positive stage II and III breast cancer. Han HS, Doliny P, Blaya M, Gluck S, Slingerland J, Silva O, Welsh C, Hurley J. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.

5061

High pathologic complete response rate effectively predicted by proliferation index in HER2-positive localized breast cancer treated with weekly paclitaxel followed by FEC with concurrent trastuzumab. Pernas S, Urruticoechea A, Falo C, Pardo B, Villanueva R, Ortega R, Garcia A, Moreno A, Perez J, Gil M. Institut Català d’OncologiaH.U. de Bellvitge. IDIBELL, L’Hospitalet-Barcelona, Spain.

5062

The influence of T-cells on the response to a neodjuvant therapy with docetaxel/epirubicin/cyclophosphamide (TEC). Kemming D, Bosse U, Vogt U, Schlotter CM, Tidow N, Brandt BH. University Medical Center Hamburg Eppendorf, Hamburg, Germany; Institute of Pathology, Osnabrueck, Germany; European Laboratory Association, Ibbenbueren, Germany; Clinic Center Ibbenbueren, Ibbenbueren, Germany; Uiniversity of Muenster, Muenster, Germany.

5055

Primary systemic therapy using docetaxel/ cyclophosphamide/bevacizumab (TCB) followed by doxorubicin (A) in operable or locally advanced breast cancer (BC). Makhoul I, Klimberg S, Henri-Tillmen R, Westbrook K, Hutchins L. University of Arkansas for Medical Sciences, Little Rock, AR.

5063

Preliminary recurrence and survival analysis of patients (pts) receiving neoadjuvant q4week carboplatin and weekly paclitaxel ± weekly trastuzumab in resectable and locally advanced breast cancer: update of BrUOG BR-95. Sikov WM, Fenton MA, Strenger R, Dizon DS, Legare RD, Graves TA, Brown University Oncology Group. Rhode Island Hospital, Providence, RI; Women and Infants Hospital, Providence, RI; The Miriam Hospital, Providence, RI.

5064

Pharmacokinetic and pharmacodynamic analysis of cyclophosphamide, epirubicin and capecitabine vs 5-FU, epirubicin and cyclophosphamide as neoadjuvant therapy in breast cancer patients. Milano G, Deporte R, René N, Etienne-Grimaldi M-C, Berton Rigaud D, Ferrero J-M, Dalenc F, Piutti M, Homokos H, Fumoleau P. Centre Antoine Lacassagne, Nice, France; Centre René Gauducheau, Saint Herblain, France; Institut Claudius Regaud, Toulouse, France; Roche, Neuilly sur Seine, France; Centre Georges François Leclerc, Dijon, France.

5071

The farnesyl transferase (FT ase) inhibitor (FTI) tipifarnib inhibits FT ase in vivo and enhances the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer (LABC). Sparano JA, Coppola D, Kazi A, Merajver S, Vahdat L, Li T, Pellegrino C, Munster P, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Sebti S. Montefiore-Einstein Cancer Center, Bronx, NY; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Weill Medical College of Cornelly University, NY, NY; Columbia University, NY, NY; National Cancer Institute, Bethesda, MD.

5072

A phase 2 trial of neoadjuvant letrozole for postmenopausal patients with stage 2 and 3 ER and/or PgR+ breast cancer endpoint comparisons. Ellis M, Luo R, Tao Y, Crowder R, Hoog J, Guintoli T, Commean P, Carey L, Harris L, Fleming G, Esserman L, Budd T, Iversen E, Olson J. Siteman Cancer Center, MO; UNC-CH, NC; DFCI, MA; U Chicago, IL; UCSF, CA; Cleveland Clinic, OH; Duke, NC.

5065

Does combination of neoadjuvant and adjuvant chemotherapy improve outcome in operable breast cancer patients? Knauer M, Haid A, de Vries A, Schneider Y, Lang A, Winder T, Alton R, Wenzl E. University Teaching Hospital, Feldkirch, Austria.

5073

A randomized phase II neoadjuvant trial in patients with stage II-III and inflammatory breast cancer. Somlo G, Paz B, Shen J, Garberoglio C, Luu T, Chung C, Hurria A, Frankel P, Baker N, Wilczynski S, Arnold K, Yeb Y. City of Hope Comprehensive Cancer Center, Duarte, CA.

5066

Pathologic complete response following paclitaxel (cremophor or albumin bound) + carboplatin ± trastuzumab ± bevacizumab sequenced after in vivo chemosensitivity-adapted dose-dense doxorubicincyclophophamide in inflammatory breast cancer. Mehta RS, Schubbert T, Jackson D, Hsiang D, John B. University of California, Irvine, Orange, CA.

5074

Clinical relevance of neoadjuvant chemotherapy in invasive lobular carcinoma of the breast. Vrancken Peeters M-JTFD, Linn SC, Loo CE, Peterse HL, Rutgers EJTh, Rodenhuis S. Netherlands Cancer Institute, Amsterdam, Netherlands.

5075

Tumor and normal interstitial fluid proteomic characterization in breast cancer patients receiving neoadjuvant chemotherapy. Cortesi L, Barchetti A, De Matteis E, Ruscelli S, Della Casa L, Tazzioli G, Lazzaretti MG, Iannone AC, Federico MR. University of Modena and Reggio Emilia, Modena, Italy; Carpi Hospital, Carpi, Modena, Italy.

5076

Pathological and clinical outcomes in response to neoadjuvant chemotherapy: a comparison of basal-like, hormone receptor-positive and HER2-positive breast cancers. Allada N, Osborne CR, Xie X-J, Ashfaq R, Bian A, Tripathy D. UT Southwestern Medical Center, Dallas, TX; Baylor Sammons Cancer Center, Dallas, TX.

5067

Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study. Lombardi D, Scalone S, Crivellari D, La Mura N, Miolo G, Murrone A, Perin T, Coran F, Candiani E, Massarut S, Veronesi A. Centro di Riferimento Oncologico, Aviano, PN, Italy.

5068

Neoadjuvant biweekly chemotherapy with liposomal doxorubicin and docetaxel in patients with stage II-III breast cancer. Alvarez I, Modolell A, Mayordomo JI, Heras L, Villadiego K, Rolfo CD, Garcia-Bueno JM, Pica P, Murillo L, Morales S, Valero P, Florian J. H San Jorge, Huesca; Inst Oncologia Corachan, Barcelona; H Clinico, Zaragoza; Cruz Roja, Hospitalet; H Sagrat Cor, Barcelona; Clin Roger, Palma de Mallorca; Clin Serosa, Palma de Mallorca; Hosp Infanta Cristina, Badajoz; H Reina Sofia, Tudela; Clin Perpetuo Socorro, Lerida; Clin Infanta Luisa, Sevilla; H Barbastro, Barbastro, Spain.

5069

Phase II study of a 3-weekly liposome-encapsulated doxorubicin/docetaxel/pegfilgrastrim in combination with weekly trastuzumab as primary treatment in HER2 positive (HER2+) early stage breast cancer patients (II-IIIa). Intermediate analysis of 26 patients. GEICAM 2003-03 study. Antón A, Ruiz-Simon A, Plazaola A, Segui MA, Muñoz M, Calvo L, Puértolas T, Guerrero A, Alfaro J. Spanish Breast Cancer Research Group (GEICAM), Spain.

5070

A phase IV study of neo-adjuvant combination chemotherapy with pegylated liposomal doxorubicin (CAELYX®) and vinorelbine for locally advanced breast cancer. Shen ZZ, Shao MZ, Xu HB, Wang L, Wang SY, Liu J, He QP, Su XF, Jiang FZ, Zhang B. Fudan Univ. Affiliated Tumor Hospital, Shanghai, China; Cancer Institute & Hospital Chinese Academy of Medical Sciences, Beijing, China; The Fourth Military Medical Univ. Affiliated No1. Hospital, Xi’an, Shanxi, China; Shandong Tumor Hospital, Jinan, Shandong, China; Fujian Provincial Tumor Hospital, Fuzhou, Fujian, China; Shanghai 6th People Hospital, Shanghai, China; Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China; 307 Hospital of PLA, Beijing, China; Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.

Treatment: Surgery 5077-5101 5077

Optimal loco-regional treatment of the primary tumor in metastatic breast cancer patients is associated with a significant survival advantage. Vlastos G, Rapiti E, Bouchardy C, Fioretta G, Verkooijen HM, Storme G, Vinh Hung V. Geneva University Hospitals, Geneva, Switzerland; Institute for Social and Preventive Medicine, University of Geneva, Geneva, Switzerland; National University of Singapore, Singapore, Singapore; Oncology Center UZ, Brussels, Belgium.

5078

NEW START: the United Kingdom sentinel lymph biopsy training programme. A model of how multi-professional training can achieve competent national performance whilst maintaining patient safety. MacNeill F, Mansel R, Horgan K, Keshtgar M, Kissin M, Wishart G, Brown D, NEW START Steering Group and Trainers. Royal College of Surgeons (England), London, United Kingdom.

5079

The effect of dedicated breast surgeons on the short term outcomes in breast cancer. Zork NM, Komenaka IK, Bowling MW, Norton LE, Pennington RE, Clare SE, Goulet RJ. Indiana University School of Medicine, Indianapolis, IN.

5080

Shared decision-making in routine clinical practice: the example of breast cancer in a regional cancer centre in France. Hervé M, Nora M-F, Christelle F, Anne M, Marie Odile C. Centre Léon Bérard, Lyon, France.

5091

Staged sentinel node biopsy to guide timing of breast reconstruction. Ahrendt G, Johnson R, Horton F, Bonaventura M, Falk J, Keenan D, Soran A. Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA.

5081

Paget’s disease of the nipple in a population based cohort. Dalberg K. Danderyds University Hospital, Stockholm, Sweden.

5092

5082

Infiltration of ropivacaine efficacy on acute breast pain after surgery for breast cancer. Preliminary results of a multicentric study. Emmanuelle F, Aline A-F, Catherine B, Alain B, Smail H, Max B, Cyrus M, Jean-Remi G, Sameh Y, Serge L, Jean-Louis B, Louis B, Catherine N, Christian J. Rene Huguenin Cancer Centre, Saint-Cloud, France; Institut Paoli Calmettes, Marseille, France; Institut Gustave Roussy, Villejuif, France; Ambroise Pare Hospital, Boulogne, France.

Rib fractures: a complication of radiation therapy and tissue expansion for breast reconstruction. Huang AH, Wong MS, Whetzel TP, Stevenson TR. University of California-Davis Medical Center, Sacramento, CA.

5093

Does quality of life after breast reconstruction change with time? Thomson HJ, Fallowfield LJ, Winters ZE. University of Bristol, Bristol, United Kingdom; Psychosocial Oncology Group, Brighton, United Kingdom.

5094

Three-dimensional imaging provides valuable clinical data to aid in unilateral tissue expander-implant breast reconstruction. Tepper OM, Karp NS, Small K, Unger J, Pritchard A, Roses D, Shapiro R, Guth A, Axelrod D, Choi M. New York University School of Medicine, New York, NY.

5095

Postoperative analgesia and flap perfusion after pedicled TRAM flap reconstruction - continuous wound instillation with ropivacaine 0.2% - a pilot study. Dagtekin O, Thomas A, Hotz A, Kampe S, Auweiler M, Warm M. University of Cologne, Cologne, Germany; University of Medicine, Charité, Berlin, Germany.

5096

Optimizing surgical technique for total skin-sparing mastectomy. Chattopadhyay R, Radzio A, Kumar A, Foster R, Ewing C, Shelley H, Michael A, Esserman LJ. University of California, San Francisco, San Francisco, CA.

5097

Quality of life and morbidity at medium term follow up after sentinel lymph node, and immediate or delayed axillary disssection. Maryam ANM, Max BM, Laeticia HL, Carole TC, Jean Marc EJM, Agnes TA, Gilles HG. Institut Paoli Calmettes, Marseille, Bouches du Rhone, France.

5098

Radiation after axillary lymph node dissection: impact of neoadjuvant chemotherapy. Kirstein LJ, MacDonald S, Abi Raad R, Taghian AG, Smith BL, Specht MC. Massachusetts General Hospital, Boston, MA.

5099

Intraoperative ultrasound localization of nonpalpable breast cancers. Salmon RJ, Petitperrin F, Ngo C, Fourchotte V, Pollet AG. Institut Curie, Paris, French Polynesia.

5100

Tumor stage of the primary breast cancer is a predictor of the size of local recurrence. Kahlert SD, Roth J, Mayr D, Bauerfeind I, Friese K. Klinikum Grosshadern, LMU, Munich, Germany.

5101

Minimally invasive excision of gynaecomastia - a novel and effective surgical technique. Qutob O, Garimella V, Ihsan N, Drew PJ. University of Hull, Hull, United Kingdom; Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom.

5083

Surgical follow up and clinical presentation of 142 of breast papillary lesions diagnosed by ultrasound guided breast biopsy. Rizzo M, Lund MJ, Oprea G, Schniederjan M, Mosunjac M. Emory University, School of Medicine, Atlanta, GA; Emory University, Rollins School of Public Health, Atlanta, GA.

5084

Oncologic safety of nipple areola complex preservation for breast cancer; 5 year follow-up result. Lee SJ, Kang SH, Baek NW, Kim EM. Yeungnam University of Medical Center, Daegu, Republic of Korea.

5085

Breast surgery for women presenting with stage IV breast cancer. Barkley CR, Bafford AC, Burstein HJ, Winer EP, Lipsitz SR, Smith BL, Iglehart JD, Golshan M. Brigham and Women’s Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA.

5086

Can the resection of primary breast cancer improve survival of patients with stage IV breast cancer? Shien T, Kinoshita T, Shimizu C, Yonemori K, Kohno T, Hojo T, Ando M, Akashi-Tanaka S, Katsumata N, Fujiwara Y. National Cancer Center Hospital, Tokyo, Japan.

5087

Cosmetic outcome after latissimus dorsi based breast reconstruction: comparing the effects of radiotherapy and time. Thomson HJ, Greenwood RJ, Bahl A, Cawthorn S, Winters ZE. University of Bristol, Bristol, United Kingdom; United Bristol Healthcare Trust, Bristol, United Kingdom; Bristol Haematology and Oncology Centre, Bristol, United Kingdom; Frenchay Hospital, Bristol, United Kingdom.

5088

Interval inset of TRAM flaps in immediate breast reconstruction: a technical refinement. Comizio R, Yurkewich K, Collins D. Darmouth Hitchcock Medical Center, Lebanon, NH; Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH.

5089

Immediate two-stage breast reconstruction and irradiation with a tissue expander and an implant: results, risk factors for failure and self-evaluation. Gurriet B, Padovani L, Tallet A, Letrosne E, VAINI V, Boyer A, Houvenaeghel G, Cowen D. Hop Timone, Marseille, France; IPC Cancer Center, Marseille, France; Axium Clinic, Aix en Provence, France; Etoile Clinic, Puyricard, France.

5090

Skin-sparing mastectomy and immediate ‘mini-flap’ reconstruction - a novel technique. Vestey SB, Court FG, Bristol JB, Ghilchick M, Chan CY. Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom.

Tumor Cell Biology: Estrogen and Progestin Receptors 5102-5109 5102

Evidences that progesterone receptor b decreases estrogen receptor gene expression through its interaction to a halfPRE site at estrogen receptor gene promoter. De Amicis F, Zupo S, Malivindi R, Andò S. University of Calabria, Arcavacata di Rende, Italy.

5103

Influence of estrogen receptor expression on HER2 mRNA levels in HER2-gene amplified breast cancer tumors as measured using FISH and the novel DASL assay. Abramovitz M, Audet R, Catzavelos C, Li Z, Provencher C, Ponton A, Leyland-Jones B. VM Institute of Research, Montreal, QC, Canada; McGIll University, Montreal, QC, Canada; Emory University, Atlanta, GA.

5104

Detection of elevated HER2/neu levels in breast cancer cell lines overexpressing estrogen receptor ĝ. Lattrich C, Juhasz-Böss I, Ortmann O, Treeck O. University of Regensburg, Regensburg, Germany.

5105

5106

5107

5108

5109

5114

Biomarker analyses in Japanese refractory advanced breast cancer patients treated with lapatinib monotherapy. Toi M, Iwata H, Fujiwara Y, Wakamatsu T, Kanezaki M, Katsura K, Koehler M, Ellis C, Gagnon R, Allen K, Martin AM, Sasaki Y, Takashima S. Tokyo Metropolitan Komagome Hosp, Japan; Aichi Cancer Ctr Hosp, Japan; Nat. Cancer Ctr, Tokyo, Japan; GSK, Japan; GSK, PA; Saitama Med Univ, Japan; Shikoku Cancer Ctr, Ehime, Japan.

5115

EGFR, pAkt and pPI-3 kinase are co-expressed in circulating tumor cells of breast cancer patients. Kallergi G, Kalykaki A, Agelaki S, Mavroudis D, Georgoulias V. School of Medicine, University of Crete, Heraklion, Crete, Greece; University General Hospital of Heraklion, Heraklion, Crete, Greece.

5116

Expression of estrogen receptors ĝ in triple negative breast cancer. Litwiniuk M, Filas V, Breborowicz J. Poznan University of Medical Sciences, Poznan, Poland.

CD146-downstream signaling mediating breast tumour invasion/metastasis. Yousief ZA, Abdraboh ME, Masood HM, Ouhtit A. Louisiana State University Health Sciences Center; Stanley S Scott Cancer Center, New Orleans, LA.

5117

Immunohistochemical expression of CK5/6, CK17, ERß in triple negative breast cancer patients. Liu Z, Wu J, Ping B, Shao Z, Shen Z. Cancer Hospital, Shanghai, China.

Xenograft model for the evaluation of breast cancer metastatic progression. Zang XP, Lerner MR, Brackett DJ, Pento JT. University of Oklahoma, HSC, Oklahoma City, OK.

5118

High phosphorylation of estrogen receptor Ĝ serine 167 and low p53 protein accumulation improve survival in estrogen receptor-positive breast cancer patients treated with tamoxifen. Sugiura H, Toyama T, Kondo N, Kobayashi S, Fujii Y, Yamashita H. Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.

Rhodiola crenulata decreases invasion and regulates cyclooxygenase-2 expression in a highly metastatic ER-negative breast cancer cell line. Doerner JL, Smith-Schneider S, Arenas RB. University of Massachusetts, Amherst, MA; Pioneer Valley Life Sciences Institute, Springfield, MA; Baystate Medical Center, Springfield, MA.

5119

Lymphangiogenesis in breast cancer: correlation with lymphatic microvessel density and clinicopathologic parameters. Lee I-k, Park Y, Kim D, Jo B-h, Lee W, Yoon S, Kim H, Park S-y. MizMedi Hospital, Seoul, Korea.

Mammary fibroblasts express ERĝ1 and ERĝ2 and can modulate breast cancer behaviour in a co-culture model. Green CA, Scott DJ, Hughes TA, Cummings M, Hanby AM, Shaaban AA, Speirs V. University of Leeds, Leeds, W Yorks, United Kingdom.

Characterization of estrogen receptor positive breast cancers: gene expression analysis of archived tumours. Thorat M, Morimiya A, Sledge G, Badve S. Indiana University, Indianapolis, IN.

Tumor Cell Biology: Metastasis / Invasion 5110-5119 5110

5111

5112

5113

7:00-9:30

Controversies in Adjuvant Endocrine Therapy for Breast Cancer

Identification of gene expression differences in primary breast tumors from node-negative and node-positive women. Field LA, Seebach JF, Love BJ, Deyarmin B, Kane J, Hooke JA, Ellsworth RE, Shriver CD. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC; Invitrogen Informatics, Carlsbad, CA.

Sponsored by Physicians Education Resource Register on line at: www.adjuvantai.cancerconferences.com For information, contact: Kathryn Wallace 214-367-3329 Fax: 214-367-3303 [email protected]

Identification of a gene expression breast cancer metastasis profile. Seebach J, Field LA, Love B, Hollern K, Hooke JA, Ellsworth RE, Shriver CD. Walter Reed Army Medical Center, Washington, DC; Windber Research Institute, Windber, PA; Invitrogen Informatics, Carlsbad, CA. Genomic discrimination of metastatic from non-metastatic primary breast tumors. Ellsworth RE, Patney HL, Ellsworth DL, Love B, Hooke JA, Shriver CD. Windber Research Institute, Windber, PA; Invitrogen Informatics, Carlsbad, CA; Walter Reed Army Medical Center, Washington, DC. Tumor microenvironment in breast cancer metastasis: direct tissue protein profiling of tumor-associated stroma from invasive breast cancer patients with versus without axillary lymph node metastasis. Ellsworth DL, Seeley EH, Ellsworth RE, Deyarmin B, Sanders ME, Hooke JA, Caprioli RM, Shriver CD. Windber Research Institute, Windber, PA; Vanderbilt University, Nashville, TN; Walter Reed Army Medical Center, Washington, DC.

SATELLITE SYMPOSIUM - Ballroom A

Supported by an educational grant from Novartis Pharmaceuticals Corporation

Sunday, December  7:00-9:00

POSTER SESSION 6 & CONTINENTAL BREAKFAST – Exhibit Hall B

(#6001-6119, 5015) Prognosis and Response Predictions: Prognostic Factors II 6001-6034 6001

Loss of nuclear p27 is independently associated with young age at breast cancer diagnosis. DeMichele A, Mick R, Beaver J, Ruddy K, Sherman L, McNally S, Acs G, Wang Y, Feldman M, Norman S, Rebbeck T, Lee W, Weber B. University of Pennsylvania, Philadelphia, PA.

6002

Stratifying primary operable breast cancers by steroid and HER-2 expression status predicts short term disease free survival. Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens M-R, Neven P. UZ Leuven, Leuven, Belgium; ESAT; UZ Leuven.

6003

Comparison of prognostic value of hormonal receptors (HR) and HER-2 overexpression on overall survival (OS) in breast cancer. Tacca O, Abrial C, Penault-Llorca F, Mouret-Reynier M-A, Raoelfils I, Ferrière J-P, Gimbergues P, Curé H, Chollet P, Durando X. Centre Jean Perrin, Clermont Ferrand, France; INSERM U484, Clermont Ferrand, France; Université d’Auvergne, Clermont Ferrand, France; Institut Jean Godinot, Reims, France.

6004

6005

6006

6007

6008

Correlation of ER/PR status and HER-2 status in invasive breast carcinoma. Bloom KJ, Kyshtoobayeva A, Chen S, Hii A. CLARiENT, Aliso Viejo, CA. Prognostic significance of HER2 status in women with inflammatory breast cancer. Dawood S, Broglio K, Yang W-T, Cristofanilli M, Kau S-W, Hortobagyi GN, Gonzalez-Angulo AM. MD Anderson Cancer Center, Houston, TX. Validation of an immunohistochemical biomarker for identifying Her2+ patients at high risk of recurrence. Seitz RS, Ross DT, Ring BZ, Beck RA, Khoury T, Vardarajan R, Iqbal J, Kulkarni S, Janarthanan BR, Hicks DG. Applied Genomics, Inc, Huntsville, AL; Applied Genomics, Inc, Burlingame, CA; Roswell Park Cancer Institute, Buffalo, NY. Prognostic value of both HER-2 and VEGF-A mRNA overexpression in primary tumors of high-risk breast cancer patients. Fountzilas G, Skarlos D, Wirtz RM, Dafni U, Stropp U, Pectasides D, Papakostas P, Markopoulos C, Karapanagiotis K, Polichronis A, Timotheadou E, Grimani I, Samantas E, Kosmidis P, Kalogeras KT. Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Siemens Medical Solutions Diagnostics GmbH, Leverkusen, Germany. The pathological characteristics of gestational breast cancer. What is different? Ives A, Harvey J, Sterrett G, Saunders C, Semmens J. The University of Western Australia, Perth, WA, Australia; PathWest, Perth, WA, Australia; Curtin University of Technology, Perth, WA, Australia.

6009

The mitotic activity index is able to separate two prognostic subgroups in grade II estrogen receptor (ER)-positive nodenegative breast carcinomas. Geha S, Mazouni C, Spielmann M, Garbay J-R, Bourgier C, Delaloge S, Andre F, Mathieu M-C. Institut Gustave-Roussy, Villejuif, France; Hopital La Timone, Marseille, France.

6010

Assessing final pathological response to neoadjuvant chemotherapy using diffuse optical spectroscopy. Tanamai VW, Cerussi AE, Hsiang D, Mehta R, Tromberg BJ. University of California, Irvine, CA.

6011

The ProEx Br immunohistochemical assay has prognostic utility in early stage breast cancer using a manual scoring method. Chatterjee A, He Q, Nelson R, Gore M, Hudson R, Murphy PG, Malinoski D, Fisher TJ, Bigras G, Hugh J, Whitehead CM. BD Diagnostics Tripath, Durham, NC; Dynacare Kasper Medical Laboratories, Edmonton, AB, Canada.

6012

CXCR4 coexpression with EGFR/HER2 positivity in breast cancer is a poor prognostic factor in patients with isolated tumor cells in bone marrow. Cabioglu N, Igci A, Ozmen V, Muslumanoglu M, Dagoglu T, Sahin AA, Yildirim EO, Aktas E, Bilgic S, Price JE, Deniz G, Kecer M. University of Istanbul, Istanbul Medical Faculty, Istanbul, Turkey; UT MD Anderson Cancer Institute, Houston, TX; University of Istanbul, Institute of Experimental Medical Research, Istanbul, Turkey; UT MD Anderson Cancer Center, Houston, TX.

6013

Characterization of a good prognosis set of genes in breast cancer patients with at least 5 involved lymph nodes. Sevenet N, Badel A, Marquand E, Cuvier C, de Roquancourt A, Geneix C, Janin A, Launay J-M, Cottu PH, Camproux A-C, Marc E. Hospital Lariboisiere, Paris, France; Universite Denis Diderot, Paris, France; Hospital Saint Louis, Paris, France; Institut Curie, Paris, France.

6014

Cytogenetic heterogeneity within breast tumor specimens is revealed by the eXagenBC test. Davis LM, Tang L, Carpio C, Garcia N, Bauer R, Perrine M, Sanchez L, Chakraborty S, Zhou F, Flejter W, Tepperberg J, Alsobrook J. Exagen Diagnostics, Albuquerque, NM; LabCorp America, Brentwood, TN; LabCorp America, Research Triangle Park, NC.

6015

An alternatively spliced variant of cyclin D1 is present in human breast carcinoma. Gupta-Abramson V, Feldman M, Troxel A, Wang Y, Sherman L, McNally S, Lee W, Diehl A, DeMichele A. University of Pennsylvania, Philadelphia, PA.

6016

Evaluation of prognostic factors influencing the therapeutic management of post-treatment metastatic breast cancer. A retrospective study on 1096 patients who have been treated between 1980 to 2005 at the Centre Antoine Lacassagne. Largillier R, Chamorey E, Doyen J, Courdi A, Ettore F, Maestro C, Raoust I, Lallement M, Namer M, Ferrero JM. Centre Antoine Lacassagne, Nice, France.

6017

Brain metastases in HER2+ metastatic breast cancer patients: analysis of prognostic factors. Henry S, Pierga J-Y, Asselah J, Cottu P, Mignot L, Sigal-Zafrani B, Bollet M, Diéras V. Institut Curie, Paris, France.

6018

Clinical outcome of patients with triple negative breast cancer who develop brain metastasis. Hines SL, Vallow L, Tan W, Jain A, Perez E. Mayo Clinic, Jacksonville, FL.

6019

Characteristics of breast cancer patients with central nervous system metastases and factors associated with survival after development of central nervous system metastasis. Harputluoglu H, Dizdar O, Aksoy S, Kilickap S, Dede DS, Ozisik Y, Guler N, Barista I, Gullu I, Selek U, Cengiz M, Zorlu F, Tekuzman G, Altundag K. Hacettepe University Institute of Oncology, Ankara, Turkey.

6020

Brain metastases in breast cancer: a retrospective cohort study of 187 patients and prognostic markers determination. Svoboda M, Fabian P, Ondrova B, Palacova M, Grell P, Gombosova J, Princ D, Slaby O, Slampa P, Vyzula R. Masaryk Memorial Cancer Institute, Brno, Czech Republic.

6022

Topoisomerase 2 Ĝ gene amplification and protein expression in fresh and recurrent breast cancers. Tseng LM, Liu JM, Lan C, Lin LC, Hsu DH, Chang CP, Kao HL. Taipei-Veterans General Hospital and National Yang Ming University Medical School, Taipei, Taiwan; National Health Research Institutes, Taipei, Taiwan; Roch Products Ltd., Taipei, Taiwan.

6023

6024

6025

6026

6027

Cyclin-dependent kinase 1 and 2 activity as prognostic markers in early breast cancer. van Nes JGH, Smit VTHBM, Putter H, Kuppen PJ, Kim SJ, Masuda N, Inaji H, Yoshidome K, Tsujimoto M, Akiyama F, Tsukamoto F, Ishihara H, Noguchi S, van de Velde CJH. Leiden University Medical Centre (LUMC), Leiden, Netherlands; LUMC, Leiden, Netherlands; Graduate School of Medicine, Osaka Univ., Suita, Japan; Sysmex Corporation, Kobe, Japan; Osaka National Hospital, Osaka, Japan; Osaka Medical Center for Cancer & Cardiovascular Diseases, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Cancer Institute Hospital, Koto-ku, Japan; Osaka Kosei-Nenkin Hospital, Osaka, Japan. Prognosis and clinical outcome of patients with node negative ≤ 1cm breast cancer. Amar S, Ann ME, Geiger XJ, Rebecca MB, Winston T, Kyle CE, Beiyun C, Boughey JC, Edith PA. Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Mayo Clinic Rochester, Rochester, MN. MAPK expression is associated with poor outcome in patients with hormone receptor negative breast cancer. Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, Kucucuk S, Dincer M, Aydiner A, Topuz E. Istanbul University Institute of Oncology, Istanbul, Turkey; Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey. The role of the stromal immune response in breast cancer recurrence. Hall JA, Bertos N, Finak G, Pepin F, Zhao H, Sadekova S, Meterissian S, Hallett M, Park M. McGill University, Montreal, QC, Canada. Comparison of patients with “triple negative” breast cancer (ER-, PR-, HER2-) in a cohort of 1052 patients treated in a single institution between 1999 and 2007. Kantelhardt EJ, Pauli N, Grosse R, Vetter M, Holzhausen HJ, Strauss HG, Thomssen C. Martin Luther University, Halle, Germany.

6028

Obesity at diagnosis increases relapse rate and shortens disease free interval in breast cancer patients. Quispe D, Hussain S, Leveau MQ, Mansour R, Burton GV, Shi R, Sun A. Louisiana State University Health Sciences Center, Shreveport, LA.

6029

Elevated MIB-1(%) and c-myc amplification are relevant prognosticators of ER positive/HER2 negative (“luminal A”) primary breast cancers. Schlotter CM, Wassmann K, Vogt U. Klinikum Ibbenbueren, Ibbenbueren, NRW, Germany; European Laboratory Association, Ibbenbueren, NRW, Germany.

6030

Allelic imbalance and predictors of outcome in ipsilateral breast tumor recurrences after systemic therapy for early stage breast cancer. Zekman R, Jaiyesimi I, Nadeau L, Mitchell C, Wallace M, McGrath S, Wills S, Goldstein N, Vicini F. Division of Hematology/ Oncology; William Beaumont Hospital, Royal Oak, MI.

6031

Impact of progesterone receptor (PR) status on survival of estrogen receptor (ER) positive women with invasive breast cancer (IBC). Ingle AM, Kumar P, Dagen T, Day K, Baney B, Galley AS. Children’s Oncology Group, Arcadia, CA; Mount Nittany Medical Center, State College, PA.

6032

Tumor biology of breast carcinoma in elderly women: comparison between elderly and young postmenopausal women. Okanami Y, Iwase T, Kimura K, Morizono H, IIjima K, Miyagi Y, Nishimura S, Tada K, Makita M, Horii R, Akiyama F. Cancer Institute, Koto-ku, Ariake 3-10-6, Tokyo, Japan.

6033

A community-based single institution registry study of treatment outcomes in breast cancer patients with 4 or more positive lymph nodes. Rivkin SE, Moon J, Atwood M, Tennent N. Swedish Medical Center, Seattle, WA.

6034

HMGA2 with uPAI/PAI-1 as prognostic factors in node negative breast cancer patients. Wischnewsky M, Boecker W, Meyer A, Milde-Langosch K, Bullerdiek J. University of Bremen, Bremen, Germany; University of Muenster, Muenster, Germany; University Hospital HamburgEppendorf, Hamburg, Germany.

Epidemiology and Outreach: Advocacy/Education 6035-6046 6035

Defining endpoints for recurrence in randomized controlled trials of systemic therapy for early breast cancer: a call for standardization. Kilburn LS, Peckitt C, Ireland E, Bliss JM. The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

6036

Has the quality of early breast cancer randomized controlled trials publications improved since CONSORT? A systematic review. Peckitt C, Ireland E, Kilburn LS, Bliss JM. The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

6037

Moving from informed consent to informed choice: an ethical imperative. Devine P, Perlmutter J, Carbine N, Chingos D, Brady C. Cancer Information & Support Network (CISN), Auburn, CA.

6038

BreastCancerTrials.org: from regional pilot to nation-wide clinical trial matching service. Cohen EJ, Bechtold T, Laird J, Anand A, Ernest ML, Pederson, Melisko M, Park J, Hogarth M, Esserman LJ. UCSF, San Francisco, CA; UC Davis, Davis, CA.

6039

Inflammatory breast cancer biorepository: research collaboration. Mason G, Johnson O. Inflammatory Breast Cancer Research Foundation, Bainbridge Island, WA.

6040

Community-based outreach is an effective strategy for linking underserved women to breast cancer screening: data from the Avon Foundation Breast Care Fund. Opdyke KM, Gujrati ML, McCulloch A, Gates-Ferris K, Hurlbert M. Cicatelli Associates Inc., New York, NY; Avon Foundation Breast Cancer Crusade, New York, NY.

6041

Improving access to care in an AVON Foundation Comprehensive Breast Center (AFCBC) serving a predominantly urban African American (AA) patient population. Gabram S, Lund MJ, Lamson P, Harrison C, Koenig E, Bates S, Bumpers H, Green V, Gundry K, Okoli J, Rizzo M, Roberson S, Brawley O. Winship Cancer Institute, Emory University; Georgia Cancer Center for Excellence at Grady; Rollins School of Public Health, Emory University; Morehouse School of Medicine, Atlanta, GA.

6042

A comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population. Palmieri FM, DePeri ER, Mincey BA, Smith JA, Wen LK, Chewar DM, Perez EA. Mayo Clinic, Jacksonville, FL; First Coast Dermatology and Internal Medicine, Jacksonville Beach, FL; Pfizer Oncology, New York, NY.

6043

Enhancing communication between oncologists and breast cancer patients. Kirk MC, Parker B. Y-ME National Breast Cancer Organization, Chicago, IL.

6044

Upfront: new perspectives on breast cancer – report by the Canadian Breast Cancer Foundation-Ontario Chapter (CBCF-OC). Easton B, Trussler T, Wood S, Verma S. Canadian Breast Cancer Foundation, Ontario Chapter, Toronto, ON, Canada; Ottawa Regional Cancer Center, Ottawa, ON, Canada.

6055

Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Hofvind S, Sørum R, Thoresen S. The Cancer Registry of Norway, Oslo, Norway; University of Vermont, Burlington, VT; GlaxoSmithKline Norway, Oslo, Norway.

6045

Counselling women with breast cancer - whose line is it anyway? Court FG, Scarrott S, Cassidy-Gray M, Thomas A, Vestey S, Bristol J, Ghilchik M, Chan HY. Cheltenham General Hospital, Cheltenham, United Kingdom.

6056

6046

Identification and prioritization of unmet medical, educational and psychosocial needs in patients with metastatic breast cancer: results of a patient survey. Kirk M. Y-ME National Breast Cancer Organization, Chicago, IL.

The wish for pregnancy after breast cancer, results of a French survey on 269 youngs breast cancer survivors. Dupré P-FPF, Menez-Orieux CC, Dravet FF, Barrière PP, Classe J-MJM. University Hospital of Brest, Brest, Finistère, France; University Hospital of Nantes, Nantes, Loire Atlantique, France; Anti Cancer Center, Saint Herblain, Loire-Atlantique, France.

6057

Survival of breast cancer over the last 30 years in a cohort of 7651 women and up-to-date estimates for patients recently diagnosed. Huiart L, Bardou V-J, Jacquemier J, Puig B, Tallet A, Reyrat E, Tarpin C, Buttarelli M, Extra J-M, Houvenaeghel G. Institut Paoli-Calmettes; FNCLCC, Paris; Institut Paoli-Calmettes, Marseille, France.

6058

Ethnicity, multiparity and the risk of premenopausal breast cancer. A population-based, multi-ethnic study from Singapore. Verkooijen HM, Yap K, Bhalla V, Chow KY, Chia KS. National University of Singapore, Singapore, Singapore; Geneva University, Geneva, Switzerland; Health Promotion Board, Singapore, Singapore.

6059

Time distribution of the recurrence risk for Chinese breast cancer patients undergoing surgery. Yin W, Lu J, Liu G, Di G, Wu J, Shen K, Shen Z, Shao Z. Cancer Hospital/Cancer Institute, Fudan University, Shanghai, China.

6060

The rates of chemotherapy-induced amenorrhea in patients treated with different regimen at different ages in Chinese breast cancer paients. Zhou L, Yin W, Lu J, Di G, Wu J, Shen K, Han Q, Shen Z, Shao Z. Cancer Hospital, Shanghai, China.

Epidemiology and Outreach: Epidemiology 6047-6060 6047

6048

6049

A family history of breast or ovarian cancer further increases the risk of secondary leukemia, especially chronic leukemia, in breast cancer patients. Verkooijen HM, Fioretta G, Rapiti E, Vlastos G, Neyroud-Caspar I, Chappuis PO, Bouchardy C. Geneva Unversity, Geneva, Switzerland; National University of Singapore, Singapore, Singapore; Geneva University Hospitals, Geneva, Switzerland. HER2 status in a US population-based cohort: results from a tissue microarray-based analysis of 2,898 breast cancers from women enrolled in the nurses’ health study. Tamimi RM, Deitz AC, Schnitt SJ, Colditz GA, Collins LC. Brigham and Women’s Hospital and Harvard School of Public Health, Boston, MA; GlaxoSmithKline, Philadelphia, PA; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Washington University School of Medicine, St. Louis, MO. registHER: patient characteristics and time course of CNS metastases in patients with HER2-positive metastatic breast cancer. Yardley DA, Kaufman PA, Mayer M, Ulcickas Yood M, Tan-Chiu E, Brufsky AM, Rugo HS, Tripathy D, Brammer MG, Paik S. Sarah Cannon Research Institute, Nashville, TN; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Patient Advocate, New York, NY; EpiSource LLC, Yale University School of Medicine, New Haven, CT; Florida Cancer Care, Tamarac, FL; University of Pittsburgh Cancer Center, Pittsburgh, PA; UCSF Comprehensive Cancer Center, San Francisco, CA; University of Texas Southwestern Medical Center, Dallas, TX; Genentech, Inc., South San Francisco, CA; National Surgical Breast and Bowel Project, Pittsburgh, PA.

6050

Short-term cancer risk in a cohort of 2,353 women with high-risk breast lesions. Shim V, Puliganda B, Collins L, Jiang SF, Callahan ME, Kutner S, Habel LA. Kaiser Permanente, Oakland, CA; Beth Israel Deaconess Medical Center, Boston, CA; Kaiser Permanente, Santa Teresa, CA.

6051

Carcinoma and atypical hyperplasia are frequent findings in women with macromastia undergoing reduction mammoplasty: a prospective study. Ambaye AB, Goodwin A, MacLennan SE, Suppan T, Naud S, Weaver DL. Pathology; University of Vermont, Burlington, VT.

6052

Osteoporosis and breast cancer treatment. Quispe D, Shi R, Leveau MQ, Burton G, Sun A. Louisiana State University Health Sciences Center, Shreveport, LA.

6053

Prevalence of anemia in hospitalized French cancer patients: results of a one-day cross-sectional survey. Delaloge S, Hennequin C, Lemarie E, Zureik M, Castaigne S, Tourani J-M. Institut Gustave Roussy, Villejuif Cedex, France; Hopital Saint Louis, Paris, France; CHU - Hopital Bretonneau, Tours Cedex, France; Faculte de Medecine Bichat, Paris, France; Hopital Andre Mignot, Le Chesnay, France; CHU - Hopital La Miletrie, Poitier Cedex, France.

Treatment: Chemotherapy - New Drugs and Formulations 6061-6074 6061

HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer. Burstein H, Awada A, Badwe R, Dirix L, Tan A, Jacod S, Lustgarten S, Vermette J, Zacharchuk C. Dana Farber Cancer Institute, Boston, MA; Medical Oncology Clinic, Brussels, Belgium; Tata Memorial Hospital, Mumbai, India; Medische Oncologie, Wilrijk, Belgium; Cancer Institute of New Jersey, New Brunswick, NJ; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA.

6062

Preliminary results of a phase 2 study of bosutinib (SKI606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer. Campone M, Bondarenko I, Brincat S, Epstein RJ, Munster PN, Dubois E, Martin EC, Turnbull K, Zacharchuk C. Centre René Gauducheau, St. Herblain, France; Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine; Sir Paul Boffa Hospital, Floriana, Malta; Queen Mary Hospital, Pokfulam, Hong Kong; H. Lee Moffitt Cancer Center, Tampa, FL; Wyeth Research, Paris, France; Wyeth Research, Cambridge, MA.

6063

mTOR inhibitor nanoparticle albumin-bound (nab) rapamycin is effective in a breast cancer xenograft model. Trieu V, De T, Yim Z, Cordia J, Yang A, Beals B, Ci S, Nguyen P, Louie L, Desai N. Abraxis BioScience, Inc., Los Angeles, CA.

6064

6065

6066

A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. Infante J, Burris HA, Lewis N, Donehower R, Redman J, Friedman S, Scherle P, Fridman J, Li J, Emm T, Troy S, Eckhardt SG. Sarah Cannon Research Institute, Nashville, TN; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins Cancer Center, Baltimore, MD; Incyte Corporation, Wilmington, DE; University of Colorado Health Sciences Center, Denver, CO. Preclinical characterization of INCB7839, a potent and selective inhibitor of ErbB ligand and HER2 receptor shedding: inhibition of ADAM10 and ADAM17 for the treatment of breast cancer. Fridman JS, Scherle PA, Liu X, Caulder E, Hansbury M, Yang G, Wang Q, Lo Y, Zhou J, Yao W, Newton RC, Yeleswaram S, Friedman SM, Vaddi K. Incyte Corporation, Wilmington, DE. Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial. Modi S, Stopeck A, Kinden H, Sugarman S, Ma W, Solit D, Kersey K, Johnson R, Hannah AL, Hudis C. Memorial Sloan-Kettering Cancer Center, New York, NY; Arizona Cancer Center, Tucson, AZ; Seattle Cancer Care Alliance, Seattle, WA; Kosan Biosciences, Hayward, CA.

6067

Withdrawn.

6068

CTEP-sponsored phase I/II trial of paclitaxel and low dose suramin in metastatic breast cancer. Shapiro CL, Sheils D, Barton L, Young D, Shen T, Chen L, Wei Y, Au J. The Ohio State University Medical Center and James Cancer Hospital, Columbus, OH; The Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH; The Ohio State University, Columbus, OH.

6069

Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2negative breast cancer resistant to anthracyclines and taxanes. Rugo HS, Thomas ES, Lee RK, Fein LE, Peck R, Verrill M. UCSF Comprehensive Cancer Center, San Francisco, CA; Kaiser Permanente, Oakland, CA; The St. Luke’s Medical Center, Quezon City, Philippines; The Centro de Oncologia Rosario, Sante Fe, Argentina; Bristol-Myers Squibb, Wallingford, CT; Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom.

6070

A phase II trial of trastuzumab, weekly ixabepilone (BMS247550) and carboplatin (TIC) in patients with HER2/neupositive (HER2+) metastatic breast cancer (MBC): a trial coordinated by the Eastern Cooperative Oncology Group (E2103). Moulder S, Wang M, Gradishar W, Perez EA, Sparano J, Pins M, Sledge G. University of Texas, M.D. Anderson Cancer Center, Houston, TX.

6071

A phase 1 study of ARRY-543, a potent, selective, reversible inhibitor of ErbB receptors. Gelmon K, Kane K, Kollmannsberger C, Maloney L, Gordon G, D’Aloisio S, W C, Litwiler K, Berlin J, Rothenberg M. BC Cancer Agency, Vancouver, BC, Canada; Vanderbilt-Ingram Cancer Center, Nashville, TN; Array Biopharma, Boulder, CO.

6072

Identification of a small molecule estrogen related receptor Ĝ specific antagonist that inhibits cell growth in MCF-7 and T47D breast cancer cells. Chisamore MJ, Cai S-J, Birzin ET, O’Donnell GT, Mosley RT, Zuck PD, Flores OA, Schaeffer JM, Rohrer SP, Wilkinson HA. Merck Research Laboratories, West Point, PA; Merck Research Laboratories, Rahway, NJ; Merck Research Laboratories, North Wales, PA.

6073

Exogenous histone H2A induces senescence and differentiation in breast cancer cells. Hadnagy A, Kaouass M, Mansour S, Beaulieu R, Balicki D. HôtelDieu du CHUM, Montréal, QC, Canada; Université de Montréal, Montréal, QC, Canada.

6074

Safety and pharmacokinetics of motesanib diphosphate (AMG 706) with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer. de Boer R, White S, Mainwaring P, Koczwara B, Ye Y, Sun Y-N, Parson M, Braun A, Kotasek D. Western Hospital, Footscray, VIC, Australia; Austin Health, Heidelberg, VIC, Australia; Mater Hospital, South Brisbane, QLD, Australia; Flinders Medical Centre, Bedford Park, SA, Australia; Amgen Inc., Thousand Oaks, CA; Ashford Cancer Centre, Ashford, SA, Australia.

Treatment: Other Therapies 6075-6086 6075

A prospective study to determine the prevalence of hypovitaminosis D in women with early stage breast cancer treated with an aromatase inhibitor and the benefit of vitamin D supplementation on musculoskeletal symptoms and overall QOL. Khan QJ, Reddy PS, Kimler BF, Baxa SE, Sharma P, Fabian CJ. University of Kansas Medical Center, Kansas City, KS; Cancer Center of Kansas, Wichita, KS.

6076

Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer - an updated analysis from EGF105084. Lin NU, Paul D, Dieras V, Liu M, Greil R, Roche H, Rubin SD, Zembryki D, Oliva C, Jayawardene D, Winer EP. Dana-Farber Cancer Institute, Boston, MA; Institut Jules Bordet, Brussels, Belgium; Institut Curie, Paris, France; Lombardi Comprehensive Cancer Center, Georgetown University Hospital; LKH, Salzburg, Austria; Centre Claudius Regaud, Toulouse, France; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Greenford, United Kingdom.

6077

Lapatinib Expanded Access Program (LEAP): design, operation and initial safety data. De Placido S, Link J, Conte PF, Tosi D, Kaufmann B, Byrne J, Rosenlund J, Gress M, Zembryki D, Oliva C. Universita degli Studi di Napoli Federico II, Italy; Breast Link Med Group, CA; Universita degli Studi di Modena e Regio Emilia, Italy; Instituto Nazionale per lo Studio e la Cura dei Tumori, Italy; Sheba Medical Centre, Israel; GSK, PA; GSK, United Kingdom.

6078

A phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer: preliminary results. Kozloff MF, Chuang E, Roy J, Starr A, Gowland PA, Tarpey MJ, Collier M, Verk L, Kern K, Miller K. Ingalls Memorial Hospital, Harvey, IL; Cornell University, New York, NY; Indiana University Cancer Center, Indianapolis, IN; Pfizer Global Research and Development, San Diego, CA.

6079

Exploratory evaluation of a sequential administration of docetaxel and sunitinib in women with advanced breast cancer. Gianni L, Cardoso F, Mariani G, Isaksson-Friman E, BesseHammer T, Vigano L, Verk L, Rossi C, Giorgetti C, Bergh J. Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy; Institut Jules Bordet, Brussels, Belgium; Karolinska Institute and University Hospital, Stockholm, Sweden; Pfizer Global Research and Development, San Diego, CA; Pfizer Italia S.r.l., Milano, Italy.

6080

AZD2171 for refractory breast cancer: a phase 2 trial. Mayer EL, Hamel S, Savoie J, Parker LM, Lin NU, Anderson K, Heymach JV, Gelman R, Ivy SP, Winer EP, Burstein HJ. DanaFarber Cancer Institute, Boston, MA; The University of Texas M. D. Anderson Cancer Center, Houston, TX; National Cancer Institute, Rockville, MD.

6081

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo controlled, randomized phase II study. Boer K, Lang I, Llombart-Cussac A, Andreasson I, Vivanco GL, Sanders N, Pover GM, Murray E. St Margit Hospital, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Centrallasarettet, Vasteras, Sweden; Plaza de Cruces, Bizkaia, Spain; AstraZeneca, Loughborough, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; New Groote Schuur Hospital, Cape Town, South Africa.

6082

Preclinical efficacy in breast cancer xenografts and phase 1 results of PTC299, a novel VEGF expression inhibitor. Hirawat S, Davis T, Weetall M, Elfring GL, Miller LL. PTC Therapeutics Inc, South Plainfield, NJ.

6083

Radiofrequency ablation versus cryoablation of small breast cancer with dedicated probes. Initial clinical experience. Manenti G, Perretta T, Cossu E, Contino G, Gioia A, Bonanno E, Masala S, Buonomo OC, Simonetti G. University Tor Vergata, Roma, RM, Italy.

6084

Role of differing estrogen receptor status on the proliferative effects of genistein. Rajah TT, Du N, Drews N, Cohn R. DePaul University, Chicago, IL.

6094

Triple negative, “basal-like” breast cancer: an institutional review. Herms BT, Jain D, Chagpar AB. University of Louisville Health Sciences Center, Louisville, KY.

6095

Assessment of efficacy and health related quality of life of proprioceptive neuromuscular facilitation (PNF) arm rehabilitation after surgical treatment of breast carcinoma. Bonanni V, Contino G, Lezzerini S, Buonomo OC. University Tor Vergata, Roma, RM, Italy.

6096

The physical therapist’s role in minimising impaired shoulder movement after axillary dissection. Tass DM. Capio Rivers Hospital, Sawbridgeworth, Hertfordshire, United Kingdom.

6097

Management and outcome of elderly patients (70 and over) with early stage breast cancer in rural community setting. McCoy JA, McCoy MM, Tezcan AZ, Tezcan H. North Idaho Cancer Center, Coeur d Alene, ID.

6098

High prevalence of vitamin D deficiency or insufficiency in breast cancer patients. Presant CA, Bosserman L, Ampudia M. Wilshire Oncology Medical Group, West Covina, CA.

Tumor Cell Biology: Molecular Biology 6099-6111

6085

Maintenance hormonal and immunotherapy in metastatic breast cancer with a clinical benefit from anthracyclinepaclitaxel based induction chemotherapy. Recchia F, Candeloro G, Necozione S, Rea S. Civilian Hospital, Avezzano, AQ, Italy; Università degli Studi, L’Aquila, AQ, Italy.

6099

Changes in cyclins’ and CDKs’ mRNA expression during neoadjuvant treatment with letrozole. Larionov A, Murray E, Evans DB, Miller WR, Dixon JM. Western General Hospital, Edinburgh, United Kingdom; Novartis Institutes for BioMedical Research, Basel, Switzerland.

6086

Efficacy and safety of vaginal testosterone for atrophic vaginitis in breast cancer patients on aromatase inhibitors: a pilot study. Witherby SM, Johnson JV, O’Brien P, Demers LM, Mount SL, Muss HB. Fletcher Allen Health Care (FAHC)/University of Vermont College of Medicine (UVM), Burlington, VT; FAHC/ UVM, Burlington, VT; The Pennsylvania State University, Hershey, PA.

6100

Differences in recurrent genomic alterations between the molecular subtypes of breast cancer. Han W, Hwang K-T, Cho J, Jung E-M, Bae J-Y, Kang JJ, Yang S-J, Ko E, Lee JW, Kim S-W, Park I-A, Noh D-Y. Seoul National University College of Medicine, Seoul, Korea; Macrogen, Inc., Seoul, Korea.

6101

The corepressor SAFB in breast cancer - identification of target genes. Kaipparettu BA, Hille S, Tsimelzon A, Lee AV, Meyer R, Polo JM, Melnick A, Steffi O. Baylor College of Medicine, Houston, TX; Albert Einstein College of Medicine, Bronx, NY.

6102

The efficacy of sertraline for controlling menopausal symptoms in women with breast cancer. Wu M-F, Hilsenbeck SG, Tham Y-L, Kramer RM, Elledge RM, Chang JC, Friedman LC. Baylor College of Medicine, Houston, TX; University Hospitals Case Medical Center, Cleveland, OH.

Potential role of dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) in trastuzumab response in breast cancer. Narayan M, Kumar A, Lezon-Geyda K, Nairn AC, Harris LN. Yale University, New Haven, CT.

6103

Persistent peripheral neuropathy in breast cancer survivors treated with taxane chemotherapy. Crew KD, Adelson K, Weimer LH, Raptis G, Brafman L, Fuentes D, Ortiz Y, Hershman DL. Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY.

Dysregulation of cofactor of BRCA1 expression in breast cancers. Sun J, Watkins G, Amleh A, Jiang WG, Li R. University of Texas Health Science Center at San Antonio, San Antonio, TX; School of Medicine Cardiff University, Cardiff, United Kingdom.

6104

Regulation of BRCA1 protein stability and its impact on estrogen biosynthesis in ovarian granulosa cells. Lu Y, Amleh A, Sun J, Li R, Hu Y. Institute of Biotechnology, UTHSCSA, San Antonio, TX.

6105

A novel anti-Patched1 antibody can suppress hedgehog signaling pathway in human breast carcinoma cells. Kubo M, Nakamura M, Kameda C, Tanaka H, Koga K, Mikami Y, Ikebe M, Tanaka M, Katano M. Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, Japan.

6106

MicroRNA expression in primary breast tumors. Lowery AJ, Miller N, McNeill RE, Kerin MJ. National University of Ireland Galway, Galway, Ireland.

6107

MicroRNAs in triple negative breast cancer. Weidhaas J, Slack F. Yale University.

Treatment: Patient Management 6087-6098 6087

6088

6089

6090

6091

6092

Influence of chemotherapy on bone in premenopausal women with breast cancer. Hadji P, Maskow C, Kalder M, Ziller V, Wagner U. PhilippsUniversity of Marburg, Marburg, Germany.

Standardized evaluation of regional and institutional breast cancer outcomes. Beatty JD, Rees J, Atwood M, Pugliese M, Bolejack V. Swedish Cancer Institute, Seattle, WA. Challenges in metastatic breast cancer: optimistic vs realistic goals for treatment. Sepucha K, Ozanne E, Partridge A, Moy B. Massachusetts General Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA. Differences in care of breast cancer patients in an underinsured population. Norton LE, Komenaka IK, Zork NM, Pennington, Jr RE, Clare SE, Bowling MW, Goulet, Jr RJ. Indiana University, Indianapolis, IN.

6108

6109

The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinicopathological parameters and clinical outcome. Salhab M, Jiang WG, Newbold RF, Mokbel K. St George’s University of London, London, United Kingdom; Cardiff University School of Medicine, Cardiff, United Kingdom; Brunel University, Uxbridge, Middlesex, United Kingdom. Expression of the putative breast cancer gene “breast cancer and salivary gland expression”; relationship with microRNA 154* and estrogen receptor status. Lowery AJ, Miller N, Kerin MJ. National University of Ireland Galway, Galway, Ireland.

6110

In vivo imaging of breast cancer using genetically engineered light-emitting bacteria. Park M, Yoon J, Jegal Y. Chonnam National University Hwasun Hospital, Hwasun-eup, Jeollanam-do, Republic of Korea.

6111

The four and a half LIM-only protein 2 mediates repression of Plk1 in breast cancer cells. Martin BT, Kleiber K, Kaufmann M, Strebhardt K. Medical School, University Frankfurt, Frankfurt/Main, Hessen, Germany.

6119

Rescheduled Poster Detection and Diagnosis: Circulating Markers 5015

9:00-12:00

HER-2 gene amplification is a marker for global genomic instability. Ellsworth RE, Deyarmin B, Patney HL, Hooke JA, Shriver CD. Windber Research Institute, Windber, PA; Walter Reed Army Medical Center, Washington, DC.

6113

Array-CGH identifies CCNE1 amplification in ER/HER2 negative breast cancers. Natrajan R, Rodriguez-Pinilla SM, Marchio C, Moreno-Bueno G, Vatcheva R, Mahler-Araujo B, Lambros MBK, Mackay A, Palacios J, Ashworth A, Reis-Filho JS. ICR, London, United Kingdom; CNIO, Madrid, Spain; Instituto de Investigaciones Biomedicas Alberto Sols, Madrid, Spain; HHUU Virgen del Rocio, Seville, Spain.

6114

Novel Mdm2 intron 1 single nucleotide polymorphisms and their role in breast cancer. Paulin FE, O’Neill M, McGregor G, Cassidy A, Ashfield A, Ali CW, Baker L, Munro AJ, Lane DP, Thompson AM. Ninewells Hospital, University of Dundee, Dundee, United Kingdom.

6115

HER2/TOP2A amplicon in breast cancer: a microarray-based and chromogenic in situ hybridisation analysis. Arriola E, Lambros MBK, Marchio C, Tan D, Natrajan R, Rodriguez-Pinilla SM, Tamber N, Fenwick K, Mackay A, Jones C, Dowsett, Ashworth A, Reis-Filho JS. Institute of Cancer Research, London, United Kingdom; ICR, Sutton, United Kingdom.

6116

Genetic polymorphisms in the vascular endothelial growth factor (VEGF) gene and breast cancer risk. Langsenlehner T, Gerger A, Hofmann G, Kapp KS, Langsenlehner U. Medical University of Graz, Graz, Austria.

6117

Molecular genetics and immunophenotypical characterisation of micropapillary carcinomas of the breast. Marchio C, Iravani M, Natrajan R, Lambros MBK, James M, Savage K, Mackay A, Fenwick K, Tamber N, Schmitt FC, Ellis I, Bussolati G, Sapino A, Ashworth A, Reis-Filho JS. Institute of Cancer Research, London, United Kingdom; IPATIMUP, Porto, Portugal; University of Nottingham, Nottingham, United Kingdom; University of Torino, Torino, Italy.

6118

Impact of deleterious BRCA mutations and unclassified BRCA variants upon breast cancer characteristics at presentation. Miolo G, La Mura N, Lombardi D, Scalone S, Della Puppa L, Magri MD, De Giacomi C, Dolcetti R, Veronesi A, Viel A. Centro di Riferimento Oncologico, Aviano, PN, Italy.

Heparanase expression in circulating lymphocytes of breast cancer patients is induced by the primary tumor and/or by distant metastasis. Theodoro TR, de Matos LL, Lambiasi AVL, Pinhal MAS, del Giglio A. Faculdade de Medicina da Fundação ABC, Santo André, Sãoi Paulo, Brazil.

GENERAL SESSION 7 – Exhibit Hall D

9:00

71. Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hydridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial. McCaskill-Stevens W, Procter M, Goodbrand J, Azambuja E, Leyland-Jones B, Ruschoff J, Dowsett M, Wermuth P, Dolci S, Gelber RD, Piccart-Gebhart M. National Cancer Institute, Bethesda, MD; Frontier Science, Kingussie, United Kingdom; Jules Bordet Institute, Brussels, Belgium; Emory University, Atlanta, GA; Klinikum Kasseland TARGOS Molecular Pathology Gmbh, Kassel, Germany; Hoffmann-La Roche, Basel, Switzerland; Royal Marsden National Health Service Trust, London, United Kingdom; DanaFarber Cancer Institute, Boston, MA.

9:15

72. 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. Spielmann M, Roché H, Humblet Y, Delozier T, Bourgeois H, Serin D, Romieu G, Canon JL, Monnier A, Piot G, Maerevoet M, Orfeuvre H, Extra JM, Hardy AC, Martin AL, Kramar A, Genève J. Inst Gustave Roussy, France; Inst Claudius Régaud, France; UCL St-Luc, Belgium; Centre François Baclesse, France; CHU Poitiers, France; Inst Ste Catherine, Avignon, France; Centre Val d’Aurelle, France; CH ND Reine Fabiola, Belgium; CHG Montbelliard, France; CMC les Ormeaux, Le Havre, France; Clinique St Pierre, Ottignies, Belgium; CH Bourg en Bresse, France; Inst Curie, France; Cl Armoricaine St Brieuc, France; FNCLCC, France

9:30

73. Safety of pertuzumab plus trastuzumab in a Phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy. Fumoleau P, Wardley A, Miles D, Verma S, Gelmon K, Cameron D, Gianni L, Conte PF, Ross G, McNally V, Baselga J. Centre Georges-François-Leclerc, Dijon, France; Christie Hospital, Manchester, UK; Mount Vernon Cancer Centre, Middlesex, UK; Ottawa Regional Cancer Center, Ottawa, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Western General Hospital, Edinburgh, UK; Oncologia Medica, Milano, Italy; Divisione di Oncologia Medica, Modena, Italy; *Roche products limited, Welwyn, UK; Vall d’Hebron University Hospital, Barcelona, Spain.

9:45

74. Combination of nab-paclitaxel and bevacizumab eradicates well-established tumors as well as lymphatic and pulmonary metastases in a MDA-MB-231 model of a highly metastatic human breast cancer. Ran S, Volk L, Bivens C, Trieu V, Desai N. Southern Illinois University, Springfield, IL; Abraxis BioScience, Inc., Los Angeles, CA.

Tumor Cell Biology: Genetics 6112-6119 6112

Premature thelarche variant and estrogen receptor-Ĝ coregulator single nucleotide polymorphisms. Hartmaier RJ, Richter AS, Wit JM, Walenkamp MJE, Oesterreich S. Baylor College of Medicine, Houston, TX; Leiden University Medical Center, Leiden, Netherlands.

10:00

75. ErbB-2 inhibition activates notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor: opportunity for a novel therapeutic combination. Osipo I, Patel P, Hao L, Whitehouse L, Strack P, Golde T, Albain K, Miele L. Loyola University Medical Center, Maywood, IL; Merck Research Laboratories, Boston, MA; The Mayo Clinic College of Medicine, Jacksonville, FL.

10:15

76. Parity regulates activation of p53 in human breast tissue. Crisi GM, Mathews L, Bentley B, Stueber K, Jerry DJ, SmithSchneider S. Baystate Medical Center/Tufts University School of Medicine, Springfield, MA; Pioneer Valley Life Sciences Institute, Springfield, MA; Baystate Medical Center/Baystate Plastic Surgery Associates, Springfield, MA.

10:30

77. Cytrochrome P450 2D6 activity predicts adherence to Tamoxifen therapy. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar T, Nguyen A, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V for the COBRA investigators. University of Michigan Comprehensive Cancer Center; University of Michigan School of Medicine; Indiana University; Baylor College of Medicine; Johns Hopkins University School of Medicine. COBRA is the Consortium on Breast Cancer Pharmacogenomics, an NIH supported Consortium of investigators at these institutions studying pharmacogenomics in the treatment of breast cancer.

10:45

78. Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) Trial. Ellis PA, Barrett-Lee PJ, Bloomfield D, Cameron DA, Hall E, Johnson L, Johnston SRD, Bliss JM. Guys, Kings & St Thomas’s Hospital, London, United Kingdom; Velindre Hospital, Cardiff, Wales, United Kingdom; Royal Sussex County Hospital, Brighton, Sussex, United Kingdom; University of Leeds, Leeds, United Kingdom; Institute of Cancer Research, Sutton, Surrey, United Kingdom; Royal Marsden NHS Foundation Trust, London, United Kingdom.

11:00

79. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/ cyclophosphamide « docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/ AGO intergroup-study “GeparQuattro”. von Minckwitz G, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M. University Hospital Frankfurt, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Senologie, Brustzentrum, Düsseldorf, Germany; Frauenklinik mit Poliklinik, Erlangen, Germany; Senologiezentrum Ostschweiz SENZO, St. Gallen, Switzerland; Onkologie Bethanien, Frankfurt, Germany; Frauenklinik, München, Germany; Frauenklinik, Hannover, Germany; Frauenklinik, Berlin, Germany.

11:15

80. Characterizing the biology and response of locally advanced breast cancer in women undergoing neoadjuvant therapy: preliminary results from the I-SPY trial. Hylton N, Carey L, DeMichele A, Blume J, Broadwater G, Madhavan S, Rosen M, George S, Esserman L, ISPY Clinical, Research, Pathology and Radiology Investigators. Univ of California San Francisco, San Francisco, CA; Univ of North Carolina, Chapel Hill, NC; Univ of Pennsylvania, Philadelphia, PA; ACRIN, Philadelphia, PA; CALGB, Chapel Hill, NC; NCI-SPORE, Bethesda, MD.

11:30

81. Elucidating the stem and progenitor cell hierarchy in breast development and cancer - an essential role for GATA-3. Lindeman GJ, Asselin-Labat M-L, Sutherland KD, Barker H, Thomas R, Shackleton M, Hartley L, Robb L, Grosveld FG, van der Wees J, Visvader JE. The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; The Royal Melbourne Hospital, Melbourne, Australia; Erasmus University, Rotterdam, Netherlands.

11:45

82. Decrease in tumorigenic breast cancer stem cells in primary breast cancers with neoadjuvant lapatinib. Li X, Creighton C, Wong H, Hilsenbeck SG, Osborne CK, Rosen JM, Lewis MT, Chang JC. Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX.

12:00

ADJOURNMENT, 30th Annual San Antonio Breast Cancer Symposium

Abstracts – Invited Speakers

ML-1

Biomarking the estrogen responsiveness of breast cancer.

Dowsett M. Royal Marsden Hospital Bene¿t from endocrine treatment of breast cancer is con¿ned to patients with estrogen receptor positive (ER+) disease. Development of modern endocrine treatments has been guided by the application of hormonal analyses, particularly of plasma estrogens, that can be used as pharmacodynamic markers. However, while these analyses may also be useful in de¿ning patients at risk of breast cancer they do not differentiate breast cancer patients that bene¿t from therapy from those that do not. Recent studies suggest that the differential bene¿t from tamoxifen and possibly other endocrine therapies may be partly determined by genetic host factors but molecular features of tumors are the major determinant of clinical heterogeneity. The degree of variability in responsiveness can be demonstrated and putative determinants evaluated in presurgical studies of endocrine therapy. The validity of changes in the proliferation marker Ki67 as an intermediate end-point of treatment bene¿t was demonstrated in the IMPACT trial. Reduced Ki67 occurs in over 90% of patients treated with third-generation aromatase inhibitors indicating that the large majority of ER+ patients bene¿t from a slowing of tumour growth even if this does not translate to an objective response to therapy. Similarly a global index of dependence on estrogen (GIDE) which integrates the transcriptional changes that occur with estrogen deprivation varies more than 30-fold among ER+ tumors. Unexpectedly, measures of apoptosis indicate that this is reduced during endocrine therapy. These reductions in cell death are markedly outweighed by the profound suppression of proliferation but may contribute to the relatively slow regressions seen with endocrine therapy. Despite compelling preclinical data, markers such as PgR and HER2 do not appear to de¿ne patients with a particularly high relative bene¿t of an aromatase inhibitor over tamoxifen. Further study of the molecular changes that occur with estrogen deprivation and association of these with clinical outcome may be expected to identify the hallmarks of breast cancer that are supported by estrogen stimulation and allow improved rationalisation of endocrine therapy ± other therapeutic agents.

P-1

Management of symptoms in breast cancer survivors.

Loprinzi CL. Mayo Clinic, Rochester, MN Given improved screening and early diagnosis of breast cancer, and also improved treatment for localized breast cancer, there is an increase in the number of breast cancer survivors, many destined to live for decades after their diagnosis. Breast cancer survivors can have many untoward symptoms related to their treatment and/or requiring different therapies than other women. Such symptoms include cognitive dysfunction, fatigue, chemotherapy induced neuropathy, weight gain, sexuality issues, vaginal dryness, and hot Àashes. For some of these symptoms, there are treatments which have been shown to be useful. For fatigue and weight gain, exercise and calorie restriction are helpful, while pharmacologic means of treating these symptoms have not delineated any helpful therapies. For hot Àashes, centrally acting agents, like newer antidepressants and gabapentin, have been identi¿ed as being valuable for some patients. For many of these symptoms, however, there are no good, identi¿ed therapeutic options for management. Neither the etiologies of cognitive dysfunction associated with cancer, or its treatment, nor helpful pharmacologic agents for this problem have been identi¿ed. For decreased libido, while testosterone combined with available estrogen appears to be helpful in women in general, testosterone without concomitant estrogen does not appear to be useful in female cancer survivors. While vaginal estrogen effectively treats vaginal atrophy in many women, new data demonstrating the bene¿ts of aromatase inhibitors raise concerns about the use of any treatment that could impact systemic estrogen in women with hormone sensitive cancers. At this time there are no pharmacologic therapies to recommend for preventing or treating chemotherapy-induced neuropathy. Continued research attention to the above noted issues is necessary to ¿nd improved therapies for control of these symptoms.

S1

P-2

Multidisciplinary treatment guidelines across the continuum of care: the NCCN experience.

Carlson RW, for the NCCN Breast Cancer Treatment Guidelines Panel. Stanford Cancer Center, Stanford, CA The National Comprehensive Cancer Network (NCCN) Breast Cancer Treatment Guidelines provide multidisciplinary, comprehensive, state-of- the-art treatment recommendations and strategies across the continuum of cancer care. The Guidelines are developed by a multidisciplinary expert panel using an evidence-based consensus process and are updated at least annually. Panel members represent the specialties of surgical oncology, medical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. Guideline modi¿cations are considered based upon recommendations or requests from breast cancer providers within the NCCN institutions, Panel members, patient advocacy organizations, industry, third party payors or individuals. Panel members are required to disclose ¿nancial conÀicts of interest verbally and in writing, must absent themselves from discussions where meaningful conÀicts exist, and conÀicts are published in the aggregate with the guidelines. Panel meetings over two - three days include a series of formal, issue focused presentations followed by an open discussion of any proposed guideline change. The ¿nal document is generated by an iterative process involving all panel members. All recommendations made by the guideline are associated with a corresponding category of evidence. The recommendations are presented in graphical, algorithmic form that is designed to follow the reasoning process of the expert clinician providing care. The guidelines are inclusive of treatment options, and an accompanying referenced manuscript provides the rationale and justi¿cation for the algorithmic recommendations. The guidelines are published in updated form annually on the NCCN web site (www.nccn.org) and in the Journal of the NCCN on a biennial basis. The American Cancer Society and NCCN publish a patient oriented version of the guideline updated on an annual basis. Over 250,000 copies of the guidelines are distributed or accessed annually. Separate, focused task forces are used to address in depth especially controversial issues in breast cancer treatment such as selection of adjuvant chemotherapy regimen, PET scanning, bisphosphonate use, methods of HER2 testing, and treatment of the older adult. The guidelines are complemented by an NCCN Outcomes Database that monitors the actual treatment delivered at NCCN institutions and allows for the identi¿cation of rates of compliance with guideline recommendations. A compendium is also published that allows third party payors to ef¿ciently identify the pharmaceutical agents recommended for speci¿c medical situations within the guidelines. The NCCN collaborates with breast cancer care providers in Latin America, Japan, and China to provide economically, socially, and culturely appropriate international, non-English versions of the NCCN Breast Cancer Guideline.

P-3

Energy balance, insulin, and breast cancer.

Pollak M. McGill University, Montreal, QC, Canada We will review (1) evidence for an adverse inÀuence of high body mass index (BMI) or high caloric intake on breast cancer prognosis (2) research regarding the underlying mechanisms and (3) implications for breast cancer prevention and treatment. While there is evidence that BMI inÀuences breast cancer risk, the relationship is modest and varies with menopausal status and other factors. BMI is more consistently identi¿ed as an important adverse prognostic factor. Women with higher BMI have higher circulating insulin levels associated with “insulin resistance” of classic insulin target tissues such as muscle and fat -- the extent to which cancer cells of a patient with insulin resistance and hyperinsulinism are sensitive to insulin stimulation is an important unanswered question, but insulin signaling is a candidate mediator of the effect of BMI on breast cancer prognosis. It has been recognized for decades that restriction of energy intake reduces carcinogenesis and attenuates aggressive cancer behavior in laboratory models. More recent experimental data provide early

S2

Abstracts – Invited Speakers

evidence that the growth of some cancers is increased when caloric intake of the host is increased. Increasing energy intake in these models is associated with increased insulin levels, but this does not demonstrate causality because circulating levels of many factors that might impact tumor growth are also changed. Clinical research provides further circumstantial evidence for a role of insulin or factors inÀuenced by or correlated with insulin levels in determining breast cancer prognosis: higher fasting insulin levels or c-peptide levels (a marker of insulin production) at time of diagnosis are associated with worse outcome. Furthermore, it is now recognized that breast cancers commonly express insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors, and that these can activate key downstream growth regulatory signaling pathways. All this has led to renewed interest in the clinical relevance of work carried out decades ago which provided evidence that insulin acts as a potent growth factor for breast cancer in vitro. Since obesity and hyperinsulinism are common (and increasing) in afÀuent societies, the public health impact of the adverse impact of these factors on breast cancer prognosis may be considerable. Furthermore, the population also includes women who are described as “metabolically obese, normal weight” individuals, and these may also have a relatively poor prognosis if diagnosed with cancer. Importantly, the metabolic abnormalities associated with obesity represent potentially modi¿able adverse prognostic factors. Lifestyle (diet and exercise) as well as pharmacologic (eg metformin) strategies are known to improve hyperinsulinism and the other metabolic abnormalities associated with obesity. Inhibitors of insulin/IGF signaling are also under study. There are important opportunites to use the post-operative adjuvant treatment setting to advance knowledge in this area. We hypothesize that any bene¿t of lifestyle or pharmacologic strategies that lower insulin levels will not be be homogeneously distributed in the breast cancer population, but rather will be of most bene¿t to those who are hyperinsulinemic at baseline.

P-4

Radiation treatment planning for breast cancer: a journey through time.

Pierce L. Recent improvements in breast cancer-speci¿c and overall survival shown best in the Overview are attributed, in part, to signi¿cant improvements in loco-regional control following comprehensive radiotherapy. The gains in survival, however, have been tempered by costly rates of excess mortality from causes other than breast cancer, primarily heart disease. Therefore treatment planning approaches which minimize treatment to uninvolved tissues are critical to the ultimate success achieved with radiation. Radiation treatment planning for breast cancer has changed dramatically through the years with modi¿cations in clinical target volumes, treatment delivery systems, and techniques. Early target volumes reÀected a Halstedian philosophy in which extensive (loco-) regional ¿elds were felt to be necessary for cure but through successive studies, volumes have been re¿ned that maintain high rates of loco-regional control while minimizing toxicity. Treatment delivery systems and techniques have evolved from clinically placed ¿elds treated with the limited depth dose characteristics of orthovoltage to two- and three-dimensional forward planned ¿elds and now, in some cases, to complex inversely planned ¿elds delivered with intensity modulated radiotherapy. The clinical bene¿t of these changes has been demonstrated in recent outcome studies. Optimization of each of these components of treatment planning has resulted in a convergence of treatment goals with the intent to optimize survival while decreasing toxicity. However, no one approach can be applied to all patients; thus, treatment planning must be individualized in each case. Trade-offs of treatment planning directives will be presented.

MS1-1

Systems approach to growth factor signaling and to therapeutic intervention in breast cancer.

Yarden Y. Weizmann Institute of Science, Rehovot, Israel Growth factors and their transmembrane receptors contribute to all steps of tumor progression, from the initial phase of clonal expansion, through angiogenesis and tmetastasis. Hence, the information relay system involved in growth factor signaling provides potential site for signal interception and tumor inhibition. A relevant example comprises the epidermal growth factor (EGF) and the respective receptor tyrosine kinase, namely ErbB-1/EGFR, which belongs to a prototype signaling module that drives carcinoma development. The extended module includes two autonomous receptor, EGFR and ErbB-4, and two nonautonomous receptors, namely: a ligand-less oncogenic receptor, HER2/ ErbB-2, and a kinase-dead receptor (ErbB-3). This signaling module is richly involved in human cancer and already serves as a target for several cancer drugs. Due to inherent complexity and a large amount of experimental data, we propose a systems approach to understanding ErbB signaling. EGF - to - ErbB signaling is envisioned as a bow-tie con¿gured, evolvable network, sharing modularity, redundancy and control circuits with robust biological and engineered systems. My presentation will concentrate on system controls, a plethora of negative feedback loops, which include E3 ubiquitin ligases, receptor endocytosis and newly transcribed genes. Because network fragility is an inevitable tradeoff of robustness, systems level understanding is expected to identify therapeutic opportunities for targeting aberrant activation of the network in human pathologies. Speci¿c examples will be discussed with an emphasis on gene expression and the control of metastsis.

MS1-2

Targeting the HER network in breast cancer: therapeutic successes and failures.

Osborne CK, Schiff R. Baylor College of Medicine, Houston, TX The HER network is a robust, complex, and redundant network providing important proliferation and survival signals to a subset of human breast cancer. It is a layered system consisting of an input layer of four receptors and their eleven ligands, a core processing unit or signaling pathway from the membrane to the nucleus, and an output layer consisting of transcription factors and the genes they regulate. The network is also controlled by a system of positive and negative regulatory circuits to ¿nely tune the system. Gene ampli¿cation of HER2, a critical player in the input layer, in 25% of breast cancer led to development of drugs targeting the pathway. In breast cancer, drugs that are currently in use target the receptor input layer to block the pathway. Trastuzumab binds to the external domain of HER2 and, thereby, inhibits signaling through the network. In metastatic breast cancer, the drug used alone induces responses in 30% of patients while the majority demonstrate de novo resistance. In the adjuvant setting about 50% of patients with HER2 expressing tumors bene¿t from trastuzumab with a sizable improvement in time to progression and survival. Still many patients demonstrate either de novo or acquired resistance to the drug. Considering the complexity of the network, resistance to trastuzumab could develop at several levels. One potential mechanism is incomplete blockade of signals generated by the various dimer pairs formed by this family of receptors. However, other drugs have been developed that target the pathway in slightly different ways including the tyrosine kinase inhibitors lapatinib, ge¿tinib, or erlotinib or the dimerization inhibitor pertuzumab. In preclinical models these drugs used in various combinations to more completely block signals from all heterodimers pairs is a more effective strategy than any of the agents used alone and is capable of completely eradicating some xenograft models of human breast cancer. Other xenograft models are resistant to combination therapy suggesting alternative mechanisms of resistance. The strategy of combining more than one HER pathway inhibitor in patients is now being studied in metastatic disease as well as the neoadjuvant and adjuvant settings. Strategies to identify and then circumvent other mechanism of resistance are an active area of research.

Abstracts – Invited Speakers

MS1-3

Identi¿cation of biomarkers of resistance to HER2 targeted therapy using loss of function genetic screens.

Bernards R. The Netherlands Cancer Institute, Amsterdam, Netherlands Unresponsiveness to therapy is remains a signi¿cant problem in the treatment of cancer, also with the new classes of targeted therapeutics. In my laboratory, we use functional genetic approached identify biomarkers that can be used to predict responsiveness to clinicallyrelevant cancer therapeutics. We focus on the well-established targeted cancer drugs such as Trastuzumab. This drug targets a speci¿c molecule (HER2) that is over-expressed or in breast cancer. Nevertheless, it remains poorly explained why a signi¿cant number of tumors, which express the drug target, do not respond to the therapy. We aim to elucidate the molecular pathways that contribute to unresponsiveness to targeted cancer therapeutics using a functional genetic approach. This will yield biomarkers that can be used to predict how individual patients will respond to speci¿c drugs. Furthermore, this work may allow the development of drugs that act in synergy with the established drug in the treatment of cancer. To identify biomarkers that control tumor cell responsiveness to cancer therapeutics, we use both genome-wide gain-of-function genetic screens (with cDNA expression libraries) and genome wide loss-of-function genetic screens (with RNA interference libraries) in cancer cells that are sensitive to the drug-of-interest. We search for genes whose overexpression or down-regulation in cultured cancer cells confers resistance to the drug-of-interest. Once we have identi¿ed such genes, we ask if their expression is correlated with clinical resistance to the drug-ofinterest using tumor samples of cancer patients treated with the drug in question, whose response to therapy is documented. In this presentation, I will discuss how loss-of-function genetic screens can be used to identify mechanisms of resistance to Trastuzumab in breast cancer.

MS2-1

The Women’s Health Initiative randomized trials of menopausal hormone therapy: results and impact on clinical practice.

Chlebowski RT. Los Angeles Biomed Res Institute, Torrance, CA The Women’s Health Initiative (WHI) trial of combined conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) was stopped early and reported in 2002 when overall health risks including coronary heart disease, stroke, pulmonary embolism and invasive breast cancer exceeded bene¿ts. Invasive breast cancers were diagnosed more frequently in the CEE + MPA group; hazard ratio (HR), 1.24 p=0.003 and were diagnosed at more advanced stage (p=0.04) compared with those in the placebo group. In the combined hormone group mammograms with abnormalities were increased by 74% after one year (p25% breast density on baseline mammogram, were eligible. Endpoints included changes in breast density between baseline and 12 month as estimated by a computer-assisted thresholding program and changes in serum hormones, plasma lipids, bone biomarkers, and BMD. Results: Data is available for 68 women (45 LET; 23 PLAC). Analysis of mammographic density is underway and will be presented. No statistically signi¿cant differences in mean percent changes in BMD (lumbar spine and femoral neck) and lipid parameters (cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides) were observed between the two treatment arms at 12 and 24 months. A trend toward an increase in the mean percent change of the bone resorption marker N- telopeptide was observed in the LET arm at 12 months but resolved at 24 months. Changes in serum alkaline phosphatase did not differ between treatment arms. A signi¿cant increase in the percentage change in IGF-1 was noted in the letrozole group compared to the placebo group at 24 months. Discussion: One year of letrozole therapy may increase bone resorption minimally but does not have a signi¿cant effect on bone mineral density or on lipid parameters. Forthcoming analysis of the effects of letrozole on mammographic breast density will provide insight into the possible use of breast density as a biomarker for letrozole ef¿cacy.

2083

Survival analysis of ¿rst-line tamoxifen versus aromatase inhibitors for estrogen-positive metastatic breast cancer in postmenopausal women – a BC perspective.

Kyritsis V, De Lemos M, Walker B, Kennecke H, Nakashima L. BC Cancer Agency, Vancouver, BC, Canada; Queens University Belfast, Belfast, Belfast, Ireland Background: Tamoxifen has been the gold standard of treatment in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC). Over the past decade, new aromatase inhibitors (AIs) – anastrozole, letrozole, exemestane – have emerged as equally ef¿cacious alternatives to tamoxifen. Recent data suggest that ¿rst-line AI therapy may even confer a moderate increase (∼ 4months) in overall survival compared to tamoxifen. We performed a populationbased analysis of survival associated with ¿rst-line tamoxifen versus AIs for ER+ MBC to examine whether the above ¿ndings hold true for patients in BC. Methods: This is a population-based retrospective analysis. Patients were identi¿ed from the BC Cancer Agency Information System (CAIS), systemic therapy drug database, and the provincial

Abstracts – Poster Session II S113 registry (Breast Cancer Outcomes Unit). Data was analyzed for all postmenopausal women treated with ¿rst-line tamoxifen and AIs (anastrozole, exemestane, letrozole) for ER+ MBC (stage IV disease) from January 1998 through September 2004 in BC. Patients treated with other ¿rst-line hormonal agents were excluded. The primary outcome is overall survival, de¿ned as the time to death by any cause from the date of ¿rst-line tamoxifen or AI therapy. Overall survival was compared between patients treated with tamoxifen versus AI. Results: We found that there is an overall survival bene¿t with the use of ¿rst line AI therapy in comparison to tamoxifen in our patient population. Survival data will be presented as Kaplan-Meier curves and a 2-tailed log-rank test will be used to compare the hazard rates of the survival curves. Discussion: This analysis will provide pertinent information regarding the survival benefit between the use of first-line treatment with tamoxifen and AI. The preliminary data provided by this analysis will assist in decision making regarding appropriate ¿rst-line hormonal therapy for ER+ MBC. We hope to disseminate these ¿ndings to the rest of the communities’ oncology network centers in BC.

2084

Impact of CYP2A6 genotype on pharmacokinetics, safety and efficacy of letrozole treatment in Japanese postmenopausal women with metastatic breast cancer.

Minami H, Ohsumi S, Nakamura S, Inaji H, Takenoshita S, Fujiwara Y, Iino Y, Woo M, Tanii H, Tominaga T, Takashima S. CGS20267 Collaborate Study Group, Tokyo, Japan Background: Letrozole, a potent and selective aromatase inhibitor, is metabolized by CYP2A6 and CYP3A4 enzymes. Genetic polymorphisms in CYP2A6 have been reported1. The aim of this study was to examine whether the CYP2A6 genotype status had an impact on clinical outcome of letrozole treatment in Japanese postmenopausal women with metastatic breast cancer participating in two parallel Ph II studies conducted from 2001 to 2005. Methods: Pharmacokinetics (PK), time to tumor progression (TTP), overall response rate (ORR), and adverse drug reactions (ADRs) were evaluated in 88 Japanese metastatic breast cancer patients who received letrozole 2.5 mg daily. Mean plasma letrozole trough levels were obtained starting at week 12 of treatment and repeated every 4 weeks thereafter until at least week 28 and measured by HPLC and LC-MS/MS methods. DNA was extracted from peripheral blood of 59 consenting patients and was genotyped for CYP2A6*1A, 1B (reference), *4 (gene deletion), and *7, *8, *9, *10, and *11 (variants associated with decreased enzyme activity1) using PCR-Invader method. TTP was estimated by the Kaplan-Meier product limit method. Results: CYP2A6*4 variant allele was found in 13/59 patients including one homozygote (1.6 %). Thirty-¿ve of 59 patients possessed at least one reference copy of CYP2A6*1A or 1B (35/59) including 3 patients with *1B/*4 genotype, and 24 of 59 patients did not have the reference allele but only *4 or other variant alleles. The mean trough letrozole level at the steady state was 118 ng/mL (range: 49.9-204 ng/mL, n=35) and 243 ng/mL (range: 138-487 ng/mL, n=24) in patients with at least one reference allele *1A or *1B and only with variant alleles, respectively. ORR was 20.0% (CI: 8.4-36.9) in patients with at least one reference allele compared with ORR 29.2% (CI: 12.6-51.1) in patients who had the variant alleles. Median TTP was 223 (CI: 84-506) and 280 (CI: 111-532) days in patients with at least one reference allele and variant alleles, respectively. The frequency of ADRs suspected related to letrozole in patients with at least one reference allele was not different from those with the variant alleles. Conclusions: Patients only with variant alleles had a 2-fold higher letrozole trough level than patients with at least one reference allele after letrozole treatment. However, both groups showed comparable clinical ef¿cacy and safety of letrozole treatment from the 2 studies. These results suggest that neither PK nor CYP2A6 genotype are important predictors of letrozole clinical outcome in these Japanese breast cancer patients. Reference1. Nakajima M. et al., Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6., Drug Metabolism Review, 34: 865-877, 2002.

2085

Bone health and anastrozole adverse events in Japan.

Sagara Y, Rai Y. Hakuaikai Sagara Hospital, Kagoshima City, Kagoshima Prefecture, Japan Background: Anastrozole is widely used in Japan, but the relevance of adverse events (AEs) with Japanese has not yet been researched. Material and Methods: 656 postmenopausal women with invasive ER-positive breast cancer were received anastrozole as part of their adjuvant hormone therapy from February 2001 to July 2006 in our hospital. Their average age was 63.4 years of age. Retrospective analysis was performed mainly regarding bone health and serious AEs. Bone mineral density was measured at L4-T4 spine by Discovery X (HOLOGIC.INC.). Results: Bone fractures occurred in nine cases and the accumulated fracture rate was 1.3% (Figure.1). The annual rate of bone fracture was 0.8%. Average age was 67.6 years old and average bone mineral density of young adult mean was 0.71 % (Osteopenia). 6 cases had bone fractured by falling down and 2 cases had vertebral compression fractures without trauma. Joint symptoms occurred most frequently between six and 12 months and did not occur after 36 months (Figure.2). Changes in bone mineral density while taking anastrozole was observed in 97 cases. The average observation period was 9.5 months (seven to 24 months). A signi¿cant decrease in BMD was observed in 17cases (17.5%). In 26 cases who took anastrozole with bisphosphonate, a signi¿cant decrease in BMD was observed in only two cases (7.6%). Cerebral infarction occurred in two cases (0.3%) and no cardiovascular events have occurred to date. Discussion: Incidence of AEs did not exceed that of the ATAC trial, con¿rming safety. In addition, extremely favorable results were obtained regarding bone fracture and cardio -vascular AEs compared to those generally observed with aromatase inhibitors. Several studies reported the fracture risk in Asians was lower than that of Caucasians. We will continue our investigations into its ef¿cacy and safety pro¿le.

S114 Abstracts – Poster Session II

2086

The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: preliminary results of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.

Aihara T, Hozumi Y, Suemasu K, Takei H, Takehara M, Osumi S, Saito T, Masuda N, Ohashi Y. Aihara Hospital, Minoo, Osaka, Japan; Jichi Medical University, Shimono, Tochigi, Japan; Saitama Cancer Center, Kitaadachi, Saitama, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shikoku Cancer Center, Matsuyama, Ehime, Japan; Saitama Red Cross Hospital, Saitama, Saitama, Japan; Osaka National Hospital, Osaka, Japan; The University of Tokyo, Tokyo, Tokyo, Japan Background/Aims:Postmenopausal women treated with aromatase inhibitors are known to be at risk for bone loss. We aimed to investigate the difference among exemestane, anastrozole and tamoxifen in the effect on bone mineral density (BMD) and bone turnover markers in patients with postmenopausal primary breast cancer treated with those agents as adjuvant endocrine therapy. Patients/Methods: Of the 247 postmenopausal patients randomized in the N-SAS BC04 trial, the number of the patients included in the present study for exemestane (25 mg/day) arm was 27, anastrozole (1 mg/day) arm was 23 and tamoxifen (20 mg/day) arm was 26. BMD was measured by dual-energy x-ray absorptiometry at baseline and 12 months after treatment initiation. Urinary type I collagen cross-linked N-telopeptide (NTX) and serum bone speci¿c alkaline phosphatase (BAP) were measured as bone turnover marker at baseline and 3, 6, 12 months after treatment initiation. Results: There was no signi¿cant difference in BMD level at 12 months among 3 arms. NTX level did not change during 12 months period in exemestane and anastrozole arm, while it sharply decreased at 3 months and maintained low level thereafter in tamoxifen arm. BAP level constantly increased in exemestane as well as anastrozole arm, while it decreased constantly in tamoxifen arm. Conclusion: Although there was no signi¿cant change in the BMD level at 12 months among 3 arms, favorable effect of tamoxifen in bone turnover marker pro¿le was observed.

2087

LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breast cancer. Preliminary report of activity and cardiac tolerability.

Frassoldati A, Guarneri V, Cagossi K, Bottini A, Cavanna L, Jovic G, Piacentini F, Oliva C, Conte P. University of Modena, Modena, Italy; Ramazzini Hospital, Carpi, Modena, Italy; Azienda Ospedaliera, Cremona, Italy; General Hospital, Piacenza, Italy; Glaxo SmithKline, Greenford, United Kingdom Introduction and aims: The crosstalk between hormone- and EGFRfamily pathways is considered a possible cause of hormone-resistance. To evaluate the effects of a combined blockade of these two pathways, we activated an international multicentre phase Iib double blind randomized trial in neoadjuvant setting. Primary endpoint of the study is the clinical objective response rate (cOR), and secondary endpoints are the percentage of pathological complete responses (pCR), the safety pro¿le of the combination of hormonal treatment plus lapatinib and the evaluation of the inhibition of intermediate and ¿nal biomarkers of the proliferative and the apoptosis pathways induced by the hormonal treatment plus lapatinib or placebo. Patients and methods: Postmenopausal women with stage II-IIIa, hormone receptor positive and HER2 negative breast cancer are randomized to letrozole (L) (2.5 mg/d) plus lapatinib (Lp) (1500 mg/d) or placebo (P). Treatment is given continuosly for 24 weeks before surgery. Activity (with ultrasonography) and cardiac safety (with echocardiogram) assessment are performed after 12 and 24 weeks. Sample size: assuming a 50% chance of cOR with letrozole (plus placebo), and a 40% increase in cOR with the combination of letrozole and lapatinib (equal to 70% absolute cOR), 43 patients will be initially enrolled, and additional 48 patients will be treated in case we observe 20

cOR (8 in L+P and 12 in L+Lp) in the the ¿rst step (Simon’s design). Results: Nineteen Italian and European centres partecipate to the study. Enrollment started on april 2007, and to date 7 patients have been randomized. Current accrual allows for estimated enrollment conclusion on february 2008. No treatment interruption has been reported so far, neither grade 3-4 side effects. The ¿rst IDMC evaluation of the treatment activity and safety, pre-planned after 15 evaluable patients, is scheduled for october 2007, giving the ¿rst prelimary data regarding the combination of letrozole and lapatinb/placebo. Blinded activity and safety results will be presented at the meeting. Conclusions: This is the ¿rst trial combining letrozole and lapatinib or placebo in operable breast cancer. The results could contribute to improve tailored therapy for postmenopausal breast cancer patients and to understand the mechanisms of hormone-resistance. Supported by GlaxoSmithKline.

2088

Health-related quality of life and psychological distress in Japanese patients with breast cancer treated with tamoxifen, exemestane or anastrozole for adjuvant therapy: a phase III randomized study of National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04.

Takehara M, Ohsumi S, Takei H, Shimozuma K, Ohashi Y, Suemasu K, Hozumi Y. Jichi Medical University, Shimotsuke, Tochigi, Japan; National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan; Saitama Cancer Center, Kita-Adachi, Saitama, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; University of Tokyo, Bunkyo, Tokyo, Japan; Arche Clinic Breast Center, Omiya, Saitama, Japan Background: The ongoing phase III Tamoxifen (TAM) and Exemestane (EXE) Adjuvant Multinational (TEAM) trial compares adjuvant 5 years of EXE with 2.5 to 3 years of TAM followed by EXE for a total of 5 years. The National Surgical Adjuvant Study of Breast Cancer (NSAS BC) 04 is a subprotocol of the TEAM trial, designed to compare 5 years of EXE, 5 years of anastrozole (ANA), and 2.5 to 3 years of TAM followed by EXE for a total of 5 years. Health-related quality of life (HRQOL) was one of the secondary endpoints of N-SAS BC 04, while lipid metabolism (LM) and bone mineral density (BMD) were primary endpoints. We already reported the results of an interim analysis for HRQOL of N-SAS BC 04, and in this study mature results are reported based on a longer follow-up period. Patients and Methods: Eligibility criteria were postmenopausal women with stage I to IIIA hormone responsive breast cancer treated with surgery, and with at least one of the following criteria; pathologically 3 cm or larger, nuclear grade 3, pathologically positive nodes, invasive lobular carcinoma or metaplastic carcinoma. Eligible patients (pts) who are treated for hyperlipidemia or osteoporosis, or with abnormal LM and BMD at the entry were randomly assigned to take EXE or TAM (TEAM trial); while pts who were not treated for hyperlipidemia or osteoporosis, and with normal LM and/or normal BMD at the entry were randomly assigned to take EXE, ANA or TAM (N-SAS BC 04). Pts were asked to answer the patient-based instruments to assess HRQOL, which was monitored at baseline, 3 and 12 months using the following scales: FACT-G, FACT-B, and FACT-ES and psychological distress (CES-D). Statistical signi¿cance was tested using the repeated-measures ANOVA with the baseline value as a covariant. Results: A total of 169 patients entered the N-SAS BC 04. The response rate of the HRQOL questionnaire was consistently high (90% to 98%) throughout the study period. The scores on the FACT-G, FACT-B and FACT-ES increased at 3 and 12 months from baseline in the TAM group; however, they did not increase in the EXE or ANA group with a statistically signi¿cant between-group difference for FACT-B (P=0.045). The CES-D scores showed no between-group differences for any outcome at 3 or 12 months. Conclusions: The HRQOL was generally better at 3 to 12 months after the beginning to take adjuvant TAM than to take adjuvant EXE or ANA in pts with breast cancer, being assessed by FACT-G, FACT-B and FACT-ES.

Abstracts – Poster Session II S115

2089

The lipid metabolism of SERMs and AI with primary breast cancer: combined results of Multi 01 and 02 trial.

Kusama M, Mitsuyama S, Yanagita Y, Doihara H, Komaki K, Ikeda T, Kimura M, Sano M, Miyauchi K, Anan K. Shinjuku Breast Center, Tokyo, Japan; Kitakyushu Municipal Medical Center, Fukuoka, Japan; Gunma Cancer Center, Gunma, Japan; Okayama University Medical School, Okayama, Japan; Breastopia NAMBA Hospital, Miyazaki, Japan; Teikyo University School of Medicine, Tokyo, Japan; Ota General Hospital, Gunma, Japan; Niigata Association of Occupational Health Inc., Niigata, Japan; Miyauchi Clinic, Hyogo, Japan Background: Resent evidence has suggested that the increase of elderly (≥70) breast cancer patients’ death is affected by non-breast cancer diseases, such as fracture and cardiovascular diseases SERMs (TOR, TAM) favorably modify the lipid and bone pro¿le, but there aren’t enough data between SERMs and AIs. To compare the lipids pro¿le, we studied two randomized multicenter trials (ASCO2003, Breast Cancer Res. Treat 2004, ASCO2006) and then meta-analyzed the time course effects of TOR, TAM, and ANA. Methods: Multi 01 study: patients were randomly allocated between 1997 and 2001 to a TOR 40 mg/day group (37 cases) or a TAM 20 mg/ day group (36 cases). Multi 02 study: patients were randomly allocated between 2003 and 2005 to a TOR 40 mg/day group (36 cases) or an ANA 1 mg/day group (33 cases). Serum lipids were measured before, and 6 and 12 months after the initiation of administration. Changes in the serum lipids were compared. Results: In the TOR group, total cholesterol (TC), LDL, ApoB and Triglyceride (TG) significantly decreased 6 and 12 months after the administration compared with the values before the start of administration (p 25%, 27 samples) were compared. A criterion of at least 2-fold expressional difference and statistical signi¿cance of p5 years from diagnosis, and 45 women with metastatic BC. Each sample was cultured in the presence of aphidicolin (an inducer of fragile sites); chromosomes were harvested and ¿xed using classical cytogenetic techniques. SMRTspeci¿c BAC clones were used in Àuorescence in-situ hybridization (FISH) experiments using the patient’s metaphase chromosomes. Metaphase images were collected, scored, and analyzed for a disrupted FISH signal indicative of FRA12E presence. Clinical data were also recorded.

Abstracts – Poster Session IV S171 Results: 14/55 (25%) patients with no evidence of disease >5 years from their primary diagnostic were carriers of the fragile site whereas 43/45 (96%) of the metastatic patients were carriers. Association between metastasis and fragile site carrier status was highly signi¿cant (p30% cells (21%) or Bcl2 overexpression (65%) showed not correlation with outcome (all p=ns). Discussion: A previous in vitro and in vivo study, including a small series of patients with BC, has suggested a correlation between increased levels of IGF1R protein expression and radioresistance of tumor cells. In agreement, in our series of lymph-node negative BC patients treated conservatively, we conclude that overexpression of IGF1R may contribute to development of LR, which could be associated with resistance to RT. However, the presence of IGF1R mutations or the levels of expression of PTEN, ER, PR, p53, Ki67 or Bcl2 are not relevant with respect to LR. Supported by Grant FIS 03/1411.

4016

A retrospective clinical correlation study of the breast cancer patients’ responses to anticancer drugs with the expression level of drug response indicators (DRI) measured in patient’s archival tumor tissue.

Rak Tkaczuk KH, Tait NS, Rogers WH, Tan M, Ioffe O, Lesko SA, Deamond S, Lum Z-P, Ts’o PO. University of Maryland Greenebaum Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD We conducted a retrospective tumor tissue analysis study in patients with metastatic breast cancer at the University of Maryland Greenebaum Cancer Center. The purpose of our study was to correlate the clinical response to systemic therapy for metastatic breast cancer to the quantitative measurement of DRI/biomarkers with a drug response indicator test (DRIT) which was developed by CCC Diagnostics. The DRIT was ¿rst validated in breast cancer cell lines with known sensitivities to chemotherapy agents with activity in breast cancer. We then took formalin-¿xed paraf¿n-embedded tumor tissue from breast cancer patients who received single agent therapy and analyzed it for the expression of the corresponding DRI. The DRI on the tumor tissue was classi¿ed as resistant or sensitive pro¿le/group and then the corresponding patient clinical response to given therapy was obtained and correlated with the DRI. The non-responder/responder to the respective drug and vice versa for a resistant/sensitive tumor was then de¿ned by the DRI. For example with the Topoisomerase II as the DRI for Anthracycline/Doxorubicin, the tumor will be more sensitive to the drug when the DRI expression is low and resistant to the drug when the DRI expression is high. A total of 39 cases of DRI studies on 5 classes of drugs (Trastuzumab, hormonal therapy, Taxane-based, Capecitabine, Anthracycline-based) given as monotherapy were evaluated in metastatic breast cancer patients. Among the 28 cases classi¿ed as being sensitive to an agent as predicted by the DRI, only one case was not correlated correctly. Among the 11 cases classi¿ed as resistant tumors as predicted by the DRI, only one case was not correlated correctly. In summary 39 BC cases were examined for the correlation between the predicted tumor tissue sensitivity/resistance by our DRIT and correlated with the clinical responsivness to anticancer therapy. The DRIT prediction was not accurate in only two cases (one from predicted sensitive tumor, and one from predicted resistant tumor). The accuracy of DRIT in this small patient cohort is therefore 95% (37/39). A much larger number of patients’ samples with rigorous statistical analyses of correlation are forthcoming, Our early results support the hypothesis that DRI expression in the tumor tissue may serve as a predictor of anticancer drug response of breast cancer patients.

4017

Estrogen receptor status: a prognostic predictor of outcome in HER-2 positive breast cancer with brain metastases.

Vallow L, Hines S, Jain A, Tan W, Buskirk S, Perez EA. Mayo Clinic, Jacksonville, FL Background: Metastatic breast cancer accounts for 20-30% of the 170,000 cases of brain metastases diagnosed annually. The majority of patients suffer signi¿cant neurologic disability and if untreated the median survival is 4 weeks. As improvements in systemic therapy prolong survival, brain metastases in breast cancer patients are becoming more evident. Multiple studies demonstrate an increased risk of brain metastases in HER-2 positive tumors with an incidence of 28-43%. However, there is limited data regarding the outcome of brain metastases in patients with HER-2 positive, estrogen and progesterone receptor (ER/PR) negative versus those with ER/PR positive disease. Materials and Methods: A review of all cases of breast cancer with brain metastases from Mayo Clinic Jacksonville from 4/96 to 11/06 was performed to compare the clinical characteristics and outcome of HER-2 positive patients based on hormone receptor status. The median time from diagnosis to brain metastases and brain metastases to death were evaluated. Hazard ratios for the effect of ER status on time from diagnosis to brain metastases, median time from brain metastases to death, and time from diagnosis to death among HER-2 positive patients. P-values were obtained using Cox proportional hazards analysis.

S172 Abstracts – Poster Session IV Results: Data from 120 women with brain metastases from breast cancer were reviewed with 83 patients having all 3 markers available. HER-2 positive patients comprised 39/83 (47%) of patients with brain metastases with a mean age of 50. At the time of brain metastasis, radiotherapy to the brain was received in 96%, trastuzumab in 23%, chemotherapy in 52% and hormonal therapy in 22%. Brain was the ¿rst site of failure in 15/39 (38%) HER-2 positive patients with 73% being in ER/PR negative and 27% in ER/PR positive. Brain metastases were noted to be multifocal in 30/39 (77%) with 57% being in ER/PR negative and 43% in ER/PR positive. HER-2 positive patients that were ER/PR negative had a shorter time from diagnosis to development of brain metastases, time from brain metastases to death and median survival. Table 1 Group All patients with brain mets All HER-2 + HER-2+/ER/PR pos HER-2+/ER/PR neg

Brain as the ¿rst site of failure no. (%)

Median time from diagnosis to brain mets. (mo)

Median Median time from time from diagnosis brain mets to death to death (mo) in mo. (range)

27 (33)

21

7

29 (2-231)

15 (38) 4 (27) 11 (73)

38.5 45 14.5 (p=0.15)

7 10 3 (p=0.55)

40.5 (4-118) 55 (19-99) 17.5 (4-118) (p=0.31)

Conclusion: In our review, patients with HER-2 positive disease but ER/PR negative had a worse prognosis compared to other groups. All estimates, though not statistically signi¿cant suggest that HER2 positive, ER/PR negative patients are at increased risk of time to failure. This data could potentially help clinicians subclassify patients with metastatic breast cancer and brain metastases. This con¿rms the need for novel treatment strategies for HER-2 positive, ER/PR negative patients and emphasizes the survival difference in HER-2 positive patients depending on their ER and PR status.

4018

The potential prognostic value of osteoprotegrin in ductal carcinoma of the breast.

Davies SR, Mansel RE, Jiang WG. College of Medicine, Cardiff University, Cardiff, South Glamorgan, United Kingdom Background Osteoprotegrin is a soluble decoy receptor which binds to receptor activator of NF-κB ligand (RANKL) inhibiting its interactions with RANK and so preventing osteoclast formation. It is down regulated within the bone microenvironment in the presence of metastatic caners partly as a result of parathyroid hormone-related protein (PTHrP) expression. Osteoprotegrin transcript levels have not previously been investigated to determine a relationship between their levels and prognostic outcomes in patients. Aim To investigate whether osteoprotegrin transcript levels are a predictor of poor prognosis in the largest group of breast cancers, the ductal carcinomas. Method Primary ductal breast cancer tissues (n =90) and non-neoplastic mammary tissue (n = 32) were collected and patients were routinely followed up clinically after surgery. The immunohistochemical distribution and location of osteoprotegrin was assessed in the normal breast tissue and carcinoma and the level of osteoprotegrin transcripts in the frozen tissue was determined using real-time quantitative PCR. The results were analysed against the clinical data looking principally at the levels in patients with different prognostic out comes, metastasis, local recurrence, skeletal metastasis and death but also in relation to indicators of poor prognosis: the nodal involvement, ER status and the Nottingham Prognostic Index (NPI). Results The osteoprotegrin transcript levels were signi¿cantly lower in patients who developed metastases or who passed away as a result of the breast cancer. Compared to patients who were disease free at followup the transcript levels in patients with metastases (p=0.047) or who died (p=0.050) were signi¿cantly lower. Patients who had bone and generalized metastases also had a signi¿cantly lower osteoprotegrin transcript level (p=0.049) compared to normal subjects. Indicators of poor prognosis such as nodal involvement, ER status and Nottingham Prognostic Index did not show a signi¿cant difference, however, patients

who were disease and a positive ER status (an indicator or poorer prognosis) did have a signi¿cantly lower transcript level (p=0.038). Conclusions In ductal carcinoma decreased levels of osteoprotegrin transcript correlated with a poor prognosis. The data suggests that osteoprotegrin expression is of clinical signi¿cance with patient with low transcript levels suffering from a cancer with a more aggressive phenotype making them more susceptible to metastases particularly bone metastasis and death.

4019

The initial response of circulating epithelial tumor cells to primary systemic chemotherapy in breast cancer is highly predictive for ¿nal tumor reduction and outcome.

Camara O, Kavallaris A, Rengsberger M, Koch A, Schneider U, Egbe A, Untch M, Pachmann K. Friedrich Schiller-Universität Jena, Jena, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany; Transfusionsmedizinisches Zentrum Bayreuth, Bayreuth, Germany Background: Having demonstrated in a previous report that the response of CETC during the ¿rst cycles of primary (neoadjuvant) chemotherapy perfectly reÀects the response of the tumour, in the present study the changes in cell numbers during subsequent cycles and their possible impact on the therapy’s outcome were examined. Patients and methods: In 58 breast cancer patients CETC were quanti¿ed during therapy with either EC (epirubicin/ cyclophosphamid) or dose intensi¿ed E (epirubicin) followed by taxane, with or without trastuzumab, and subsequent CMF (cyclophosphamid/methorexate/ Àuorouracil) Results: CETC numbers declined more than tenfold (good response) in 65% (her2/neu-negative) and 55% (her2/neu-positive) of patients during EC, and in 60% during dose intensi¿ed E, respectively, followed by an increase of CETC in all patients. CETC remained increased, decreasing only when adding CMF. A good initial response correlated with Estrogen-receptor negativity, a poor response with early distant relapse (p< 0,0001, hazard ratio = 11,91). Conclusion: Response of CETC already during the ¿rst cycles of neoadjuvant treatment predicts the ¿nal response of the tumour. Hitherto unknown effects of the release of tumour cells during therapy further our understanding of tumour-blood interaction and may improve access of agents like antibodies to cells. The impact on the further course of disease remains to be evaluated.

4020

Predictors of response to neoadjuvant chemotherapy in women with locally advanced breast cancer.

Parmar V, Nadkarni MS, Hawaldar R, Shet T, Nair R, Gupta S, Chinoy R, Badwe R. Tata Memorial Hospital, Mumbai, Maharashtra, India Background: Neo-adjuvant chemotherapy (NACT) for locally advanced breast cancer (LABC) is currently the standard of care with nearly twothirds of cancers responding to chemotherapy. We ran an effectiveness analysis to document response rates (RR) and its determinants. Method: All women with LABC (N=1258) registered during 1997-2006 at Tata Memorial Hospital were treated with multimodality treatment and received NACT (95.2% Anthracycline-based, 3.1% Taxane-based and 1.7% CMF). Response was documented after every cycle and chemotherapy was continued till maximum response or 6 cycles. A regression analysis was carried out for clinical responders (CR+PR) vs. non-responders (SD+PD) and for pathological complete response (PCR) vs. not. The variables in the equation were clinical tumor size, age, number of cycles of NACT (all as continuous variables), skin involvement, axillary nodes (N0-1 vs. N2), supraclavicular lymph node (N3 vs. not), hormone responsiveness (ER&/or PR positive vs. both negative), menopausal status, and presence of lymphovascular invasion (LVI). Response was evaluated at primary site as well as axillary lymph nodes. Results: Overall RR was 77.6% and PCR (primary and axilla) was 3.6%. PCR at primary site alone was 6.2%. The determinants of clinical RR were tumor size (p=0.002, OR=1.07, CI 1.028-1.125), increasing number of cycles of CT (p=0.003, OR=0.80, CI 0.69-0.92), and absence of lymphovascular invasion (p= 0.004, OR=0.87, CI 0.45-0.86). The

Abstracts – Poster Session IV S173 possibility of PCR dropped by 16% for every 1cm increase in clinical tumor size (p=0.026, OR=1.12, CI 1.00-1.25), reduced by 4.6% for unit increase in age (p=0.02, OR=1.16, CI 1.018-1.32), presence of skin involvement reduced it by 88% (p=0.005, OR=0.12, CI 0.03-0.53), and LVI reduced it by 77% (p=0.19, OR=0.23, CI 0.07-0.78). The chemotherapy response was independent of menopausal status and hormone receptor status. Conclusions: Primary tumor size is the sole determinant of PCR and chemosensitivity. RR is directly proportional to number of chemotherapy cycles but did not translate into PCR. Hormone responsiveness did not affect RR or PCR.

4021

Prognostic determinants in patients with breast cancer who are staged using sentinel lymph node biopsy.

Rosman M, Cheng Z, Sawyer K, Verbanac K, Tafra L. Anne Arundel Medical Center, Annapolis, MD; East Carolina University, Greenville, NC Background: During the last ten years sentinel lymph node biopsy (SLNB) has gained wide acceptance. Data have suggested that SLNB may be more accurate than an axillary node dissection (AND) as a staging procedure. Current prognostic models for woman with breast cancer are largely based on data from the AND era. In order to investigate if these models still hold true in the current era of SLNB staging, we evaluated outcome data from our SLNB multi-institution trial. Methods: An IRB-approved, multi-center study was initiated in 1996 enrolling 1424 patients. Of the patients enrolled from 1996-2005, 1267 had invasive breast cancer and a sentinel node identi¿ed. Sentinel nodes were serially sectioned and the majority of H+E negative nodes were analyzed by IHC. Several variables with missing data (
Loading...

Breast Cancer Research and Treatment

Breast Cancer Research and Treatment CONTENTS VOL. 106, Supplement 1, December 2007 Special issue 30th Annual SAN ANTONIO BREAST CANCER SYMPOSIUM – De...

6MB Sizes 15 Downloads 23 Views

Recommend Documents

Breast cancer brain metastases - Breast Cancer Research
tumor cells must pass through the tight blood–brain barrier (BBB). The BBB represents an obstacle for circulating tumo

Breast Cancer: Treatment Options | Cancer.Net
For larger cancers, or those that are growing more quickly, doctors may recommend systemic treatment with chemotherapy o

Treatment of metastatic breast cancer - UpToDate
Oct 23, 2017 - Regardless of primary surgery, all patients may also present with new disease in the axilla. The approach

Breast cancer stem cells: treatment resistance and therapeutic
controversial cancer stem cell (CSC) model as it described a therapy- resistant ... cells (BCSCs). Is there sufficient p

Diagnosis, staging and treatment of patients with breast cancer - HSE
PET-CT may be superior to bone scan alone. (Morris et al., 2010). Chest X-ray. Preoperative CXR is not necessary as a st

Breast Cancer - Michigan Cancer Consortium
phenomenon and of no clinical consequence. ▫ Infections (E.g. abscess) should be treated with incision and drainage or

imaging for breast cancer helps in diagnosis and treatment
The purpose of this report is to provide an overview of the role of imaging for diagnosis, treatment planning ... The mo

Cancer and Rehabilitation: Cancer Rehabilitation, Breast Cancer and
Mar 9, 2015 - Cancer rehabilitation can be defined as a process that assists the cancer patient to obtain maximal physic

Dana-Farber Cancer Institute - Cancer Treatment and Research in
From an individualized treatment plan that recognizes who you are, to specialized therapies based on the genetic profile

Cancer Treatment & Cancer Research | MD Anderson Cancer Center
Find the latest information about cancer treatments, research and prevention as well as how to become a patient at MD An